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Abstract 
Part I: Terpenes represent the largest family of natural products and comprise compounds with 
extremely diverse biological and physical properties. One unique member of this class is wickerol 
A, an antiviral diterpene isolated from the fungus Trichoderma atroviride FKI-3849. It features an 
unprecedented and highly congested carbon framework with seven stereocenters, of which two 
are quaternary carbons. Out of several failed approaches to wickerol A evolved a route which 
ultimately led to its first total synthesis. The highly convergent strategy is based on a Diels–Alder 
reaction and an intramolecular alkylation to complete the 6-5-6-6 ring system.  
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Part II: AMPA receptors are a subclass of ionotropic glutamate receptors which play a crucial role 
in excitatory neurotransmission. They are also involved in processes such as memory and learning 
as well as several psychiatric disorders. In the second part of this thesis, we present the 
development of the first photoswitchable antagonist that is selective for AMPA receptors. Our 
light-responsive ligand, ShuBQX-3, blocks the receptor in its dark-adapted trans-isomer and can be 
switched to its significantly less active cis-isomer using blue light. Control of action potential firing 
in hippocampal CA1 neurons could be demonstrated with ShuBQX-3. In addition, it exhibits a 
remarkable red-shifting of its photoswitching properties through interactions with the AMPA 
receptor ligand binding site. 
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1. General Introduction 
1.1. Biosynthesis of Terpenes 
Terpenoids, with over 55 0000 members, represent the largest family of natural products and 
comprise compounds with extremely diverse biological and physical properties. Consequently, 
their applications range from flavors[1] and fragrances[2] to hormones, therapeutic agents[3] and 
materials. The name “terpene” is derived from turpentine, an oil distilled from pine tree resin. 
Nowadays, the terms terpenoid and terpene are used interchangeably in the literature, though 
according to IUPAC the latter only comprises pure hydrocarbons. Terpenoids are defined through 
their biosynthetic origin that is the two C5-monomers isopentenyl pyrophosphate (1.2, IPP) and 
dimethylallyl pyrophosphate (1.3, DMAPP) (Figure 1.1).[4] Both units are joined in a head to tail 
fashion which results in carbon structures that consists of (C5)n members. This pattern had been 
recognized by Otto Wallach[5] by the end of the 19th century and was later formalized by Leopold 
Ruzicka[6] though they wrongly assumed that all terpenoids arose from a varying number of 
isoprene (1.1) units (the ‘isoprene rule’). Only later, through studies of Konrad E. Bloch and Feodor 
Lynen, were the true building blocks of nature identified as IPP (1.2) and DMAPP (1.3).[7] They in 
turn arise from either the mevalonate (MVA) or the methylerythritol phosphate (MEP) pathway 
(Scheme 1.1and Scheme 1.2).  
 
 
Figure 1.1. Structure of isoprene (1.1), IPP (1.2) and DMAPP (1.3). 
 
The mevalonate pathway begins with Claisen condensation of two acetyl-CoA (1.4) units to give 
acetoacetyl-CoA (1.6) which undergoes a regiochemically unusual Aldol reaction with another 
enzyme bound acetyl-CoA moiety (1.5) (Scheme 1.1). The product is then hydrolyzed to afford 3-
hydroxy-3-methylglutaryl-CoA (1.7, HMG-CoA) which is then reduced with 2 equivalents of NADPH 
to mevalonic acid (1.8, MVA). IPP (1.2) is then formed through phosphorylation of the primary 
hydroxyl group of 1.8, decarboxylation and elimination of the tertiary alcohol. Isomerization to 
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DMAPP (1.3) is catalyzed by an isomerase enzyme and proceeds via protonation and elimination 
of the HR-proton.
[4] 
 
Scheme 1.1. The mevalonate pathway. 
 
The mevalonate-independent pathway or the methylerythritol phosphate (1.14, MEP) pathway 
represents an alternative way to produce IPP (1.2) and can be found in bacteria and plants. It 
starts from the glycolytic pathway intermediate pyruvic acid (1.10) and glyceraldehyde 3-
phosphate (1.11) which form diol 1.12 in a thiamin pyrophosphate (TPP, structure not shown) 
dependent process (Scheme 1.2). A retro-Aldol/Aldol cascade affords 1.13 which is reduced to 
MEP (1.14) by NADPH. MEP (1.14) is then converted to the cyclic intermediate 1.17 through 
cytidylation (CTP-dependent), phosphorylation of the tertiary alcohol (ATP-dependent) and 
intramolecular hydrolysis. The mechanisms of subsequent transformations are the least 
understood of the pathway and subject to ongoing research. It is clear though that ring opening 
and reductive dehydration of 1.17 gives primary alcohol 1.18 that in turn is converted into both 
IPP (1.2) and DMAPP (1.3) by reductive processes, with a preference for the former. Whether the 
mevalonate pathway or the MEP pathway is the source of building blocks for a particular 
terpenoid has to be established experimentally. Animals seem to lack the MEP pathway, whereas 
many other organisms, including plants, are able to employ both, often concurrently.[8] 
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Scheme 1.2. Methylerythritol phosphate pathway. 
 
In the biosynthesis of terpenes, the two building blocks DMAPP (1.3) and IPP (1.2) are then 
connected by prenyltransferases in a tail-to-head fashion to form geranyl pyrophosphate (1.21, 
GPP) (Scheme 1.3). This process is thought to involve first the formation of an allylic cation (1.19) 
through the loss of pyrophosphate, subsequent nucleophilic attack by IPP (1.2), followed by HR-
proton loss, which leads to a double bond in the E-form. GPP (1.21) can then be transformed to 
linalyl PP (1.23) and neryl PP (1.24), most likely via ionization to the allylic cation 1.22. These three 
C10 building blocks are then used to form monoterpenoids through intramolecular cyclizations 
mediated by terpenecyclases that give rise to many different types of carboskeletons (Scheme 
1.3).[9] The resulting cation can then be quenched by nucleophilic attack (for example water), 
proton loss, Wagner-Meerwein shifts or further cyclizations. [4] 
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Scheme 1.3. a) Biosynthesis of geranyl pyrophosphate (1.21, GPP). b) Different types of 
monoterpene carbon skeletons.  
 
Sequential elongation of GPP (1.21) with IPP (1.2) units following the same mechanism as 
described above affords farnesyl pyrophosphate (1.25, FPP, C15), geranylgeranyl pyrophosphate 
(1.26, C20) or geranylfarnesyl pyrophosphate (1.27, C25) (Scheme 1.4). Analogously to 
monoterpenes, these linear precursors give rise to a plethora of structurally diverse natural 
products through cyclization reactions, rearrangements and oxidation processes. According to the 
number of C5-units, they are classified as mono- (C10), sesqui- (C15), di- (C20) and sesterterpenes 
(C25). An example of each class is depicted in Scheme 1.4. 
However, squalene (1.32, C30), from which triterpenes (C30) are derived, is not formed by 
homologation of geranylfarnesyl pyrophosphate (1.27) but from the tail-to-tail fusion of two 
farnesyl subunits. Polyene cyclization of 1.32 gives penta- and tetracarbocyclic triterpenoids such 
as lanosterol (1.33). Through the loss of three carbon atoms, 1.33 is transformed into cholestrol 
1.34, the principal animal sterol (Scheme 1.5). 
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Scheme 1.4. Biosynthetic precursors for mono-, sesqui-, di- and sesterterpenes with a 
representative member of each class. 
 
Analogously to triterpenes, tetraterpenes arise from the tail-to-tail coupling of two molecules of 
geranylgeranyl diphosphate (1.26, GGPP). They comprise only carotenoids, organic pigments that 
play an important role in photosynthesis and as protectants against photo-oxidative damage. A 
famous example is β-carotene (1.35), which is bright red-orange and serves as precursor for 
vitamin A (Scheme 1.5).  
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Scheme 1.5. Examples for tri- and tetraterpenes as well as higher terpenes. 
 
Nature also produces higher terpenoids such as rubber (1.36) and gutta percha (1.37), which 
contain polyisoprene chains. Furthermore, C40-C50 terpenoid side chains can be found in 
ubiquinones, a family of natural products that arise from the shikimate pathway, e.g. ubiquinone-
10 (1.38, Coenzyme Q10) (Scheme 1.5).
[10]  
 
1.1.1. Diterpenes 
Diterpenes represent a large and structurally diverse subgroup of terpenoids that are derived from 
GGPP (1.26). One of the simplest and most important one is phytol (1.45) (Figure 1.2) which forms 
the lipophilic side-chain of the chlorophylls. Cyclization of the linear precursor 1.26 through 
diterpene synthases gives rise to a multitude of molecular scaffolds of varying ring sizes, some 
examples being given in Figure 1.2. After construction of the carbon skeleton follows the chemo-, 
regio-, and stereoselective oxidation by P450-dependent mono-oxygenases.[4] 
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Figure 1.2. Structure of phytol (1.45) and some representative examples of diterpene carbon 
scaffolds. 
 
A very prominent diterpenoid is the best-selling drug paclitaxel (1.44) (more commonly known as 
Taxol). The cyclization leading to taxadiene (1.42), the first committed intermediate in the 
biosynthesis of 1.44 is depicted in Scheme 1.6. Loss of diphosphate induces a cyclization cascade 
resulting in the bicyclic verticillyl cation (1.41) that eliminates a proton and forms taxadiene (1.42) 
via a sequence of protonation, electrophilic cyclization and elimination. Intermediate 1.42 is then 
transformed to 10-deacetyl-baccatin III (1.43) and then paclitaxel (1.44), in which the side chains 
containing aromatic rings are derived from the shikimate pathway. Natural product 1.44 was 
isolated from the bark of the Pacific yew (Taxus brevifolia) in 1971 and was approved by the FDA 
in 1992.[11] Ever since then it has become one of the most important anticancer drugs on the 
market. In the beginning, accessing enough material for therapeutic use presented a significant 
challenge since three 100-year-old trees gave about one gram of paclitaxel (1.44), whereas 
treatment of a single patient may need double that amount. To meet this challenge, tremendous 
efforts throughout the 1980’s and 1990’s were made to access 1.44 through total synthesis. 
Though several endeavors were successful, the routes proved to be too costly for industrial 
production. Ultimately, paclitaxel (1.44) was made through semi-synthesis from more easily 
isolated 10-deacetyl-baccatin III (1.43) and nowadays it can be produced through plant cell 
cultures.[12]  
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Scheme 1.6. Biosynthesis of taxadiene (1.42), the precursor of 10-deacetyl-baccatin III (1.43) and 
then paclitaxel (1.44). 
 
In contrast to the cyclization sequence shown in Scheme 1.6, where loss of pyrophosphate 
generates the initial carbocation, many diterpenes arise by a different mechanism. Carbocation 
formation can also be initiated by protonation of the double bond at the head of the GGPP (1.26) 
chain leading to a polyene cyclization (Scheme 1.7). The stereochemistry in the product is 
controlled by the folding of the substrate on the enzyme surface, which either leads to (+)-or (–)-
copalyl PP (1.46). Subsequent loss of diphosphate produces another carbocation that can undergo 
a multitude of transformations, resulting in the broad spectrum of scaffolds and oxidation 
patterns found in nature.[4] 
 
Scheme 1.7. Formation of (–)-copalyl PP (1.46). 
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The structural diversity of terpenoids combined with their broad range of biological activities have 
made them the focus of extensive research and inspired organic chemists to access these natural 
products through total synthesis. Some recent examples thereof will be discussed in the following 
chapter. 
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1.2. Synthesis of Complex Diterpenes 
Terpenoids, with their interesting structural, physical and biological properties, have prompted 
extensive studies of their biosynthesis (see Chapter 1.1.) and function in nature. For organic 
chemists, terpenoids have been a source of intriguing targets since the dawn of natural product 
synthesis.[13] One of the earliest examples is the preparation of camphor (1.47) on an industrial 
scale at the beginning of the 1900´s.[14] By mid-century, pioneering work by Robert B. Woodward 
resulted in the synthesis of complex steroids such as cholesterol (1.34).[15] The following decades 
saw the rise of crucial technological advances, including chromatography techniques and NMR 
spectroscopy, which enabled the synthesis of terpenoids with increasing complexity.[13a] Some 
interesting examples from the 1970´s and 80´s are gibberellic acid (1.48),[16] gingkolide B (1.49)[17] 
and retigeranic acid (1.50)[18] (Figure 1.3.a). In addition to being interesting targets, terpenes serve 
also as useful building blocks („chiral pool“) to access a wide variety of other molecular 
scaffolds.[19] Some recent examples of natural products syntheses based on this strategy are 
jiadifenolide (1.52)[20] and ryanodol (1.54) (Figure 1.3.b).[21] In both cases, the complex targets 
could be synthesized in a concise way starting from simple monoterpenes. 
 
 
Figure 1.3. a) Some historic examples of terpenes made by total synthesis. b) Recent examples of 
natural products syntheses using terpenes as building blocks.  
 
Despite the successful preparation of many complex molecular scaffolds through total synthesis, 
and the guidelines that can be followed when subjecting a new target to retrosynthetic analysis, it 
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is impossible to predict the outcome when embarking on such a project. Success is often based on 
a combination of ingenious disconnections, problem solving, extensive experimentation and 
perseverance, thus making total synthesis such a challenging endeavor. 
In the following chapter the key transformations in selected total syntheses of complex diterpenes 
will be discussed. The chosen examples were published in the past decade and are ordered 
according to the number of carbocycles. Far from being comprehensive, they should give the 
reader an overview of recent methods employed for the construction of challenging molecular 
structures.[22] 
Isolated in 1987, vinigrol (1.55),[23] through its unique decahydro-1,5-butanonaphthalene ring 
system containing eight contiguous stereocenters, had prompted numerous attempts at its 
synthesis[24] but it took over two decades until the first total synthesis was disclosed by the Baran 
group (Scheme 1.8).[25] Their strategy was based on first an inter- followed by an intramolecular 
Diels–Alder reaction to forge the carbon scaffold. Thus, AlCl3 mediated [4+2]-cycloaddition of silyl 
enol ether 1.56 and ester 1.57 afforded intermediate 1.58 which was further elaborated to triene 
1.59. Even though the olefinic moieties in 1.59 were electronically not favorable for a Diels–Alder 
reaction, 1.59 still underwent the thermally induced cycloaddition to give tetracycle 1.60, 
presumably due to a strong proximity effect. The decahydro-1,5-butanonaphthalene motif was 
then established through Grob fragmentation of alcohol 1.61. To functionalize the decalin system 
an ingenious dipolar cycloaddition using dibromoformaldoxime (1.65) was used. The formed 
bromoisoxazole gave later rise to the vicinal methyl and tertiary hydroxyl group in 1.55. This 
required first LAH reduction to amine 1.64 followed by primary isonitrile formation and radical 
deamination. Further six-step-modifications of the carbon framework lead to vinigrol (1.55). 
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Scheme 1.8. Baran´s synthesis of vinigrol (1.55). 
 
In 2013 the Njardason group disclosed a different approach to (1.55) (Scheme 1.9), which built up 
the carbocyclic core in only two steps via a one-pot oxidative dearomatization/Diels–Alder 
sequence of 1.66 followed by a Heck cyclization cascade of product 1.67 to afford intermediate 
1.68.[26] Further functional group transformations resulted in alcohol 1.69 which upon treatment 
with base fragmented to unravel the bridged bicyclic framework of 1.55, similar to the Baran 
synthesis. In the following 14 steps the isopropyl and the secondary, allylic hydroxyl groups were 
installed and the tertiary alcohol deprotected to give vinigrol (1.55). 
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Scheme 1.9. Njardason´s approach to vinigrol (1.55). 
 
Taxadiene 1.42 is the least oxidized member of the taxanes, a family of terpenes comprising over 
350 members. Its carbon skeleton has been a highly popular target as it is found in the famous 
cancer drug paclitaxel (1.44, see Chapter 1.1.1). In 2012, the Baran group disclosed a concise 
synthesis of 1.42 performed on gram-scale (Scheme 1.10).[27] To construct the tricyclic core they 
used triene 1.71, assembled in four steps, in a Lewis acid mediated intramolecular Diels–Alder 
reaction which afforded diketone 1.72. Subsequent removal of the carbonyl groups and 
introduction of a methyl moiety gave taxadiene (1.42). Based on this strategy to assemble the 
carbon framework, Baran and co-workers also developed syntheses for (−)-taxuyunnanine D 
(1.73)[28] and taxabaccatin III (1.74).[29] 
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Scheme 1.10. Synthesis of taxadiene (1.42) and higher oxidized members of the taxane family. 
 
Another unique diterpene is tetracyclic ingenol (1.75), a member of the phorboid family isolated 
from the genus Euphorbia in 1968 (Scheme 1.11).[30] Various esters of ingenol (1.75) have shown 
remarkable anticancer and anti-HIV activity.[31] Ingenol mebutate (structure not shown), the 
angelic acid ester of ingenol (1.75), has already become a FDA approved drug as topical treatment 
of actinic keratosis, a precancerous skin condition.[32] Structurally, ingenol (1.75) contains an 
unusual trans-fused (“in,out”)-bicyclo[4.4.1]undecane ring system, which makes the molecule 
considerably more strained than the cis-fused (“out,out”) analogue and represents a significant 
synthetical challenge. Ingenol´s (1.75) biological and structural characteristics have made it a very 
popular target in the organic community[33] with four total syntheses disclosed to date. The first on 
was published by the Winkler group in 2002 and was based on a DeMayo reaction to construct the 
ingenol core (Scheme 1.11). From ketone 1.77 a lengthy sequence of 32 steps led ultimately to 
ingenol (1.75).[34] In contrast to Winkler´s approach, Tanino-Kuwajima´s 43 step synthesis used a 
Pinacol-type rearrangement of epoxide 1.78 to establish the trans-fused BC-ring system.[35] The 
Wood group addressed the problem of constructing the ingenane skeleton by first building up 
spirocycle 1.80 and then closing the B-ring through a RCM.[36] 
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Scheme 1.11. Previous syntheses of ingenol (1.75). 
 
In 2013, the Baran group disclosed a novel strategy to access ingenol (1.75) (Scheme 1.12) that 
represented a tremendous improvement in comparison to the previous routes, as it cut the 
necessary steps by more than half.[32] Starting from (+)-carene (1.82), alkyne 1.83 was quickly 
assembled in four steps and then used in a Pauson-Khand cyclization to form the fused 5-7-ring 
system of 1.75. Subsequent 1,2-addition, dihydroxylation and carbonate formation gave 1.85 
which upon exposure to BF3·Et2O underwent the crucial vinylogous Pinacol rearrangement, 
forming ketone 1.86. The synthesis was then completed with a short series of standard 
transformations. 
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Scheme 1.12. Baran´s synthesis of ingenol (1.75). 
 
Another diterpene with a congested carbon framework is crotogoudin (1.87), isolated in 2010 
from Croton plants.[37] Natural product 1.87 belongs to the rare 3,4-seco atisane family and its 
tetracyclic skeleton contains four contiguous stereocenters, two of which are quaternary carbons 
(Scheme 1.13). The first and so far only total synthesis was published by the Carreira group and 
relied on an elegant radical cyclopropane-opening/annulation/elimination cascade.[38] Starting 
from diketone 1.88 and enone 1.89, bicycle 1.90 was prepared in nine steps, including an 
intramolecular aldol addition to build up the bicyclo[2.2.2]octane fragment of 1.87 and 
desymmetrization by baker´s yeast reduction. Subsequent rhodium-catalyzed cyclopropanation, 
allylic oxidation and ester formation gave the key precursor 1.91. Subjecting 1.91 to SmI2 initiated 
a sequence of cyclopropane ring opening, 6-exo trig cyclization to intermediate 1.92, reduction 
and subsequent anionic β-elimination to afford alkene 1.93. Having established the tetracyclic 
framework, (+)-crotogoudin (1.87) was synthesized in three additional steps, thereby establishing 
the absolute configuration of the natural product. 
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Scheme 1.13. Carreira´s synthesis of (+)-crotogoudin (1.87). 
 
A radical cascade was also employed as the key step in the Reisman synthesis of maoecrystal Z 
(1.94) (Scheme 1.14), a 6,7-seco-ent-kauranoid natural product that has a compact tetracyclic ring 
system with six vicinal stereocenters, two of which are all-carbon quaternary centers.[39] The first 
of them was set through a diastereoselective Ti(III)-mediated reductive coupling of epoxide 1.95 
and trifluoroethyl acrylate (1.96) that gave spirolactone 1.97 as a single diastereomer. 
Intermediate Compound 1.97 was then elaborated to dialdehyde 1.98 which underwent a radical 
cyclization cascade upon exposure to a mixture of SmI2 and LiBr, which closed two rings and 
generated four stereocenters. Having constructed the tetracyclic carbon framework, a sequence 
of acetylation, ozonolysis, methylenation and saponification of alkene 1.99 delivered maeocrystal 
Z (1.94). Using spirocycle 1.97, Reisman and co-workers could also access (–)-trichorabdal A 
(1.102) and (–)-lanogikaurin E (1.103) (Scheme 1.14),[40] two diterpenes closely related to 1.94. Key 
step in both syntheses was the Pd-mediated oxidative cyclization of silyl ketene acetal 1.100, 
derived from 1.97, to construct the bicyclo[3.2.1]-octane motif. From tetracycle 1.101, a series of 
standard transformations afforded (–)-trichorabdal A (1.102), whereas 1.103 was accessed in a six-
step sequence comprising a Sm(II)-mediated Pinacol-type coupling between an aldehyde and 
lactone moiety (not shown). 
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Scheme 1.14. Total syntheses of maoecrystal Z (1.94), (–)-trichorabdal A (1.102) and (–)-
lanogikaurin E (1.103). 
 
Crinipellins are a family of diterpenes that feature a unique tetraquinane scaffold, previously 
accessed by the Piers group in their total synthesis of crinipellin B (1.104) (Scheme 1.15.a).[41] They 
built the congested carbon skeleton in a sequential fashion, first by an Aldol condensation, 
followed by a Pd-mediated vinyl iodide coupling of 1.106. The last 5-membered ring was then 
constructed by an intramolecular 1,2-addition. In 2014, Lee and co-workers disclosed a total 
synthesis of crinipellin A (1.105) (Scheme 1.15.b) based on a tandem [2+3] cycloaddition reaction 
of allenyl diazo 1.109, generated from tosyl hydrazone 1.108.[42] Nitrogen extrusion of 1.110 gave 
the diradical 1.111 which underwent another intramolecular cyclization to afford tetraquinane 
1.112. A series of 12 additional steps was needed to reach crinipellin A (1.105). 
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Scheme 1.15.a) Total synthesis of crinipellin B (1.104). b) Total synthesis of crinipellin A (1.105). 
 
A complex pentacyclic diterpene is atropurpuran (1.113), isolated from Aconitum hemsleyanum 
var. atropurpureum in 2009.[43] To access its caged framework, the Qin group devised a strategy 
starting with an oxidative dearomatization/Diels–Alder cycloaddition cascade of phenol 1.114 
which forged the bicyclo[2.2.2]octane part of 1.113 (Scheme 1.16).[44] Intermediate 1.115 was 
then elaborated to silyl enol ether 1.116 in six steps, including a reductive Knoevenagel 
condensation. This set the stage for an intramolecular aldol reaction followed by a SmI2 mediated 
ketyl-olefin cyclization which provided the congested framework of 1.113. Interestingly, it was 
found that TBS protection of the secondary alcohol of 1.117 was crucial for the radical cyclization, 
presumably due to repulsion of the silyl group and the C4-ketone which brings the C10-carbonyl 
group into close proximity to the olefin. Further elaborations of 1.118 gave the natural product in 
additional 11 steps. 
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Scheme 1.16. Total synthesis of atropurpuran (1.113). 
 
Another pentacyclic diterpenoid, maoecrystal V (1.119), was isolated in 1994 from the Chinese 
medicinal herb Isodon eriocalyx but uncertainty about the structural assignment prevented its 
disclosure. Eventually, in 2004 X-ray structure analysis unambiguously revealed the unique 
architecture of maoecrystal V (1.119),[45] which features a highly congested pentacyclic carbon 
skeleton adorned with six stereocenters, of which two are vicinal quaternary carbons (Scheme 
1.17). In addition, 1.119 was found to display selective and potent activity against HeLa cells, with 
an IC50 value of 20 ng/mL. Its interesting biological properties in combination with its fascinating 
structure prompted many towards studies[46] resulting in several syntheses of 1.119.[47] The first 
was published in 2011 by the Yang group, who used an elegant two-step sequence for the rapid 
construction of the complex core of the natural product (Scheme 1.17).[48] Enone 1.120 was 
prepared in 9 steps including an oxidative arylation to install the C10 quaternary carbon and a Rh-
catalyzed O-H bond insertion. Treating 1.120 with Pb(OAc)4, AcOH lead to a Wessely oxidative 
dearomatization, leading to a diene that was then used in a thermally induced intramolecular 
Diels–Alder reaction, giving rise to the pentacycle 1.121. In the remaining seven steps the allylic 
position was oxidized and the acetoxy group removed to afford maoecrystal V (1.119). Five years 
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later, the same group published an asymmetric synthesis based on a semipinacol rearrangement 
to obtain enantiopure 1.120.[49] 
 
 
Scheme 1.17. Yang´s approach to maoecrystal V (1.119). 
 
Danishefsky´s approach to maoecrystal V (1.119) also hinges on an intramolecular Diels–Alder 
reaction to forge the [2.2.2] bicyclooctane motif of the molecule (Scheme 1.18), but uses silyl enol 
ether 1.122 as the substrate.[50] In order to establish the desired stereochemistry at the C5 
position, they had to elaborate tetracycle 1.123 in a lengthy sequence to intermediate 1.124 
which after epoxidation underwent a Meinwald rearrangement, setting the correct ring junction. 
Ketone 1.125 was then modified further to maoecrystal V (1.119) in nine steps. 
 
 
Scheme 1.18. Danishefsky´s approach to maoecrystal V (1.119). 
 
In another total synthesis of maoecrystal V (1.119) published by Zakarian and co-workers, the 
[2.2.2] bicyclooctane part was also constructed through an intramolecular Diels–Alder reaction but 
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in their case a silicon tethered dienophile was used (Scheme 1.19).[51] Compound 1.127 prepared 
in eight steps from sesamol (1.126), including a Rh-catalyzed C-H insertion to close the 
tetrahydrofuran ring. In contrast to Danishefsky´s synthesis, the [4+2] cycloaddition product 1.128 
already featured the central B-ring, whereas the lactone and A-ring were missing. The former was 
accessed employing a radical cyclization of selenocarbonate 1.129, whilst the latter was built 
through RCM. 
 
 
Scheme 1.19. Zakarian´s approach to maoecrystal V (1.119). 
 
A year later the Thomson laboratory published an enantioselective synthesis of 1.119, where the 
quaternary C10-carbon was forged via a Heck spirocyclization of alkene 1.131, whose one 
stereocenter was set using a Sharpless epoxidation (Scheme 1.20).[52] Intermediate 1.132 gave rise 
to silyl enol ether 1.133 in three steps, including an oxidative cyclodearomatization using 
PhI(OAc)2 to close the tetrahydrofuran ring. Diene 1.133 then underwent an intermolecular 
Diels−Alder reac^on with nitroethylene (1.134) through which the eastern bicyclic fragment of 
1.119 was generated. Ketone 1.135 was then transformed to maoecrystal V (1.119) in six 
additional steps, the final one being a C-H oxidation to introduce the lactone-carbonyl group. 
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Scheme 1.20. Thomson´s approach to maoecrystal V (1.119). 
 
In contrast to the previous routes, Baran´s strategy, published in 2016,[53] did not trace the [2.2.2] 
bicyclooctane motif back to a Diels–Alder reaction (Scheme 1.21). Instead, they prepared tertiary 
alcohol 1.137 starting from enone 1.136. Upon treatment with p-TSA 1.137 underwent a Pinacol 
shift and double bond isomerization to afford tricycle 1.138. Subsequent aldol reaction to install 
the C10 quaternary carbon represented a daunting challenge due to steric hindrance of that 
position, as well as chemo- and regioselectivity issues that needed to be overcome. After 
extensive experimentation it was found that the desired alcohol 1.139 could be obtained using 
NaHMDS with LaCl3·2LiCl. The missing B- and C-rings were then closed via ketal formation, cyanide 
addition followed by saponification. Additional transformations of intermediate 1.140 without 
work up afforded maoecrystal V (1.119) whose bioactivity was tested in different laboratories but 
contrary to previous reports, was not found to be active against various cancer cell lines (including 
HeLa). 
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Scheme 1.21. Baran´s approach to maoecrystal V (1.119). 
 
Terpenes such as maoecrystal V (1.119) or ingenol (1.75) are beautiful examples of how a single 
molecule can inspire a variety of approaches and how ingenious disconnections can lead to more 
concise and efficient syntheses. Despite the broad array of natural products that has been 
synthesized in the past decades, the construction of complex structures through synthetic means 
still remains a huge challenge, revealing the shortcomings of the tools available to organic 
chemists. Thus, intriguing molecules isolated from nature will continue to motivate chemists to 
push the possibilities of synthetic methods to their limits.  
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2. Project Background and Aims 
2.1. Isolation and Structure of Wickerol A and B 
In 2012, over the course of screening for novel antiviral compounds from microbial metabolites, 
the groups of Omura and Shiomi isolated wickerol A (2.1) and B (2.2) from the culture broth of the 
fungus Trichoderma atroviride FKI-3849.[54] They also isolated wickerol A (2.1) from a different 
fungus, T. atroviride FKI-3737, whereas B (2.2) was isolated by another group from T. atroviride 
S361, thus named trichodermanin A.[55] Elucidation of the relative configuration revealed the two 
natural products to be diterpenes with a caged tetracyclic carbon framework, with wickerol B (2.2) 
differing from A (2.1) only through the presence of a single hydroxyl group at the C8 position 
(Figure 2.1). While a 6-5-6 fused ring motif can be found in sesquiterpenes such as stereumins H-J 
(structure not shown),[56] the 6-5-6-6 carbon framework of the wickerols is unprecedented. The 
remarkable steric congestion of these molecules is reflected in the presence of numerous 1,3-
diaxial interactions and the syn-pentane interactions resulting from the boat-type conformation 
adopted by ring D. Wickerol A (2.1) and B (2.2) possess seven and eight stereocenters respectively, 
of which two are quaternary carbons. An additional interesting structural feature is the C10a-
C10b-C2a triad, which forms the BC- and BA-ring junction, both in a trans-fashion.  
 
 
Figure 2.1. Structure of wickerol A (2.1) and B (2.2). 
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2.2. Biological Activity 
In vitro evaluation of the biological activity of wickerol A (2.1) revealed that 2.1 was highly active 
against two type A/H1N1 viruses (A/PR/8/34 and A/WSN/33) with an IC50 of 0.07 µg/mL, but not 
active against two A/H3N2 viruses (A/Guizhou/54/89 and A/Aichi/2/68) nor a B-type virus 
(B/Ibaraki/2/85). In vitro cytotoxicity was tested using MDCK cells and gave an IC50 value of 7.0 
mg/mL. Interestingly, wickerol B (2.2), despite its only small structural difference from A (2.1), 
exhibited a very different biological profile. While 2.2 showed an antiviral effect against type 
A/H1N1 virus A/PR/8/34 (IC50 of 5.0 µg/mL), it did not inhibit the proliferation of other flu viruses 
at 100 mg/mL, nor of MDCK cells. The standard antiviral therapeutics amantadine hydrochloride 
(2.3), an M2 ion channel blocker, oseltamivir phosphate (2.4, Tamiflu) and zanamivir (2.5, Relenza) 
(Figure 2.2), two neuraminidase inhibitors, demonstrated a different antiviral spectrum than the 
wickerols, indicating that their mode of action might differ from 2.1 and 2.2.[54] 
 
Figure 2.2. Structure of standard influenza therapeutics. 
 
2.3. Biosynthesis of Wickerol A and B 
Based on feeding experiments with 13C-labeled sodium acetate the groups of Omura and Shiomi 
proposed the biosynthesis depicted in Scheme 2.1.[54] The novel skeleton of 2.1 and 2.2 was 
suggested to be derived from geranylgeranyl diphosphate (2.6, GGPP), from which pyrophosphate 
is ejected in the first step. The resulting cation cyclizes to form a verticillen-12-yl cation 
intermediate 2.7 that is also proposed in the first step of the phomactatriene and taxadiene 
biosynthesis (see chapter 1.1.1). Next, a 1,2-shift of a β-methyl group, followed by an α-hydride 
shift gives cation 2.8, which undergoes a ring inversion and cyclization to form the 6-5-9 fused 
intermediate 2.10. Subsequent ring expansion of 2.10 and attack of the remaining double bond 
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results in the formation of the fused 6-5-6-6 ring skeleton of the wickerols. In the final step, the 
C8-position of 2.1 is oxidized by a cytochrome P450 to form 2.2. 
 
 
Scheme 2.1. Proposed biosynthesis of wickerol A (2.1) and B (2.2). 
 
2.4. Previous Work 
To the best of our knowledge, only one study towards wickerol A (2.1) has been published. In 
2014, Richard and co-workers disclosed a five step synthesis of the 6-6-6 tricyclic carbon motif of 
2.1 (Scheme 2.2).[57] Starting from commercially available allylcyclohexanone (2.13), formylation 
and D-proline mediated Robinson annulation gave spirocycle 2.15. Subsequent Lemieux–Johnson 
cleavage and NHC-catalyzed Stetter reaction delivered tricycle 2.17. Since attempts at 
differentiating the keto groups were unsuccessful, the route was not pursued further. 
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Scheme 2.2. Synthesis of the 6-6-6 tricyclic carbon framework of wickerol A (2.1). 
 
2.5. Project Outline 
Influenza viruses have a huge socioeconomic impact worldwide since they are responsible for the 
seasonal flu and pandemics. According to the WHO, seasonal flu is estimated to result in 250,000 
to 500,000 deaths worldwide every year, whereas the occurrence and severity of a pandemic are 
unpredictable.[58] In the last 100 years, four outbreaks of influenza have developed into 
pandemics,[59] the last time in 2009, when a novel strain of the H1N1 virus, termed “swine flu“, 
spread globally and caused the deaths of over 18 000 people.[60] Despite the threat influenza 
poses, only a handful of antiviral drugs are available and there is growing concern over drug 
resistant influenza viruses rendering these treatments obsolete. As a consequence, there is a 
pressing need for the development of new antiviral therapeutics.  
Such drugs might be found in nature, for example through screening microbial metabolites. During 
the course of such an endeavor, the groups of Omura and Shiomi isolated wickerol A (2.1) and B 
(2.2) from the culture broth of the fungus Trichoderma atroviride FKI-3849. Wickerol A (2.1) was 
found to be highly active against two type A/H1N1 viruses, whereas 2.2 possessed much weaker 
potency.[54] With their interesting biological activity and remarkable structure (see Chapter 2.1.) 
wickerol A (2.1) and B (2.2) represent formidable targets for total synthesis for which our original 
retrosynthetic plan is depicted in Scheme 2.3.  
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Scheme 2.3 Retrosynthetic analysis of wickerol A (2.1) and B (2.2). 
 
We envisioned that both natural products could be prepared from the common precursor 2.19 via 
hydrogenation and subsequent methyl addition with additional deoxygenation of the C8-position 
in the case of wickerol A (2.1). Formation of tetracyclic enone 2.19 represented the key step of our 
synthetic plan and could be achieved through an organocatalytic, diastereoselective 
intramolecular Robinson annulation of aldehyde 2.20. Intermediate 2.20 could be accessed 
through epoxidation and Meinwald rearrangement of ketone 2.21 which in turn would arise from 
conjugate addition of the two building blocks 2.22 and 2.23. Ketal 2.22 could be traced back to 
geraniol (2.24), whereas compound 2.23 would be prepared from ketone 2.25. This strategy would 
lead to a highly convergent synthesis of wickerol A (2.1) and B (2.2) using of relative simple 
building blocks to quickly build up molecular complexity. 
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3. Results and Discussion 
3.1. First Generation Approach 
Our endeavor towards the synthesis of wickerol A (3.1) and B (3.2) began with the preparation of 
building block 3.12 which we envisaged to be accessible through halogenation of geraniol (3.3) 
derived alcohol 3.9. Following a route described by Yao and co-workers,[61] the sequence started 
with Sharpless asymmetric epoxidation[62] of geraniol (3.3), giving the product 3.4 in 80% ee as 
determined by Mosher ester analysis[63] (Scheme 3.1). After TBS-protection of the primary alcohol, 
3.5 was subjected to a Yamamoto rearrangement using the in situ generated bulky Lewis acid 
MABR (methylaluminum bis(4-bromo-2,6-di-t-butylphenoxide))[64] which established the first 
quaternary stereocenter of wickerol A (3.1) and B (3.2). The next step comprised a [SmI3(THF)3.5]-
complex mediated carbonyl ene-reaction of aldehyde 3.7 but in our hands product 3.8 could only 
be isolated in low yields. We therefore tested different Lewis acids and found that treating 3.7 
with Me2AlCl afforded desired alcohol 3.8 as an inconsequential mixture of diastereomers 
(d.r.1:1.8:0.6:1.8) in excellent yields.[65] Subsequent Lemieux–Johnson cleavage[66] and elimination 
of the hydroxyl group with concomitant deprotection of the primary alcohol under acidic 
conditions furnished enone 3.9. The following ketal formation could not be accomplished using 
the disclosed conditions (BF3·Et2O, ethylene glycol, HC(OEt)3 at −78 °C) but we found that p-
TSA·H2O in combination with a large excess of ethylene glycol and HC(OEt)3 worked. We then 
focused our attention on iodination of alcohol 3.10. Under Garegg–Samuelsson conditions,[67] 
iodide 3.12 could be isolated but only in low yields, due to incomplete conversion and ketone 
deprotection. This issue could not be alleviated by neither modifying the reaction parameters nor 
a two-step sequence including mesylation or tosylation of alcohol 3.10 followed by Finkelstein 
reaction.[68] Finally, we discovered that iodide 3.12 could be accessed by changing the order of 
events: halogenation of enone 3.9 first and then ketal formation gave the desired product 3.12 in 
excellent yields. 
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Scheme 3.1. Synthesis of iodide 3.12. 
 
The second building block, enone 3.17, was prepared starting from commercially available ketone 
3.13 (Scheme 3.2). In the first step, an enantioselective L-proline-catalyzed α-aminoxylation[69] 
gave 3.14 which was diastereoselectively reduced using K-selectride. Subsequent reductive 
cleavage of the N–O bond, removal of the ketal with concomitant elimination of one secondary 
alcohol, followed by TBS-protection of the remaining hydroxyl group gave rise to enone 3.16.[70] 
From 3.16, iodination and iron-catalyzed cross coupling[71] afforded enone 3.17. 
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Scheme 3.2. Synthesis of enone 3.17. 
 
With both building blocks 3.12 and 3.17 in hand, we began investigating the conjugate addition 
(Table 3.1). Initial attempts using organolithium species 3.21, generated from 3.12 with t-BuLi,[72] 
in combination a variety of copper sources were met with failure. Only starting material 3.17 and 
side products such as 3.18, 3.19 and cyclopropane 3.20 were isolated (Figure 3.1). Vinyl ether 3.20 
presumably arose from the intramolecular, nucleophilic attack of the organolithium species 3.21 
onto the double bond, which could be prevented by keeping the mixture at −78 °C. We then tried 
the conjugate addition in the presence of BF3·Et2O or TMSCl, alone or in combination with 
HMPA,[73] and could isolate some desired product using Li-thienylcyanocuprate[74] together with 
TMSCl/HMPA (Table 3.1, entry 10). After this positive result extensive screening of reaction 
conditions, changing equivalents, solvent and time was necessary (Table 3.2) but ultimately, 
robust conditions could be established that enabled performing the reaction on 2.34 mmol scale.  
 
Figure 3.1. Identified side products of conjugate addition. 
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Table 3.1. Initial screening of conditions for conjugate addition.a 
 
Entry Copper source 
(eq.) 
Eq. of t-
BuLi 
Lewis acid Observation 
1 CuI (0.5) 2 - 3.17 + side products 
2 CuBr·DMS (0.5) 2 - 3.17 + side products 
3 CuCN (0.5) 2 - 3.17 + side products 
4 CuI (0.5) 2 TMSCl 3.17 + side products 
5 CuBr·DMS (0.5) 2 TMSCl 3.17 + side products 
6 CuCN (0.5) 2 TMSCl 3.17 + side products 
7 
Li-thienyl-
cyanocuprate (1) 
2 TMSCl 3.17 + side products 
8 CuBr·DMS (0.5) 2 TMSCl/HMPA 3.17 + side products 
9 CuCN (0.5) 2 TMSCl/HMPA 3.17 + side products 
10 
Li-thienyl-
cyanocuprate (1) 
2 TMSCl/HMPA 3.17 + side products + 3.22 
a) Reactions were carried out on a 0.025 mmol scale. 
Table 3.2. Optimization of conjugate addition. a 
Entry Solvent Eq. of t-BuLi Lewis acid Observation 
1 Et2O/THF 2.0 TMSCl/HMPA 
3.22 + side products 
2 Et2O/THF 1.5 TMSCl/HMPA 
3.22 + side products 
3 Et2O/THF 1.5 TMSBr/HMPA 
3.22 + 3.17 + side products 
4 Et2O/hexane 1.5 TMSCl/HMPA 
3.22 + 3.17 + side products 
5 Et2O/THF 1.0 TMSCl/HMPA 
3.22 + 3.17 + side products 
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6 THF 1.5 TMSCl/HMPA only side products 
7b Et2O/THF 1.5 TMSCl/HMPA 
3.22 + 3.17 + side products 
8 Et2O 2.0 BF3·Et2O 
only side products 
a) Reactions were carried out on a 0.025 mmol scale. b) TMSCl/HMPA added before enone 3.17. 
 
 
Scheme 3.3. Synthesis of epoxide 3.26. 
 
Silyl enol ether 3.22 was then methylated to afford ketone 3.23 which upon treatment with HCl 
underwent global deprotection and oxa-Michael reaction to give tetrahydropyran 3.24 of which 
was verified by X-ray crystallography, confirming the correct configuration at C9 (Scheme 3.3). 
The synthesis proceeded with diastereoselective alkylation of ketone 3.23 resulting in 3.25 of 
which a X-ray crystal structure could be obtained. Subsequent Corey–Chaykovsky epoxidation[75] 
gave the product 3.26 with a d.r. of 1:0.6. Treating epoxide 3.26 with BF3·Et2O promoted ketal 
removal and the desired Meinwald rearrangement[68, 76] to aldehyde 3.27 in low yields with 
oxetane 3.28 formed as the major product (Table 3.3). This side product presumably arose from 
epoxide opening, followed by a Wagner–Meerwein shift and attack of the tertiary cation by the 
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oxygen atom. A number of different Lewis and Brønsted acids were tested (Table 3.3), but 
rearrangement to the undesired oxetane 3.28 could not be prevented. The best result was 
obtained using InCl3
[77] with a 1:0.6 ratio of product 3.27 to side product 3.28 which corresponded 
to the d.r. of epoxide 3.26. These results indicated that only one of the diastereomers of 3.26 was 
able to undergo the Meinwald rearrangement whereas the other one gave oxetane 3.28. Since it 
seemed that formation of significant amounts of 3.28 was unavoidable and its separation from 
product 3.27 was very difficult, we decided to investigate an alternative approach to access 
intermediate 3.27.  
 
Table 3.3. Conditions for rearrangement of epoxide 3.26.a 
 
Entry Lewis/ Brønstedt acid Solvent Ratio of 3.27: 3.28 
1 BF3·Et2O DCM 
0.2:1 
2 BiCl3 benzene 
1:0.6 
3 InCl3 benzene 
1:0.6 
4 p-TSA·H2O benzene 
0.2:1 
5 MgBr2 benzene 
complex mixture 
6 ZnBr2 benzene 
only ketal removal 
7 SnCl4 benzene 
only ketal removal 
8 TiCl4 DCM 
complex mixture 
9 MABR DCM complex mixture 
10 Bi(OTf)3 benzene 
0.6:1 
11 In(OTf)3 benzene 
0.6:1 
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12 Sc(OTf)3 benzene 
0.4:1 
13 Yb(OTf)3 benzene 
0.3:1 
14 PPTS benzene complex mixture 
15 NbCl5 toluene 
complex mixture 
16 (C6F5)3B toluene 
only ketal removal 
17 Et2AlCl DCM 
complex mixture 
18 InCl3 toluene 
1:0.6 
19b InCl3 DCM 
complex mixture 
20 b InCl3 MeCN 
complex mixture 
a) Reactions were carried out on a 3.2 μmol scale. b) 40 °C over night. 
Next, we resorted to the Wittig–Kluge–Levine reaction followed by hydrolysis as an alternative 
homologation strategy. Unfortunately, neither phosphonium salt 3.32[78] nor the less bulky 
phosphine oxide 3.33,[79] nor phosphonate 3.34[80] gave any product. We therefore opted for a 
Peterson olefination using methoxymethyltrimethylsilane (3.31).[81] Deprotonation of 3.31 using s-
BuLi, followed by addition of ketone 3.25 led to the 1,2-addition product 3.30 which was then 
treated with KOt-Bu to elicit the elimination to vinyl ether 3.29. This gave a complex and difficult 
to purify mixture and we therefore decided to isolate adduct 3.30 and treat it with acid, hoping for 
a one-pot elimination followed by hydrolysis. Indeed, the desired aldehyde 3.27 could be isolated 
as a 1:1 mixture of diastereomers in moderate yields. 
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Scheme 3.4. Synthesis of aldehyde 3.27. 
 
With the key intermediate 3.27 in hand, we began screening reagents for the Robinson annulation 
(Table 3.4). Inspired by work of the Yamamoto group, who used L-proline to mediate the 
diastereoselective, intramolecular Michael addition of an aldehyde onto an enone,[82] we 
subjected 3.27 to the same conditions (Table 3.4, entry 1) but observed no reaction, neither at 
elevated temperature nor in the presence of benzylamine[83] (Table 3.4, entry 2 and 3). Attempts 
to engage substrate 3.27 in a productive fashion with other cyclic amines[84] (Table 3.4, entry 4-7) 
were also met with failure. Trying to elicit the intramolecular ring closure with different bases 
mainly led to decomposition (Table 3.4, entry 8-13). We attributed these results to the steric 
hindrance of the substrate and the unfavorable conformation (both large substituents in axial 
positions) necessary to bring the nucleophilic and electrophilic site into close proximity. In light of 
these issues, we decided to focus our attention on a different strategy which is outlined in the 
next section. 
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Table 3.4. Conditions for intramolecular ring closure of 3.27. 
 
Entry Reagents Solvent T [°C] Observation 
1 L-proline DMF r.t. no reaction 
2 L-proline DMF 150 no reaction 
3 
L-proline. 
benzylamine 
DCE 90 no reaction 
4 pyrrolidine DMF 150 decomposition 
5 NH
Ph
Ph
OH
3.36 , benzylamine 
DCE 90 complex mixture 
6 morpholine DMF 150 no reaction 
7 
 
THF 80 complex mixture 
8 NaOMe MeOH r.t. decomposition 
9 NaOMe THF 75 complex mixture 
10 KOt-Bu/TBAB toluene 130 decomposition 
11 KOt-Bu THF r.t. decomposition 
12 DBU toluene 130 decomposition 
13 Et3N toluene 130 
decomposition 
a) Reactions were carried out on a 7.1 μmol scale. 
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3.2. Second Generation Approach 
3.2.1. Retrosynthetic Analysis 
In our 2nd generation strategy (Scheme 3.5), the endgame for wickerol A (3.1) and B (3.2) would 
basically stay the same but we envisioned the common precursor 3.38 to be formed via an 
intramolecular alkylation of 3.29, followed by reduction. Enone 3.29 could be accessed through a 
1,2-methyl addition and Dauben oxidation[85] of spirocycle 3.40 which in turn would arise from a 
double-Michael-reaction[86] of enone 3.41 and diene 3.42. Enone 3.41 is literature known[87] and 
can be prepared from commercially available 3-methyl cyclohexenone (3.43) in three steps 
whereas silyl enol ether 3.42 could be derived from alcohol 3.9, an intermediate from our previous 
approach. This route would allow for rapid assembly of the congested central stereocenters with 
an early stage key step that can be tested with readily available building blocks.  
 
 
Scheme 3.5. 2nd generation retrosynthetic analysis of wickerol A (3.1) and B (3.2). 
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3.2.2. Results and Discussion 
Building block 3.42 was prepared from 3.9 through TBS-protection of the hydroxyl group followed 
by silyl enol ether formation using TBSOTf and Et3N (Scheme 3.6). We could also access 3.43 via 
elimination of the secondary alcohol of compound 3.8 after Lemieux–Johnson cleavage, thereby 
avoiding a deprotection-reprotection sequence, but the overall yield was significantly lower. 
Next, we focused our attention on the synthesis of enone 3.41 (Scheme 3.6). In the first step, 3-
methyl cyclohexenone (3.44) was subjected to conjugate addition with trapping of the enolate as 
TMS-silyl ether 3.45,[88] followed by alkylation to give amine 3.46. This in turn was oxidized with m-
CPBA and underwent a Cope elimination[89] to form volatile enone 3.41 which was kept as a 
solution in toluene at −26 °C to avoid hetero-Diels–Alder reaction. 
 
 
Scheme 3.6. Synthesis of silyl enol ether 3.42 and enone 3.41. 
 
With both building blocks in hand, we began investigation the envisioned double-Michael reaction 
(Scheme 3.7). Intrigued by the work of the Jung group, who reported the double-Michael reaction 
of hindered silyloxydiene-dienophile pairs,[90] we treated 3.42 with Tf2NH in the presence of enone 
3.41 in DCM at −78 °C. In addition to desilylation of 3.42, we did observe the product of the 
Mukaiyama–Michael addition but neither addition of more Tf2NH nor letting the reaction mixture 
warm up to 0 °C led to spirocycle formation, contrary to the examples disclosed by Jung. Changing 
the reaction parameters such as concentration, equivalents, temperature and solvent did not 
change the outcome. We therefore tried to close the 6-membered ring in a separate step and 
subjected silyl enol ether 3.47 to a variety of Lewis acids (Table 3.5). Unfortunately, no product 
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3.48 was isolated and mainly desilylation was observed, presumably due to steric hindrance of the 
substrate. 
 
Scheme 3.7. Attempted double-Michael reaction. 
 
Table 3.5. Conditions for intramolecular Mukaiyama–Michael reaction of 3.47.a 
 
Entry Lewis Acid T [°C] Observation 
1 TBSOTf −78 desilylation 
2 Me3Al −78 to r.t. 
desilylation 
3 Me2AlCl −78 to −20 
desilylation 
4 Et2AlCl −78 to −50 
complex mixture 
5 Sc(OTf)3 0 to r.t. 
complex mixture 
6 Zn(OTf)2 0 to r.t. 
complex mixture 
7 Bi(OTf)3 r.t. 
desilylation 
8 Yb(OTf)3 r.t. 
desilylation 
9 Me3Al/AlBr3 −5 
complex mixture 
10 MeAl(NTf2)2 0 to r.t. 
decomposition 
11 TiCl4 −78 
desilylation 
12 SnCl4 −78 
desilylation 
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13 BF3·Et2O −78 
desilylation 
a) Reactions were carried out on a 7.7 μmol scale. 
Since ring closure via an intramolecular Mukaiyama–Michael reaction was unfruitful, we turned 
our attention to a radical cyclization. Radicals offer the advantage that they can be generated 
under mild conditions and are highly reactive which makes them very useful for the formation of 
congested bonds.[91] To that end, we prepared α-iodoketone 3.49 from 3.47 with I2 in the 
presence of Cu(NO3)2·3H2O
[92] and subjected it to a variety of conditions (Table 3.6). Using AIBN 
with different hydride sources such as Bu3SnH,
[93] TTMSS[94] or Et3SiH
[95] mainly resulted in 
dehalogenation. That was also the case when substoichiometric Bu3SnCl with NaBH4, a 
combination developed by Corey that keeps the Bu3SnH concentration low,
[96] was employed. 
Trying to elicit ring closure using SmI2
[97] was also met with failure so we shifted focus to a Diels–
Alder based strategy to construct spirocycle 3.48, which will be described in the next section. 
 
Table 3.6. Conditions for intramolecular, radical cyclization of 3.49.a 
 
Entry Reagents Solvent Conc.[M] Observation 
1 AIBN, Bu3SnH (ΔT) benzene 0.014 
dehalogenation 
2 AIBN, Bu3SnH (ΔT) benzene 0.002 
dehalogenation 
3 AIBN, TTMSS (h·ν) benzene 0.009 dehalogenation 
4 AIBN, TTMSS (ΔT) benzene 0.002 dehalogenation 
5 AIBN, Et3SiH (h·ν) benzene 0.009 
dehalogenation 
6 AIBN, Bu3SnCl, NaCNBH3 (ΔT) t-BuOH 0.008 
dehalogenation 
7 AIBN, Bu3SnCl, NaCNBH3 (ΔT) EtOH 0.008 
complex mixture 
8 AIBN, Bu3SnCl, NaCNBH3 (h·ν) t-BuOH 0.009 
dehalogenation 
9 Bu6Sn2 (h·ν) benzene 0.009 
dehalogenation 
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10 SmI2 THF 0.015 
dehalogenation 
11 SmI2 THF 0.008 
dehalogenation 
12 SmI2, HMPA THF 0.008 
dehalogenation 
13 SmI2, HMPA, t-BuOH THF 0.008 
dehalogenation 
14 SmI2, HMPA, MeOH THF 0.008 
decomposition 
a) Reactions were carried out on a 7.5–9.4 μmol scale. 
 
 
Part I  45 
 
3.3. Asymmetric Synthesis of the Antiviral Diterpene Wickerol A 
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S.-A. Liu and D. Trauner,  
J. Am. Chem. Soc., 2017, ASAP. 
 
Copyright © 2017 The American Chemical Society 
 
 
 
 
 
 
 
  
Part I  46 
 
 
 
Part I  47 
 
 
 
Part I  48 
 
 
 
Part I  49 
 
 
 
Part I  50 
 
4. Conclusion and Outlook 
In conclusion, the first total synthesis of the complex diterpene wickerol A was accomplished in an 
enantioselective fashion.  
The initial approach envisaged an intramolecular Robinson annulation to construct the complex 
scaffold of the natural product. Preparation of the key precursor 3.27 included a challenging 
conjugate addition, stereoselective methylation and homologation using a Peterson olefination. 
Unfortunately, the desired Robinson annulation could not be achieved, presumably due to the 
steric hindrance of the substrate. In our second generation strategy, we attempted to access 
wickerol A via spirocycle 3.48 which we tried to prepare using a double-Michael reaction of 3.41 
and 3.42 or a radical cyclization of 3.49. But all our efforts in this regard were met with failure, 
which led us to our third and final approach. 
Our successful synthesis was highly convergent through the use of two readily accessible building 
blocks that underwent an extremely challenging Diels–Alder reaction. This cycloaddition built up 
two crucial stereocenters of wickerol A, both of which are neopentyl and one a quaternary carbon, 
demonstrating the remarkable power of the Diels–Alder reaction. Establishing the trans-BA-ring 
junction proved to be problematic but could be achieved through a Pinacol-type rearrangement 
using Grainger´s conditions. The last ring was closed through a remarkable intramolecular 
alkylation between two neopentyl carbons. Having built the congested carbon framework of the 
natural product, stereoselective conjugate addition to the sterically hindered enone introduced 
the C6-methyl group which was followed by a Barton–McCombie deoxygenation. Installation of 
the tertiary alcohol was challenging due to a strong, unfavorable substrate bias but could be 
accomplished using a sequence of olefination followed by Mukaiyama hydration. 
The developed strategy could be used to access wickerol B in the future. 
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Development of a Photoswitchable  
AMPA Receptor Antagonist 
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5. Photopharmacology 
5.1. Introduction 
Pharmacotherapy is a form of therapy that treats a disease through the administration of drugs.[98] 
In a broader sense, this dates back to prehistoric times when herbs were used as medicine. Later 
on, ancient cultures such as the Egyptians or the Babylonians developed treatments for a broad 
variety of ailments. In India and China a large body of pharmacotherapy evolved over centuries 
and has become the basis of aryuveda and traditional Chinese medicine, which are still employed 
today.[99] 
Modern pharmacotherapy is based on pharmacology, the scientific study of the biological effect of 
drugs. The broad range of therapeutics that is available to us nowadays has drastically improved 
the quality and length of life.[100] Nevertheless there are still issues that need to be addressed such 
as drug-selectivity and resistance.[101] Poor drug selectivity is caused by the undesired interaction 
of a drug with targets other than that intended. This is not easily prevented since a drug acts by 
interfering with processes that belong to complex signaling and metabolic pathways.[102] Good 
examples are anti-cancer drugs that impair mitosis of malignant cells but can also affect healthy, 
fast-dividing cells, causing severe side effects such as hair loss, mucositis, and anemia. To alleviate 
this problems, substantial research is aimed at targeted therapy[103] but a universal solution is still 
lacking.[104] Poor selectivity also leads to a lower threshold level of toxicity and consequently a 
smaller therapeutic window. This means that even if a compound is discovered that causes the 
desired effect, its insufficient selectivity precludes it from being used as a treatment.[105]  
To improve drug selectivity, it would be necessary to have better control over its activity in time 
and space; i.e. when and where the drug is active. To achieve this by employing light is the 
fundamental principal underlying photopharmacology.[106] Light as a regulatory element has a lot 
of potential since it can be delivered with very high spatial and temporal precision and regulated 
in a qualitative and quantitative manner by adjusting wavelength and intensity, respectively.[107] In 
previous approaches, ligands with a photolyzable moiety were used, so called “caged ligands”.[108] 
The major limitation of this method is its irreversibility: once photodeprotected, control over the 
drug’s activity is lost. Reversible optical control over biological functions can be achieved using 
optogenetics, which relies on the expression of photoresponsive proteins.[109] Though an 
extremely useful research tool, the necessity for genetic manipulation limits its application. 
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In order to control the function of a bioactive compound with light, photopharmacology uses 
photoswitchable substructures that are introduced into the pharmacophore of a known drug, or 
as an appendage to it. These photo-responsive moieties change the structure of bioactive agents 
upon irradiation with light and consequently their pharmacodynamic and pharmacokinetic 
properties, which are directly related to their molecular structure. In the following section, some 
photoswitchable structures that have been successfully employed are discussed. 
 
5.2. Photoswitches 
Being able to control the conformation and activity of biomolecules in a reversible manner is 
important for studying and interfering with complex processes in living cells. To do this, 
photopharmacology renders small, freely diffusible and bioactive molecules light-sensitive through 
the introduction of molecular photoswitches that undergo a reversible change in their structure 
upon irradiation with light.[110]  
The most common chromophores employed in the field of photopharmacology can be divided into 
two groups: compounds that interconvert between closed and open forms (spiropyrans, 
diarylethenes, and fulgides) (Figure 5.1) or switch between cis- and trans- isomers (azobenzenes, 
stilbenes, and hemithioindigos) (Figure 5.2).[107e] Apart from the geometry, photoisomerization 
may also change the polarity and charge distribution of the compound. Important characteristics 
of photoswitches are the absorption maxima of their isomeric forms which shouldn’t be too 
similar and the photostationary state, defined as the equilibrium composition during irradiation. 
Ideally, photoswitches possess a highly fatigue resistant switching process that is also fast in order 
to prevent competing side-reactions that lead to deexcitation (fluorescence, phosphorescence, 
and unproductive relaxations to the ground state). Furthermore, they should have slow thermal 
relaxation rates and a large extinction coefficient with high quantum yield at wavelengths that are 
nondestructive for a living cell. [107e] 
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Figure 5.1. Photochromic switches that interconvert between closed and open forms. 
 
Diarylethenes possess a hexatriene motif that is incorporated in a tricyclic structure normally 
containing two (hetero)aromatic moieties (Figure 5.1).[111] The triene can undergo a reversible 
conrotatory 6π-electrocyclization to a cyclohexadiene ring upon irradiation. The first diarylethenes 
were established in the mid-1960´s from detailed investigations of the photochemistry of stilbenes 
and heteroarylstilbenes.[112] Later on, the potential of 1,2-diheteroarylethenes as thermally stable 
photochromic switches was recognized and investigated.[113] It was found that their absorption 
spectrum can be modified through the substitution pattern on the rings and that they exhibit very 
high fatigue resistance, meaning that switching cycles can be repeated over several thousand 
times. Diarylethenes with thiophen rings (simplest example being 5.1) have been used to 
photocontrol the inhibition of human carbonic anhydrase I[114] and to regulate the helicity of a 
DNA-binding peptide incorporated into nucleobases.[115] 
As in the case of diarylethenes, the photochromism of fulgides is based on the reversible 
photochemical cyclization of a hexatriene system (Figure 5.1). They were discovered at the 
beginning of the 20th century but it took several decades until the first thermally stable member 
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was synthesized.[116] For the electrocyclization to occur the three conjugated double bonds need 
to be in a s-cis-conformation which is dependent on the steric bulk of the substituents. This means 
that the conformation of fulgides at their ground state influences the quantum yield of 
photocyclization. Thiophenefulgide based switches (for example 5.3) were shown to be able to 
regulate activity of the protease α-chymotrypsin.[117] 
Spiropyrans (simplest example being 5.5, Figure 5.1) also exist in an open and closed form. In their 
case, the spiro-C–O bond undergoes heterolytic cleavage upon UV irradiation which results in a 
zwitterionic conjugated system, called the merocyanine form (5.6).[118] This process is reversible 
both thermally and photochemically, by irradiation with visible light. But there are also cases 
where the isomerization behavior is reversed, that is, visible light shifts the equilibrium toward the 
open state and UV light leads to the closed form.[107e] The photoisomerization also results in a very 
large change in polarity (8−15 D) which has been found to be crucial for protein interactions.[119] 
 
 
Figure 5.2. Photochromic switches that interconvert between cis- and trans-isomers. 
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Stilbenes can be considered a subclass of diarylethene chromophores but they isomerize between 
an E and Z form, instead of undergoing electrocyclization (Figure 5.2).[120] The irradiation of the 
parent compound 5.7 at 313 nm light leads to the cis-isomer, in which the angle between the 
planes of the phenyl rings is 43°.[121] They are stable switches since their barrier for thermal 
relaxation is too high for it to occur at room temperature. Stilbene switches have been used as 
phosphate backbone linkers in DNA oligomers and photoswitchable peptidomimetic inhibitors of 
M. tuberculosis ribonucleotide reductase.[122] A major disadvantage of stilbenes is their tendency 
to undergo irreversible cyclization and oxidation reactions in their cis-form.[123] 
Photochromism based on E to Z isomerization can also be found in hemithioindigos (parent 
compound being 5.8, Figure 5.2), unsymmetrical molecules consisting of a thioindigo fragment 
connected to a stilbene moiety. The Z form is thermodynamically more stable than the E form and 
the barrier for thermal relaxation is usually above 27 kcal/mol making hemithioindigos very 
bistable switches. Their main advantageous feature is that visible light suffices for isomerization 
and their switching behavior can be further tuned through the substituents on the aromatic rings. 
Drawbacks are possible side reactions that can occur upon irradiation such as intermolecular [2+2] 
cycloadditions.[124] Hemithioindigo-based amino acids incorporated into gramicidin ion channels 
were used to modulate the ion current by photoisomerization.[125] 
The most widely employed photoresponsive moieties in photopharmacology are azobenzenes 
(simplest congener being 5.9, Figure 5.2).[106, 126] They were discovered in the 1830´s and due to 
their intense color were used as dyes in the beginning of the 20th century. Other applications 
include therapeutics (prontosil (5.10), sulfasalazine (5.11)) and food-colorants (sunset yellow FCF 
(5.12, E110), allura red AC (5.13, E129)) (Figure 5.3).[127] 
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Figure 5.3. Structure of azobenzenes used as therapeutics and food-colorants. 
 
Azobenzens are diazene derivatives that switch between the trans- and cis-form which results in a 
big geometrical change (the end-to-end atom distance of trans-5.9 is 1.6 times larger than the cis 
one) and a shift in polarity.[128] Relaxation to the thermodynamically more stable trans-form (the 
difference between cis and trans is about 10 kcal/mol) can be achieved either by irradiation with 
light or via thermal isomerization with the half-life of cis-5.9 being about two days.[129] 
Azobenzenes exhibit many favorable features such as high extinction coefficients and quantum 
yields, which means that light of relatively low intensity can be used for photoisomerization. In 
addition, they switch at very fast rates, thus avoiding intersystem crossing and the formation of 
triplet diradicals that could lead to the generation of highly reactive and cytotoxic singlet oxygen. 
Therefore, azobenzenes are relatively photostable and can be switched over many cycles. 
Furthermore, they are easy to synthesize[130] and their spectral properties can be tuned by 
incorporations of different substituents on the aromatic rings. (see Chapter 5.3.). For these 
reasons, azobenzenes have become the most applied photoswitch in photopharmacology to 
date.[106, 109a, 127] 
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5.3. Design Principles 
The following section will discuss various aspects that should be considered when designing a 
photoswitch.[106, 127] The focus will be on azobenzenes but many principles can also be applied to 
other switches. 
 
Biological Activity  
Two general design strategies for turning a drug photoresponsive have evolved so far (Figure 
5.4.a). The first is based on coupling of a photoswitch with the pharmacophore, either through 
partial incorporation into the parent structure or by appendage to it. For this strategy to be 
successful, the photochromic derivative must show a high affinity to the receptor in only one of its 
photoisomeric states. The decrease in binding affinity upon switching can be caused by either 
unfavorable drug-receptor interactions or the inability of the isomer to enter the binding pocket 
due to its shape, size, or polarity. 
The second strategy is only applicable to multivalent drugs, that is, drugs possessing two or more 
pharmacophores connected by a spacer unit (Figure 5.4.b).[131] This spacer unit can be replaced by 
a photoswitch which upon photoisomerization alters the rigidity of the spacer and the distance 
between pharmacophores consequently leading to a change in drug activity. This method has 
been exploited for the development of photoswitchable mast cell activation inhibitors[132] and 
photoswitchable peptidomimetics.[133] 
 
 
Figure 5.4. Schematic representation of the two major strategies employed for designing a 
photochromic ligand. a) The photochromic ligand is not able to bind to the receptor upon 
switching. b) A multivalent ligand that possesses a photoswitch in the spacer unit. The change in 
distance upon isomerization prevents interaction with the receptor.[106] 
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After incorporation of a photoswitchable moiety, the biological activity of the parent compound 
needs to be retained in at least one of the isomers. Most of the time, the structure of therapeutics 
is highly optimized in order to obtain maximal potency and efficacy.[134] Therefore, light-
responsive derivatives of a drug will frequently exhibit decreased activity and further SAR 
(structure activity relationship) studies will be necessary. It is therefore advisable to look at SAR 
studies of the drug one aims to modify and at crystal structures of it bound to the receptor as 
indicators for the likelihood of activity loss. When looking for suitable targets for derivatization, 
one can search for isosteres that can be replaced by the photochromic switch to be employed. In 
the case of azobenzenes, a selection of structural motifs that can be mimicked by an azobenzene 
is depicted in Figure 5.5 They include styrenes (5.7), N-phenyl benzamides (5.14), other types of 
(hetero)aryl−(hetero)aryl amides (5.15, 5.16), benzyl anilines (5.17), benzyl phenyl (thio)ethers 
(5.18, 5.19), 1,2-diaryl ethanes (5.20), and related structures.[127] Several examples for this 
approach (“azologization”) are depicted in Figure 5.6. Azocholine (5.22) is a photoswitchable 
agonist selective for α7 nAChRs based on the antagonist MG-624 (5.21).[135] With alloswitch-1 
(5.24), a positive allosteric modulator of metabotropic glutamate receptors derived from VU-
415374 (5.23), Gorostiza and co-workers were able to control the motility of living tadpoles with 
light.[136] In fotocain (5.26), the benzyl phenyl ether of the anesthetic fomocain (5.25) was 
successfully replaced by an azobenzene.[137] 
 
 
Figure 5.5. A selection of structural motifs that can be mimicked by azobenzenes. 
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Figure 5.6. Examples of isosteres being replaced by azobenzenes. 
 
Another strategy to guide the development of a light-responsive ligand is based on SAR studies. 
These data often reveal which substituents of the parent compound can be varied without 
completely losing biological activity, indicating a good position to incorporate a photoswitchable 
moiety. Some examples of successful appendage of an azobenzene to an existing bioactive 
scaffold are depicted in Figure 5.7. The Feringa group developed quinolone-2 (5.28) based on 
ciprofloxacin (5.27) and demonstrated optical control of antibacterial activity using it.[138] Propofol 
(5.29), a structurally simple GABAA receptor potentiator, could be extended in the 4-position, 
resulting in AP-2 (5.30) which was used as a light-dependent anesthetic in translucent 
tadpoles.[139] The third example is AC-4 (5.32) which is a photoswitchable antagonist of the TRPV1 
ion channel derived by replacing the chlorine residue of capsazepine (5.31) with an azobenzene 
moiety.[140]  
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Figure 5.7. Examples of azobenzene appendage to a known ligand. 
 
After having synthesized a suitable photoresponsive ligand, it is possible that the isomerization is 
inhibited after binding to the receptor. Usually, this does not pose a problem though, since 
receptor binding is a dynamic event and as soon as the compound leaves the binding pocket, it will 
switch.[106] 
 
Photoisomer Ratio at Photostationary State  
It is important to consider the difference in relative concentration of the two photoisomers since 
the extent of isomerization translates directly to the biological effect. For most of the 
photoswitches, it is impossible to push them completely into their thermodynamically less stable 
state through irradiation. Therefore, one needs to take into account the background activity of the 
remaining isomer. In the case of azobenzenes, they can exist 100% in the thermodynamically more 
stable trans-form (also called the dark-adapted form) and their photostationary cis/trans-ratios 
have been reported to exceed 9:1 using appropriate wavelengths.[141] But even if a ligand 
isomerizes only partially, the biological response can easily be optimized by changing the 
concentration of the drug. This independence of a direct attachment to the receptor is one of the 
advantages of photopharmacology in comparison to other methods such as optogenetics. 
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Tuning of Wavelength and Thermal Relaxation 
The wavelength needed for isomerization is a crucial characteristic of a photoswitch and should be 
amenable to tuning. For potential clinical application, UV light cannot be employed as it is 
carcinogenic and can cause mutations. Ideally, only light in the range of 600 to 1200 nm can be 
used, since hemoglobin absorbs shorter wavelengths and water longer ones. For non-invasive 
treatment, tissue penetration of light is an important factor. It is estimated that wavelengths of 
800 nm reach about 2 cm deep and can therefore only interact with areas that are lying close to 
the skin surface.[142]  
The absorption spectra of most chromophores can be modified by changing the substitution 
pattern. Azobenzenes offer the advantage that many methods are available for their synthesis[130] 
and it is possible to adorn the aromatic rings with a broad variety of substituents. In addition, the 
influence of different functional groups on their switching behavior is well studied.[143] Since 
unmodified azo compounds need UV-light for photoisomerization, shifting their absorption 
spectra to longer wavelengths (red-shifting) is important for biological research and future 
applications in vivo. It was found that red-shifting can be achieved by introducing an electron 
donating group (EDG) on one side of the azo unit and electron withdrawing group (EWG) on the 
other, creating a so called “push-pull system”[144] (Figure 5.8, compound 5.33). It is also possible to 
put a single electron-donating group (EDG) at the para- or ortho-position to change the absorption 
maximum to higher wavelengths (Figure 5.8, compound 5.30).[139] This shift is generally 
accompanied by a significant increase in the thermal relaxation rate, which makes an intense light 
source necessary to produce a large steady state fraction of the cis-isomer. Recently though, tetra-
ortho-substituted azobenzenes such as compound 5.34 or 5.36 were developed that can be 
isomerized with visible light and are thermally stable, i.e. exhibit a half-life of several days.[141c] 
Using this strategy, Woolley and co-workers could photoisomerize tetrachloro-5.35 cross-linked 
with fluorescent reporter peptide with red light (λ = 635 nm) in zebrafish embryos.[145]  
Another type of azobenzene that can be switched with visible light is characterized by a C2-linker 
between the two phenyl groups (Figure 5.8). This bridge generates a highly twisted trans-isomer 
that is less stable than the cis-isomer, conversely to standard azobenzenes. It was shown that the 
conformation of a helical peptide linked with cycloazobenzene 5.37 could be controlled with 
visible light.[141b] 
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Figure 5.8. Examples of red-shifted azobenzenes. 
 
Stability in the Cellular Environment and Toxicity  
Two other issues that need to be addressed with regards to clinical applications is the possible 
degradation of photochromic ligands through enzymes[146] or glutathione, the predominant 
intracellular reductant. For azobenzenes, it was shown that reduction to the respective 
hydrazobenzenes by glutathione is possible but that this process is also dependent on the 
substitution pattern and can therefore be prevented.[147]  
Also important is the toxicity of the modified drug and its metabolites. Since azobenzenes have 
been used as dyes for decades, their toxicity has been the subject of various studies. They showed 
that azobenzenes can be cleaved to carcinogenic aromatic amines or oxidized to strongly 
electrophilic diazonium salts.[148] But these findings should not preclude this class of compounds 
from future applications since metabolic stability depends on the exact structure of a molecule. In 
the case of azobenzenes, some congeners have already been used as therapeutics as well as food 
dyes (see Chapter 5.2., Figure 5.3).  
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Even though extensive research still needs to be done to fulfill all the prerequisites for 
pharmacotherapy with photoswitchable drugs, the field of photopharmacology is still in its infancy 
and offers great potential for development. 
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6. AMPA Receptors 
6.1. Ionotropic Glutamate Receptors 
Glutamate receptors (GluRs) are integral membrane proteins that are activated by L-Glutamate 
(6.1, Figure 6.2), the major excitatory neurotransmitter in the mammalian central nervous system 
(CNS). GluRs are responsible for excitatory synaptic transmission and influence synaptic plasticity, 
which is important for memory formation, learning, and regulation.[149] Glutamate receptors can 
be divided into two families: ionotropic (ligand-gated cation channels) and metabotropic (G-
protein coupled) receptors, of which only the former will be discussed in this thesis. 
Ionotropic GluRs (iGluRs) consist of four large subunits (>900 residues) that form a central ion 
channel pore (Figure 6.1). These receptor subunits are modular and contain four discrete domains: 
the extracellular amino-terminal domain (ATD), the extracellular ligand-binding domain (LBD), the 
transmembrane domain (TMD) that forms the cation-selective pore and an intracellular carboxyl-
terminal domain (CTD). The form of both the ATD and LBD of iGluRs are often described as 
clamshells (or Venus fly-traps).[150] 
 
Figure 6.1. Schematic depiction of iGluRs. 
 
iGluRs are grouped into four distinct classes based on pharmacology and structural homology: 
AMPA receptors (GluA1–GluA4), kainate receptors (GluK1–GluK5), NMDA receptors (GluN1, 
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GluN2A–GluN2D, GluN3A, and GluN3B), and the δ receptors (GluD1 and GluD2). The first three 
subtypes are well studied and are named after their selective agonists: N-methyl-D-aspartate (6.2), 
kainic acid (6.3) and 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid (6.4) (Figure 
6.2).[150-151] The last class, δ receptors, is placed within the family of iGluRs only based on sequence 
homology.[152] So far, no ligand-mediated activation was observed and whether they serve as ion 
channels or have a metabotropic function is still a subject of ongoing research.[153] 
 
 
Figure 6.2. The universal and the three subtype-selective agonists, and co-agonist glycine (6.5). 
 
NMDA receptors function as modulators of synaptic response as well as co-incidence detectors. 
They are heterotetramers and their activation requires the binding of both glutamate (6.1) and 
glycine (6.5). While this process is responsible for opening and closing of the ion channel, the 
current flow through the channel is voltage dependent. Extracellular Mg2+- and Zn2+-ions can block 
the channel pore, preventing the flow of ions. Depolarization of the cell is necessary to release this 
channel inhibition, allowing Na+- and Ca2+-ions into the cell and K+ out of the cell. The influx of 
Ca2+-ions can then lead to the activation of a variety of signaling pathways.[154] 
Kainate receptors are selectively activated by kainic acid (6.3) which was isolated from red algae 
Digenea simplex and is a powerful neurotoxin that when injected into the mammalian brain leads 
to neuropathological lesions and seizures. Kainate receptors are built from multimeric assemblies 
of GluK1-3 and GluK4,5 subunits. Their function is less understood compared to NMDA or AMPA 
receptors but recent studies have shown that they are not predominantly found in excitatory 
postsynaptic signaling complexes but act principally as modulators of synaptic transmission and 
neuronal excitability. One way to perform these functions is as presynaptic regulators of 
neurotransmitter release. In addition, findings indicate that some of their neuronal function is 
mediated through non-canonical metabotropic signaling pathways.[155] 
AMPA receptors are responsible for fast synaptic transmission in the CNS and their expression, 
assembly, trafficking and turnover are crucial for synaptic plasticity, neuronal development and 
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neurological diseases.[156] They consist of tetramers composed of the subunits GluA1-4.[157] In 
addition, all AMPA subunits exist as two spliced forms, known as Flip and Flop. Although the 
change in the receptor subunits is small (they differ only in a few amino acids), the effect results in 
altered desensitization kinetics. 
Each AMPA receptor exhibits four agonist-binding sites of which two need to be occupied by a 
ligand for activation of the ion channel to occur. Upon binding, a change in protein conformation 
opens the ion channel and cation influx leads to a local change in membrane potential known as 
an excitatory post-synaptic potential. Most AMPA receptors are permeable to only Na+ and K+ but 
not Ca2+.[158] It was found that this selectivity is regulated by the presence of the GluA2 subunit 
and receptors lacking GluA2 are Ca2+ permeable.[159] 
 
6.2. AMPA Agonists and Antagonists 
Studies of crystal structures of agonists and antagonists bound to iGluR LBDs have shown that 
agonists bind in the cleft between each shell which leads to a partial closure of the LBD-
clamshell.[160] Most agonists and partial agonists of AMPA receptors are derivatives of glutamate 
(6.1) as they invariably feature the α-amino acid moiety of the neurotransmitter. In contrast, the 
carboxylic acid end of 6.1 can be replaced by a variety of structural motifs without losing agonist 
activity.[151a] Some selected examples of agonists are shown in Figure 6.3. Quisqualic acid (6.6) is 
one of the most potent AMPA agonists known and is used in neuroscience to induce excitotoxicity. 
Originally, AMPA receptors were named after quisqualic acid (6.6) but were renamed because 6.6 
would also bind to other glutamate receptors.[161] Willardiine (6.7) is another natural occurring 
agonist and has been subject to SAR studies. It was found that halogenation at the C5-position has 
a huge influence on potency (decreases with increasing bulk of the residue) and selectivity.[162]  
Many agonists bind to both AMPA and kainate receptors but despite the large number of ligand-
bound X-ray structures, it is not possible to predict selectivity based on the molecular scaffold. 
AMPA (6.4) has been used as a template for many derivatives and the structure-activity 
relationships of this class of agonists are well defined. The isoxazole ring can be substituted with a 
variety of residues at position 5, which can lead to selectivity within receptor families. For 
instance, the bulky tert-butyl substituent on the heterocycle in ATPA (6.8) provides very high 
selectivity for GluK1[163] while Bn-Tet-AMPA (6.9) was found to be selective for GluA2-4.[164] 
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Figure 6.3. Examples of AMPA receptor agonists. 
 
The two biggest classes of AMPA antagonists comprise amino acid derivatives and 
quinoxalines.[165] For the former, the structure of AMPA (6.4) has been used as a template, an 
interesting example being APPA (6.10) whose (S)-form is a full agonist whereas the (R)-form acts 
as an antagonist (Figure 6.4).[166] Other examples are AMOA (6.11), a selective but weak AMPA 
receptor antagonist,[167] ATOA (6.12) and ATPO (6.13) which are more potent and selective than 
AMOA (6.11). SAR studies showed that the distal acid moiety is important for the activity, with the 
phosphonic acid generally being more effective than the corresponding carboxylic acid.[168] 
Another well studied amino-acid based family of antagonists is the decahydroisoquinolines. In this 
case, receptor activity was found to depend on the length of the polar side chain and the ring-
junction (trans-derivatives are inactive).[169] Two examples are compounds LY293558 (6.14) and 
LY377770 (6.15) which both have shown in vivo efficacy as neuroprotectants. 
 
Figure 6.4. Examples of amino acid derived AMPA receptor antagonists. 
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The second big class of AMPA antagonists constitutes quinoxaline derivatives with CNQX (6.16), 
DNQX (6.17) and NBQX (6.18) being some of the first members of this family (Figure 6.5.a).[170] 
While 6.16 and 6.17 also bind to the Gly/NMDA binding site, NBQX (6.18) exhibits better 
selectivity and was therefore frequently used to study AMPA receptors in the past.[171] One of the 
biggest drawbacks of these first generation antagonists is their poor water solubility. To alleviate 
this issue, hydrophilic groups were introduced to the quinoxalinedione scaffold, resulting in 
compounds such as YM872 (6.19, Zonampanel)[172] or MPQX (6.20, fanampanel, ZK200775).[173] 
Both have entered clinical trials for treating cerebral ischemia, but these trials had to be halted 
due to severe side effects.[174]  
Based on a broad body of SAR studies, a number of structural features could be revealed that are 
important for antagonist activity: (i) the amino group at position 1 that acts as a proton donor and 
binds to a proton acceptor site of the receptor; (ii) the 2,3-dione moiety, which serves as a potent 
hydrogen bond acceptor; (iii) a strong EWG, such as NO2, CN, CF3 or halogen, as R4, which 
increases the acidity of the nitrogen at position 1 and can engage in a weak hydrogen bond 
interaction with a suitable receptor site. In addition, the introduction of a polar hydrophilic 
functionality as R1 improves solubility (Figure 6.5.b). 
[165, 175] 
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Figure 6.5. a) Examples of quinoxaline based AMPA receptor antagonists. b) Crucial structural 
features for quinoxaline-antagonists. 
 
6.3. Photochromic AMPA Receptor Agonist 
Due to the crucial role AMPA receptors play in the CNS, the ability to control their activity by light 
represents a useful tool for studying their function. Previous efforts in our group have resulted in 
the development of a photochromic AMPA receptor agonist.[176] The design of the photoswitch 
was based on the highly selective agonist Bn-Tet-AMPA (6.9), a derivative of AMPA (6.4). The X-ray 
structure of Bn-Tet-AMPA (6.9) bound to the GluA2 LBD, published in 2005, indicated that 
substitution of the benzene ring of 6.9 in meta-position would be tolerated without loss of 
activity.[177] Based on this hypothesis, azobenzenes 6.21–6.23 were synthesized and termed ATAs 
(azobenzene tetrazolyl AMPAs) (Figure 6.6). Their biological activity was assessed using whole-cell 
patch-clamp electrophysiology in mouse cortical slices and HEK293T cells, transiently expressing 
GluA2 receptors. Out of compounds 6.21–6.23, 6.23 proved to be the most effective trans-agonist 
in HEK293T cells. ATA-3 (6.23) elicited the strongest inward current in its dark-adapted trans-state, 
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while irradiation with 480 nm light led to isomerization to its inactive cis-form (Figure 6.7). In 
addition, ATA-3 (6.23) was able to control the action potential firing of mouse cortical neurons and 
exhibited selectivity for AMPA over kainate and NMDA receptors. 
 
 
Figure 6.6. Structure of Bn-Tet-AMPA (6.9) and ATA-2-4 (6.21–6.23). 
 
 
Figure 6.7. Light-induced current recorded from GluA2-expressing cells. a) Action spectrum of 
ATA-3 (6.23), b) Action spectrum recorded with intermittent darkness from a different cell (c = 50 
mM). 
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Subsequent studies in blind mice retinae revealed that ATA-3 (6.23) was able to confer light 
sensitivity on the retinal tissue by primarily acting on amacrine and retinal ganglion cells. This 
approach represented a conceptually novel way for the restoration of vision, as previously 
demonstrated using photochromic channel blockers.[178] 
 
6.4. Project Outline 
AMPA receptors have been the focus of extensive research since they are responsible for the 
majority of the fast excitatory communication at synapses in the brain and influence synaptic 
plasticity, assumed to be crucial for memory and learning.[149, 151a, 179] In addition, they are involved 
in many neurological diseases such as amyotrophic lateral sclerosis, epilepsy and Alzheimer’s 
disease which make them potential therapeutic targets.[180] Much effort has been put into the 
development of AMPA antagonists for clinical applications and in 2012 perampanel (6.24) was the 
first non-competitive antagonist to be approved (Figure 6.8). Sold under the name Fycompa, 6.24 
is used for the treatment of partial-onset seizures in people with epilepsy.[181] 
 
 
Figure 6.8. Structure of perampanel (6.24), the first non-competitive AMPA antagonist used as a 
therapeutic and and ANQX (6.25), a caged AMPA antagonist. 
 
Even though AMPA receptors have been the focus of many studies, there is still a lot unknown 
about their function and regulation. Being able to reversibly activate an AMPA selective ligand 
with light would provide a useful tool for investigating these issues with unparalleled 
spatiotemporal control. At that point, only one light-responsive antagonist existed, the caged 
ligand ANQX (6.25) (Figure 6.8).[182] With 6.25 the England group showed the inhibition of AMPA 
receptors in Xenopus oocytes upon irradiation with UV light. The disadvantage of this approach is 
its irreversibility: uncaging of ANQX (6.25) leads to the formation of a nitrene species (structure 
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not shown) that inserts into either the peptide backbone or the amino acid side chains of the 
protein to which it is bound, permanently altering the receptor. We therefore aimed to develop a 
photoswitchable antagonist that can be reversibly turned on and off. To this end, we used the 
antagonist MPQX (6.20)[173] as a template and wanted to replace the morpholine group with an 
azobenzene. Previous work in our group focusing on the synthesis of azobenzene 6.27 (Scheme 
6.1) showed that intermediate 6.26 could be accessed via Suzuki-coupling but reduction of the 
nitro group was problematic. In light of this issue, we wanted to synthesize 6.27 using a different 
route, including Suzuki coupling of 6.29 and 6.30 and late-stage formation of the azobenzene 
moiety through an azo-coupling with 6.31. This strategy would also be amenable for the 
preparation of other derivatives with different substitution patterns. 
 
 
Scheme 6.1. Past and future approach towards azobenzene 6.27. 
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7. Results and Discussion 
 
7.1. Optical control of AMPA receptors using a photoswitchable quinoxaline-2,3-
dione antagonist 
 
 
 
 
Reprinted with permission from: 
D. M. Barber, S.-A. Liu, K. Gottschling, M. Sumser, M. Hollmann, D. Trauner,  
Chem. Sci. 2017, 8, 611-615. 
 
Copyright © 2016 The Royal Society of Chemistry 
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8. Conclusion and Outlook 
In the second part of this thesis, the development of the first photoswitchable AMPA receptor 
antagonist, named ShuBQX-3, is described. The design is based on the known antagonist MPQX 
(6.20) in which the morpholine residue is replaced by a phenylazo group. ShuBQX-3 was 
synthesized in six steps from commercially available material including a Buchwald-Hartwig cross-
coupling to connect the two aromatic rings. Using patch-clamp electrophysiology of HEK293T cells 
expressing GluA1 receptors ShuBQX-3 was identified as an excellent photoswitchable antagonist 
of AMPA receptors. ShuBQX-3 is active in its trans-form and switches to its less active cis-isomer 
upon illumination with 460 nm light. We could also show that ShuBQX-3 is able to control action 
potential firing in hippocampal CA1 neurons. In addition, a significant difference between the 
optimal photoswitching wavelengths established by the UV-Vis experiments and the physiological 
patch-clamp experiments was observed. Presumably, this interesting red-shift is caused by 
interactions with the AMPA receptor ligand binding site.  
Efforts to make a tethered ligand out of ShuBQX-3 are under way in our laboratory. 
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9. Summary 
Part I: In the first part of this thesis, the total synthesis of wickerol A is described. Our initial 
approach was based on a Robinson annulation to construct the congested scaffold of the natural 
product. To this end, we prepared building block 9.1 and 9.2 which were combined through a 
conjugate addition. Silyl enol ether 9.3 was then methylated twice and elaborated to aldehyde 9.4 
using a Peterson olefination, followed by hydrolysis. With key intermediate 9.4 in hand, we tested 
various amines and bases for the intramolecular conjugate addition, the initial step of the 
Robinson annulation but could not observe any product 9.5, presumably due to the steric 
hindrance of the substrate. In light of these results, we began investigating a different approach 
towards the synthesis of wickerol A.  
 
Scheme 9.1.1st generation route to wickerol A featuring a Robinson annulation as key the step. 
 
In our 2nd generation approach we planned to access wickerol A via spirocycle 9.8 which could 
arise from either an intramolecular Mukaiyama–Michael reaction of 9.6 or a radical cyclization of 
α–iodoketone 9.7. Unfortunately, all our attempts to close the 6-membered ring were met with 
failure, therefore we turned our attention to a Diels–Alder reaction to access 9.8, which ultimately 
led to the successful synthesis of wickerol A.  
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Scheme 9.2. Attempts at formation of spirocycle 9.8. 
 
The envisioned intermolecular cycloaddition represented a major challenge since both partners 
(9.9 and 9.10), though electronically matched, were very sterically hindered. After extensive 
experimentation, we found that a mixture of AlBr3/AlMe3 gave the desired product 9.11 as a single 
diastereomer. Through this single step, two crucial stereocenters of wickerol A, both of which are 
neopentyl and one a quaternary carbon, were set. 
With three of the four rings of the natural product established, we installed the challenging trans-
BA ring junction using a Pinacol-type rearrangement of diol 9.12. Alcohol 9.13 was then 
elaborated to enone 9.14 which underwent the key intramolecular alkylation, completing the 
congested 6-5-6-6 scaffold of wickerol A. This ring closure is rather remarkable considering the 
syn-pentane strain built up in the C–C bond formation between the two neopentyl positions. 
Subsequent modifications of enone 9.15 include a stereoselective conjugate addition to introduce 
the C6-methyl group and a Barton–McCombie deoxygenation. The final challenge was the 
installation of the tertiary alcohol. Addition of a nucleophilic methyl group to the requisite ketone 
gave the undesired epimer of wickerol A. To overcome this strong, unfavorable substrate bias a 
sequence of olefination followed by Mukaiyama hydration was employed. 
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Scheme 9.3. Synthesis of wickerol A. 
 
Part II: The second part of this thesis focuses on the development of a photoswitchable AMPA 
receptor antagonist. AMPA receptors represent one of four subclasses of ionotropic glutamate 
receptors and mediate most excitatory neurotransmission in the central nervous system. They are 
also implicated in processes such as memory and learning as well as various psychiatric disorders. 
Based on the antagonist MPQX (6.20), several derivatives incorporating an azobenzene moiety 
were synthesized and evaluated using patch-clamp electrophysiology of HEK293T cells expressing 
GluA1 receptors. Amongst them, ShuBQX-3 was identified as an excellent photoswitchable 
antagonist of AMPA receptors. Active in its trans-form, ShuBQX-3 can be switched to its less active 
cis-isomer upon illumination with 460 nm light.  Using Xenopus oocytes expressing a variety of 
glutamate receptors, we found that ShuBQX-3 is partially selective for AMPA receptors over 
kainate, whilst having significantly reduced levels of antagonism at NMDA receptors. We could 
also show that ShuBQX-3 is able to control action potential firing of mouse cortical neurons. 
Furthermore, a remarkable difference between the optimal photoswitching wavelengths 
established by the UV-Vis experiments and the physiological patch-clamp experiments was 
observed. Presumably, this interesting red-shift is caused through interactions of ShuBQX-3 with 
the AMPA receptor ligand binding site.  
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Figure 9.1. a) trans- and cis -form of ShuBQX-3. b) Action spectrum of ShuBQX-3 (20 µM) under 
illumination with orange light (600 nm) and varying wavelengths (400 nm – 500 nm). 
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10. Experimental Section 
10.1. General Experimental Details 
All reactions were carried out with magnetic stirring, and if moisture or air sensitive, under 
nitrogen atmosphere using standard Schlenk techniques in oven-dried glassware (200 °C oven 
temperature), further dried under vacuum with a heat-gun at 450 °C. External bath temperatures 
were used to record all reaction temperatures. Low temperature reactions were carried out in a 
Dewar vessel filled with Et2O/liq. N2 (–115 °C), acetone/dry ice (–78 °C) or distilled water/ice (0 °C). 
High temperature reactions were conducted using a heated silicon oil bath in reaction vessels 
equipped with a reflux condenser or in a pressure tube. Tetrahydrofuran (THF) and diethyl ether 
(Et2O) were distilled over sodium and benzophenone prior to use. Dichloromethane (DCM), 
triethylamine (Et3N), diisopropylethylamine (DIPEA) and diisopropylamine (DIPA) were distilled 
over calcium hydride under a nitrogen atmosphere. All other solvents were purchased from Acros 
Organics as ‘extra dry’ reagents. All other reagents with a purity > 95% were obtained from 
commercial sources (Sigma Aldrich, Acros, Alfa Aesar and others) and used without further 
purification. 
 
Flash column chromatography was carried out with Merck silica gel 60 (0.040-0.063 mm).  
 
Analytical thin layer chromatography (TLC) was carried out using Merck silica gel 60 F254 glass-
backed plates and visualized under UV light at 254 nm. Staining was performed with ceric 
ammonium molybdate (CAM) or by oxidative staining with an aqueous basic potassium 
permanganate (KMnO4) solution and subsequent heating. 
 
NMR spectra (1H NMR and 13C NMR) were recorded in deuterated chloroform (CDCl3), benzene 
(C6D6) or dichloromethane (CD2Cl2) on a Bruker Avance III HD 400 MHz spectrometer equipped 
with a CryoProbe™, a Varian VXR400 S spectrometer, a Bruker AMX600 spectrometer or a Bruker 
Avance III HD 800 MHz spectrometer equipped with a CryoProbe™ and are reported as follows: 
chemical shift δ in ppm (multiplicity, coupling constant J in Hz, number of protons) for 1H NMR 
spectra and chemical shift δ in ppm for 13C NMR spectra. Multiplicities are abbreviated as follows: 
s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, br = broad, m = multiplet, or 
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combinations thereof. Residual solvent peaks of CDCl3 (δH = 7.26 ppm, δC = 77.16 ppm), C6D6 (δH = 
7.16 ppm, δC = 128.06 ppm), CD2Cl2 (δH = 5.32 ppm, δC = 54.00 ppm), CD3OD (3.31 ppm) and 
(CD3)2SO (2.50 ppm) were used as an internal reference. The 
19F NMR shifts are reported in ppm 
related to the chemical shift of trichlorofluoromethane. The 31P NMR shifts are reported in ppm 
related to the chemical shift of 85% phosphoric acid. NMR spectra were assigned using 
information ascertained from COSY, HMBC, HSQC and NOESY experiments. All raw fid files were 
processed and the spectra analysed using the program MestReNova 9.0 from Mestrelab Research 
S. L. 
 
High resolution mass spectra (HRMS) were recorded on a Varian MAT CH7A or a Varian MAT 711 
MS instrument by electron impact (EI) or electrospray ionization (ESI) techniques at the 
Department of Chemistry, Ludwig-Maximilians-University Munich. 
 
Infrared spectra (IR) were recorded from 4000 cm−1 to 600 cm−1 on a PERKIN ELMER Spectrum BX 
II, FT-IR instrument. For detection a SMITHS DETECTION DuraSamplIR II Diamond ATR sensor was 
used. Samples were prepared as a neat film or a thin powder layer. IR data in frequency of 
absorption (cm−1) is reported as follows: w = weak, m = medium, s = strong, br = broad or 
combinations thereof. 
 
Melting points were measured with a BÜCHI Melting Point B-450 instrument in open 
glascapillaries and are uncorrected. 
 
Optical rotation values were recorded on an Anton Paar MCP 200 polarimeter. The specific 
rotation is calculated as follows: [α]
D
25
 = 
∝ × 
 × 
 
Thereby, the wavelength λ is reported in nm and the measuring temperature in °C. α represents 
the recorded optical rotation, c the concentration of the analyte in 10 mg/mL and d the length of 
the cuvette in dm. Thus, the specific rotation is given in 10−1·deg·cm2 ·g−1. Use of the sodium D line 
(λ = 589 nm) is indicated by D instead of the wavelength in nm. The sample concentration as well 
as the solvent is reported in the relevant section of the experimental part. 
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X-ray diffraction analysis was carried out by Dr. Peter Mayer (Ludwig-Maximilians-Universität 
München). The data collections were performed an a Bruker D8Venture using MoKα-radiation (λ = 
0.71073 Å, graphite monochromator). The CrysAlisPro software (version 1.171.33.41) was applied 
for the integration, scaling and multi-scan absorption correction of the data. The structures were 
solved by direct methods with SIR9713 and refined by least-squares methods against F2 with 
SHELXL-97.14. All non-hydrogen atoms were refined anisotropically. The hydrogen atoms were 
placed in ideal geometry riding on their parent atoms. Further details are summarized in the 
tables at the different sections. Plotting of thermal ellipsoids in this document and in the main text 
was carried out using Ortep-3 for Windows. 
UV-Vis spectra were recorded on a Varian Cary 50 Scan UV-Vis spectrometer using Helma 
SUPRASIL precision cuvettes (10 mm light path).  
 
LCMS was performed on an Agilent 1260 Infinity HPLC System, MS-Agilent 1100 Series, Type: 
1946D, Model: SL, equipped with a Agilent Zorbax Eclipse Plus C18 (100 × 4.6 mm, particle size 3.5 
micron) reverse phase column. Retention times (tR) are given in minutes (min). 
 
All yields are isolated, unless otherwise specified. 
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10.2. Supporting Information for Chapter 3.1. 
10.2.1. Experimental Procedures 
Synthesis and characterization of compound 3.11 
 
 
To a pale yellow solution of alcohol 3.9 (1.00 g, 6.48 mmol, 1.00 eq.) in THF (75 mL) was added 
PPh3 (1.87 g, 7.13 mmol, 1.10 eq.) and imidazole (0.883 g, 13.0 mmol, 2.00 eq.). The solution was 
cooled to 0 °C and I2 (2.14 g, 8.43 mmol, 1.30 eq.) was added. The mixture was stirred for 5 h at 
r.t. and then quenched with a sat. aq. solution of Na2S2O3 (100 mL). The aqueous phase was 
extracted with Et2O (3 x 100 mL) and the combined organic layers were dried over MgSO4, 
filtrated, concentrated in vacuo to give a yellow-brown solid. Purification by flash column 
chromatography (hexanes/EtOAc = 1:0 to 9:1) afforded iodide 3.11 (1.30 g, 4.92 mmol, 76%) as a 
yellow oil.  
 
Rf = 0.30 (hexanes/EtOAc 9:1). 
 
1
H NMR (400 MHz, C6D6): δ = 5.80 (q, J = 1.6 Hz, 1H), 2.65 (d, J = 1.5 Hz, 2H), 2.53 – 2.36 (m, 2H), 
1.89 (d, J = 1.0 Hz, 3H), 1.58 – 1.48 (m, 1H), 1.32 (ddd, J = 13.7, 8.7, 5.6 Hz, 1H), 0.86 (d, J = 1.0 Hz, 
3H). 
 
13
C NMR (100 MHz, C6D6): δ = 195.2, 147.1, 144.9, 50.1, 36.1, 30.1, 26.4, 25.7, 19.2. 
 
IR (ATR): ṽ = 2957 (m), 2862 (w), 1667 (s), 1616 (m), 1452 (m), 1367 (m), 1306 (m), 1271 (m), 1199 
(m), 1131 (w), 933 (w), 867 (m) cm−1. 
 
HRMS (EI): calc. for C9H13OI [M+H]
+: 265.0084, found: 265.0079. 
 
[α]
D
25
 = −8.1 (c = 1.0, CHCl3) 
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Synthesis and characterization of compound 3.12 
 
 
To a solution of iodide 3.11 (0.553 g, 2.09 mmol, 1.00 eq.) in DCM (31mL) was added p-TSA·H2O 
(39.8 mg, 0.209 mmol, 0.100 eq.), ethylene glycol (2.52 mL, 41.8 mmol, 20.0 eq.) and HC(OEt)3 
(3.48 mL, 20.9 mmol, 10.0 eq.). The solution was stirred for 1 h at r.t. before the reaction was 
quenched through addition of Et3N (1 mL) and a sat. aq. solution of NaHCO3 (30 mL). The reaction 
mixture was extracted with DCM (4 x 30 mL), dried over MgSO4, filtered and concentrated in 
vacuo. Thus obtained crude material was purified by flash column chromatography 
(hexanes/EtOAc = 1:0 to 9:1) to give acetal 3.12 (0.586 g, 1.90 mmol, 91%) as a colorless oil.  
 
Rf = 0.42 (hexanes/EtOAc 9:1). 
 
1
H NMR (400 MHz, C6D6): δ = 5.43 (q, J = 1.7 Hz, 1H), 3.59 – 3.52 (m, 4H), 2.83 (s, 1H), 2.39 – 2.19 
(m, 3H), 1.78 (ddd, J = 13.9, 8.8, 5.4 Hz, 1H), 1.52 (s, 3H), 1.51 – 1.45 (m, 1H), 0.99 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 146.0, 132.9, 107.3, 64.8, 64.6, 49.1, 37.2, 30.8, 26.3, 24.2, 21.8. 
 
IR (ATR): ṽ = (cm−1): 2951 (m), 2882 (m), 1452 (w), 1371 (m), 1302 (w), 1254 (m), 1187 (s), 1131 
(m), 1107 (m), 1039 (s), 946 (m), 858 (s) cm−1. 
 
HRMS (EI): calc. for C11H17O2I [M-H]
+: 307.0195, found: 307.0191. 
 
[α]
D
25
 = −19.7 (c = 1.00, CHCl3 )  
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Synthesis and characterization of compound S3.1 
 
 
A solution of enone 3.16 (1.72 g, 7.61 mmol, 1.00 eq.) and pyridine (1.66 mL, 20.5 mmol, 2.70 eq.) 
in DCM (39 mL) was cooled to 0 °C. I2 (2.90 g, 11.4 mmol, 1.50 eq.) was added and the solution 
warmed to r.t.. After stirring for 3 h a sat. aq. solution of Na2S2O3 (40 mL) was added and the 
aqueous phase was extracted with Et2O (3 x 40mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash column 
chromatography (hexanes/EtOAc = 1:0 to 9:1) to give iodocyclohexenone S3.1 (2.04 g, 5.78 mmol, 
76%) as a dark yellow oil. The analytical data of S3.1 was in accordance to the reported one.[183] 
 
 
Synthesis and characterization of compound 3.17 
 
 
To solution of cyclohexenone S3.1 (1.93 g, 5.48 mmol, 1.00 eq.) in THF (67 mL) and NMP (4.8 mL) 
was added Fe(acac)3 (0.194 g, 0.548 mmol, 0.100 eq.). The solution was cooled to 12 °C and a 
solution of MeMgCl in THF (3.0 M, 2.00 mL, 6.03 mmol, 1.10 eq.) was added slowly. After stirring at 
12 °C for 40 min, the reaction was quenched through addition of aq. HCl (1M, 20 mL) and H2O (50 
mL). The aqueous phase was extracted with Et2O (4 x 50 mL), the combined organic layers were 
washed with a sat. aq. solution of NaHCO3 (200 mL), dried over MgSO4, filtered and concentrated 
in vacuo. Thus obtained crude product was subjected to flash column chromatography 
(hexanes/EtOAc = 1:0 → 98:2 → 97:3 → 95:5) to afford methylcyclohexenone 3.17 (1.11 g, 4.60 
mmol, 84%) as a pale yellow liquid.  
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Rf = 0.32 (hexanes/EtOAc 9:1). 
 
1
H NMR (400 MHz, CDCl3): δ = 6.59 (q, J = 1.8 Hz, 1H), 4.49 (ddd, J = 9.1, 4.7, 2.3 Hz, 1H), 2.57 (dt, J 
= 16.7, 4.5 Hz, 1H), 2.31 (ddd, J = 17.0, 12.9, 4.6 Hz, 1H), 2.18 (dq, J = 11.0, 4.6 Hz, 1H), 1.95 (tdd, J 
= 13.0, 9.1, 4.3 Hz, 1H), 1.76 (s, 3H), 0.91 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H). 
 
13
C NMR (100 MHz, CDCl3): δ = 199.3, 149.1, 135.1, 67.5, 35.7, 33.5, 25.9, 18.3, 15.9, −4.5, −4.6. 
 
IR (ATR): ṽ = 2953 (m), 2929 (m), 2886 (w), 2857 (m), 1681 (s), 1471 (w), 1359 (m), 1252 (m), 1118 
(m), 1103 (s), 1075 (s), 987 (w), 965 (w), 868 (s), 836 (s), 808 (m), 776 (s), 667 (w) cm−1. 
 
HRMS (EI): calc. for C13H24O2Si [M]
+: 240.1540, found: 240.1543. 
 
[α]
D
25
 = −54.2 (c = 0.31, DCM) 
 
 
Synthesis of compound 3.22 
 
A solution of iodide 3.12 (1.33 g, 4.32 mmol, 2.00 eq.) in Et2O (77  mL) was cooled to −78 °C and a 
solution of t-BuLi in pentane (1.44 M, 4.7 mL, 6.77 mmol 3.00 eq.) was added. The mixture was 
stirred for 1 h at −78 °C before a solu^on of Li-thienylcyanocuprate in THF (0.25 M, 17.3 mL, 4.32 
mmol, 2.00 eq.) was added. After 30 min stirring at −78 °C, a solu^on of compound 3.17 (562 mg, 
2.34 mmol, 1.00 eq.) with freshly distilled TMSCl (0.90 mL, 7.09 mmol, 3.03 eq.) and HMPA 
(1.00 mL, 5.75 mmol, 2.46 eq.) in THF (23 mL) was added. After stirring for 1 h at −78 °C the 
reaction was quenched through addition of a mixture of aq. sat. NH4Cl-solution and aq. NH3-
solution (9:1, 200 mL). The aqueous layer was extracted with n-pentane (3 x 150 mL) and the 
combined organic layers were washed with brine. The organic phase was dried over MgSO4, 
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filtered and concentrated in vacuo to afford the crude product 3.22 (1.53 g, 3.10 mmol) as a blue-
green oil which was used in the next step without further purification.  
 
Rf = 0.53 (hexanes/EtOAc 9:1)  
 
 
Synthesis and characterization of compound 3.23 
 
 
A solution of silyl enol ether 3.22 (1.53 g, 3.10 mmol, 1.00 eq.) in THF (130 mL) was cooled to 0 °C 
and a solution of MeLi in Et2O (1.6 M, 2.35 mL, 3.76 mmol, 1.21 eq.) was added. The solution was 
stirred for 30 min at 0 °C before it was cooled to −78 °C and HMPA (8 mL) followed by MeI (2.30 
mL, 37.0 mmol, 11.9 eq.) was added slowly. The reaction mixture was warmed to −30 °C over 2 h 
and then quenched through addition of an aq. sat. solution of NH4Cl (150 mL) and H2O (100 mL). 
The aqueous layer was extracted with EtOAc (3 x 200 mL), the combined organic layers were 
washed with brine (3 x 200 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash column chromatography (hexanes/Et2O = 1:0 to 85:15) to afford 
compound 3.23 (788 mg, 1.80 mmol, 77% over two steps) as a pale yellow oil.  
 
Rf = 0.43 (hexanes/EtOAc 85:15)  
 
1
H NMR (600 MHz, C6D6): δ = 5.60 (t, J = 1.9 Hz, 1H), 3.75 (td, J = 5.3, 3.3 Hz, 1H), 3.58 (dd, J = 3.1, 
1.7 Hz, 4H), 2.67 (ddd, J = 14.0, 10.4, 6.0 Hz, 1H), 2.46 – 2.41 (m, 2H), 2.12 (dt, J = 14.1, 5.9 Hz, 1H), 
1.93 (ddd, J = 12.8, 8.7, 6.5 Hz, 1H), 1.83 (dddd, J = 13.7, 10.3, 5.6, 3.3 Hz, 1H), 1.73 (ddt, J = 7.4, 
4.3, 1.4 Hz, 1H), 1.56 (s, 3H), 1.55 – 1.51 (m, 2H), 1.47 (dd, J = 14.7, 2.6 Hz, 1H), 1.39 (s, 3H), 1.04 
(s, 3H), 1.02 (dd, J = 8.7, 5.9 Hz, 1H), 1.00 (s, 3H), 0.96 (s, 9H), 0.11 (s, 3H), 0.04 (s, 3H). 
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13
C NMR (100 MHz, C6D6): δ = 213.2, 144.5, 135.3, 107.5, 72.9, 64.8, 64.8, 51.0, 49.0, 48.5, 39.6, 
37.2, 34.0, 32.4, 30.9, 28.2, 28.1, 26.1, 24.4, 23.5, 18.2, −4.1, −4.7. 
 
IR (ATR): ṽ = 2951 (m), 2931 (m), 2886 (m), 2858 (m), 1707 (s), 1471 (w), 1463 (w), 1387 (w), 1371 
(w), 1309 (w), 1254 (m), 1189 (m), 1087 (m), 1069 (m), 1041 (s), 1006 (w), 989 (w), 946 (w), 875 
(m), 855 (s), 835 (s), 810 (m), 773 (s), 735 (m), 702 (w), 667 (w) cm−1. 
 
HRMS (EI): calc. for C25H44O4Si [M]
+: 436.3003, found: 436.3011. 
 
[α]
D
25
 = +4.95 (c = 1, DCM) 
 
 
Synthesis and characterization of compound 3.25 
 
 
A solution of ketone 3.23 (300 mg, 0.687 mmol, 1.00 eq.) in THF (20 mL) was cooled to −78 °C and 
a solution of LDA in THF (0.5 M, 1.50 mL, 0.75 mmol, 1.10 eq.) was added. The solution was stirred 
for 30 min at −78 °C before HMPA (0.72 mL) followed by MeI (0.210 mL, 3.37 mmol, 4.90 eq.) was 
added. The reaction mixture was stirred for 1 h and then quenched through addition of an aq. sat. 
solution of NaHCO3 (50 mL) and H2O (20 mL). The aqueous layer was extracted with EtOAc (3 x 
100 mL), the combined organic layers were washed with brine (3 x 100 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The crude material was purified by flash column 
chromatography (hexanes/Et2O = 1:0 to 85:15) to afford compound 3.25 (207 mg, 0.460 mmol, 
67%) as a pale green oil. A small sample was repurified by flash column chromatography 
(hexanes/Et2O = 1:0 to 85:15) to afford a pale yellow solid of which a X-ray crystal structure could 
be obtained. 
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Rf = 0.56 (hexanes/EtOAc 85:15). 
 
1
H NMR (600 MHz, C6D6): δ = 5.62 – 5.61 (m, 1H), 3.77 (ddd, J = 10.6, 9.3, 4.3 Hz, 1H), 3.61 – 3.55 
(m, 4H), 2.52 – 2.46 (m, 3H), 2.39 – 2.32 (m, 1H), 1.98 (ddd, J = 12.8, 6.0, 4.3 Hz, 1H), 1.59 – 1.58 
(m, 1H), 1.56 (s, 3H), 1.52 (ddd, J = 12.9, 6.1, 3.3 Hz, 2H), 1.48 (dd, J = 13.8, 3.0 Hz, 1H), 1.26 – 1.23 
(m, 1H), 1.19 (s, 3H), 1.13 (s, 3H), 1.00 (d, J = 6.4 Hz, 3H), 0.97 (s, 9H), 0.79 (s, 3H), 0.11 (s, 3H), 0.06 
(s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 213.3, 144.3, 136.3, 107.6, 72.4, 64.9, 64.8, 49.7, 49.2, 48.3, 43.9, 
38.9, 37.9, 36.0, 31.2, 29.7, 26.3, 25.2, 24.4, 21.1, 18.3, 15.4,−3.4, −4.8. 
 
IR (ATR): ṽ = 2931 (m), 2884 (m), 2858 (m), 1709 (m), 1472 (w), 1371 (w), 1255 (m), 1189 (w), 1085 
(s), 1041 (s), 1005 (w), 914 (w), 835 (s), 774 (s), 664 (w) cm−1. 
 
HRMS (EI): calc. for C26H46O4Si [M]
+: 450.3160, found: 450.3151. 
 
Melting point = 81.5–83.0 °C. 
 
[α]
D
25
 = −32.8 (c = 0.97, DCM) 
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Synthesis and characterization of compound 3.26 
 
 
To a solution of trimethylsulfonium iodide (52.0 mg, 0.255 mmol, 1.50 eq.) in DMSO/THF (1:1, 2 
mL), was added a solution of KOt-Bu in DMSO (1 M, 0.190 mL, 0.190 mmol, 1.11 eq.) at 0 °C. The 
reaction mixture was stirred for 5 min. and then a solution of ketone 3.25 (77.0 mg, 0.171 mmol, 
1.00 eq.) in DMSO/THF (1:1, 2.8 mL) was added. After 2 h stirring at 0 °C the reaction was 
quenched through the addition of H2O (5 mL). The aqueous phase was extracted with EtOAc (3 x 
10 mL) and the combined organic layers were washed with brine (5 x 20 mL), dried over MgSO4, 
filtered and concentrated in vacuo. Subsequent flash column chromatography (hexanes/Et2O = 1:0 
to 85:15) gave product 3.26 (54.0 mg, 0.116 mmol, 68%) as a 1:1.3 mixture of diastereomers in 
form of a colorless oil.  
 
Rf = 0. 43 (hexanes/EtOAc 9:1). 
 
Data for the minor diastereomer: 
 
1
H NMR (800 MHz, C6D6): δ =5.59 (t, J = 1.9 Hz, 1H), 3.64 – 3.62 (m, 3H), 3.58 – 3.57 (m, 1H), 3.57 – 
3.55 (m, 1H), 2.67 (ddd, J = 13.1, 9.6, 6.3 Hz, 1H), 2.55 – 2.54 (m, 1H), 2.35 (d, J = 4.2 Hz, 1H), 2.17 
(ddq, J = 13.4, 6.8, 2.8 Hz, 1H), 1.93 (dt, J = 12.6, 4.1 Hz, 1H), 1.61 (d, J = 1.5 Hz, 2H), 1.61 (d, J = 2.0 
Hz, 1H), 1.58 (s, 4H), 1.49 (dd, J = 14.6, 3.6 Hz, 1H), 1.19 (d, J = 5.7 Hz, 1H), 1.17 (s, 4H), 1.01 (s, 9H), 
0.97 (s, 3H), 0.84 (s, 3H), 0.66 (d, J = 6.7 Hz, 3H), 0.12 (s, 3H), 0.07 (s, 3H). 
 
13
C NMR (200 MHz, C6D6): δ = 143.7, 137.3, 107.7, 73.5, 65.1, 64.9, 64.8, 49.3, 46.3, 44.9, 44.3, 
39.0, 38.8, 35.7, 31.4, 30.2, 29.7, 26.4, 24.3, 23.9, 19.2, 18.4, 15.1, -3.3, -4.7. 
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Data for the major diastereomer: 
 
1
H NMR (800 MHz, C6D6): δ = 5.67 (t, J = 1.9 Hz, 1H), 3.73 – 3.69 (m, 2H), 3.65 – 3.63 (m, 1H), 3.60 
– 3.58 (m, 2H), 2.73 (ddd, J = 12.9, 9.3, 6.4 Hz, 1H), 2.58 – 2.55 (m, 1H), 2.52 (ddt, J = 7.3, 6.5, 1.8 
Hz, 1H), 2.42 (d, J = 4.2 Hz, 1H), 2.30 (d, J = 4.2 Hz, 1H), 2.00 (ddt, J = 13.3, 6.6, 3.4 Hz, 1H), 1.80 (dt, 
J = 12.4, 4.1 Hz, 1H), 1.66 (s, 3H), 1.66 – 1.64 (m, 1H), 1.64 – 1.62 (m, 2H), 1.54 (dd, J = 4.7, 3.5 Hz, 
1H), 1.38 (dt, J = 10.0, 3.5 Hz, 1H), 1.20 (s, 3H), 1.01 (s, 9H), 0.78 (s, 6H), 0.62 (d, J = 6.6 Hz, 3H), 
0.14 (s, 3H), 0.10 (s, 3H). 
 
13
C NMR (200 MHz, C6D6): δ = 144.2, 136.3, 107.9, 73.6, 64.8, 64.7, 64.3, 49.4, 49.4, 46.8, 43.6, 
39.2, 38.8, 36.3, 31.5, 30.3, 28.7, 26.4, 24.5, 23.3, 20.8, 15.1, −3.2, −4.6. 
 
IR (ATR): ṽ = 291 (s), 2931 (s), 2884 (m), 2858 (m), 1472 (w), 1371 (w), 1256 (m), 1191 (w), 1091 
(s), 1046 (s), 1005 (w), 836 (s), 774 (m) cm−1. 
 
HRMS (EI): calc. for C26H45O4Si [M]
+: 464.3316, found: 464.3305. 
 
 
Synthesis and characterization of compound 3.27 and 3.28 
 
 
To a solution of epoxide 3.26 (15 mg, 32.3 μmol, 1.00 eq.) in toluene (1 mL) was added InCl3 (3.5 
mg, 15.8 μmol, 0.50 eq.) and the mixture was heated to 44 °C for 5 h after which it was filtered 
through a short plug of silica. Subsequent flash column chromatography (hexanes/EtOAc = 1:0 to 
8:2) gave a 1:0.6 mixture of product 3.27 and side product 3.28 (8.08 mg, 19.2 μmol, 60%) in form 
of a colorless oil. A small sample was repurified for analysis using prep-TLC.  
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Data for aldehyde 3.27: 
 
Rf = 0.36 (hexanes/EtOAc 85:15). 
 
1
H NMR (800 MHz, C6D6): δ = 9.70 (d, J = 5.0 Hz, 1H), 6.17 (t, J = 1.8 Hz, 1H), 3.49 (td, J = 10.8, 4.0 
Hz, 1H), 2.73 (dddd, J = 16.2, 9.5, 4.7, 1.7 Hz, 1H), 2.66 (dddd, J = 16.6, 8.9, 6.6, 2.0 Hz, 1H), 2.42 
(ddd, J = 13.1, 9.5, 6.5 Hz, 1H), 2.05 (s, 2H), 1.72 – 1.68 (m, 3H), 1.63 (dt, J = 10.4, 3.5 Hz, 1H), 1.53 
– 1.48 (m, 3H), 1.46 – 1.43 (m, 1H), 1.37 – 1.34 (m, 1H), 1.02 (s, 3H), 0.97 (s, 9H), 0.75 (s, 3H), 0.74 
(d, J = 6.7 Hz, 3H), 0.60 (s, 3H), 0.06 (s, 3H), 0.04 (s, 3H). 
 
13
C NMR (200 MHz, C6D6): δ = 204.8, 195.3, 151.5, 143.8, 74.0, 63.8, 50.7, 45.1, 42.2, 37.9, 35.7, 
30.7, 28.9, 28.7, 28.6, 26.7, 26.4, 26.1, 22.7, 19.5, 18.4, −3.3, −4.7. 
 
IR (ATR): ṽ = 2954 (s), 2929 (s), 2857 (m), 1718 (m), 1669 (s), 1616 (w), 1458 (w), 1369 (m), 1257 
(m), 1097 (m), 1063 (m), 1005 (w), 836 (s), 774 (s), 667 (w) cm−1. 
 
HRMS (EI): calc. for C25H44O3Si [M]
+: 420.3054, found: 420.3050. 
 
[α]
D
25
 = +28.0 (c = 0.1, DCM) 
 
Data for oxetane 3.28: 
 
Rf = 0.39 (hexanes/EtOAc 85:15). 
 
1
H NMR (800 MHz, C6D6): δ = 5.96 (t, J = 1.8 Hz, 1H), 4.29 (t, J = 5.4 Hz, 1H), 4.10 (d, J = 9.8 Hz, 1H), 
4.01 (d, J = 9.8 Hz, 1H), 2.59 (ddd, J = 8.7, 6.7, 1.8 Hz, 2H), 1.97 (s, 3H), 1.79 (dd, J = 12.3, 8.4 Hz, 
1H), 1.66 (dddt, J = 9.7, 4.8, 2.9, 1.5 Hz, 1H), 1.49 (dt, J = 12.8, 7.2 Hz, 1H), 1.43 – 1.39 (m, 1H), 1.26 
(dd, J = 14.3, 3.5 Hz, 1H), 1.19 (s, 4H), 1.18 – 1.15 (m, 1H), 1.11 (d, J = 6.9 Hz, 3H), 1.03 (s, 3H), 1.01 
– 0.99 (m, 1H), 0.97 (s, 9H), 0.83 (s, 3H), 0.04 (s, 3H), 0.04 (s, 3H). 
 
13
C NMR (200 MHz, C6D6): δ = 195.3, 150.7, 143.9, 89.7, 80.9, 61.3, 50.8, 49.6, 43.0, 37.9, 37.2, 
33.7, 33.1, 29.8, 29.0, 26.4, 26.0, 25.6, 21.7, 19.2, 18.3, −5.6, −5.8. 
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IR (ATR): ṽ = 2954 (s), 2929 (s), 2858 (m), 1670 (s), 1616 (w), 1462 (w), 1367 (w), 1257 (m), 1095 
(s), 978 (w), 935 (w), 838 (s), 775 (s) cm−1. 
 
HRMS (EI): calc. for C25H44O3Si [M]
+: 420.3054, found: 420.3055. 
 
[α]
D
25
 = +12.7 (c = 0.49, DCM) 
 
 
Synthesis of compound 3.30 
 
 
To a solution of 3.31 (0.38 mL, 2.44 mmol, 7.05 eq.) in THF (0.52 mL) at −78 °C wad added a 
solution of s-BuLi (1.2 M, 1.80 mL, 2.16 mmol, 6.24 eq.). The mixture was stirred at 24 °C for 35 
min after which an aliquot of 1.80 mL ( 1.44 mmol, 4.16 eq.) was taken and added to ketone 3.25 
(156 mg, 0.346 mmol, 1.00 eq.) dissolved in THF (4 mL) at −78 °C. After 45 min, the reaction was 
quenched through addition of an aq. saturated solution of NH4Cl (20 mL). The aqueous phase was 
extracted with Et2O (3 x 10 mL) and the combined organic layers were washed with brine, dried 
over Na2SO4, filtered and concentrated in vacuo. The crude product (207 mg) was used in the next 
step without further purification.  
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Synthesis of compound 3.27 
 
 
To a solution of crude 3.30 in DCM at 0 °C was added trichloroacetic acid (0.58 mL, 5.79 mmol, 
16.7 eq.). The reaction mixture was stirred for 1 h at 0 °C and 30 min at r.t. after which it was 
quenched through the addition of an aq. NaOH-solution (10%) (5 mL). The aqueous phase was 
extracted with DCM (3 x 10 mL) and the combined organic layers were washed with brine, dried 
over Na2SO4, filtered and concentrated in vacuo. Subsequent flash column chromatography 
(hexanes/Et2O = 1:0 to 85:15) gave product 3.27 (81.5 mg, 0.194 mmol, 56%) as a 1:1.8 mixture of 
diastereomers together with an inseparable side product in form of a colorless oil.  
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10.2.2. NMR Spectra for Chapter 3.1. 
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10.2.3. X-ray Crystallographic Data for Chapter 3.1. 
 
Tetrahydropyran 3.24 
 
Figure 10.1. ORTEP depiction of 3.24. 
 
Table 10.1. Crystallographic data for 3.24. 
net formula C17H26O3 
Mr/g mol
−1 278.38 
crystal size/mm 0.100 × 0.090 × 0.080 
T/K 100(2) 
radiation MoKα 
diffractometer 'Bruker D8Venture' 
crystal system orthorhombic 
space group 'P 21 21 21' 
a/Å 9.3994(3) 
b/Å 10.0557(4) 
c/Å 16.2420(6) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1535.15(10) 
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Z 4 
calc. density/g cm−3 1.204 
μ/mm−1 0.081 
absorption correction multi-scan 
transmission factor range 0.9075–0.9585 
refls. measured 28512 
Rint 0.0472 
mean σ(I)/I 0.0230 
θ range 2.382–26.38 
observed refls. 2980 
x, y (weighting scheme) 0.0385, 0.4296 
hydrogen refinement constr 
Flack parameter 0.4(3) 
refls in refinement 3161 
parameters 185 
restraints 0 
R(Fobs) 0.0362 
Rw(F
2) 0.0835 
S 1.097 
shift/errormax 0.001 
max electron density/e Å−3 0.209 
min electron density/e Å−3 −0.234 
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Ketone 3.25 
 
 
Figure 10.2. ORTEP depiction of 3.25. 
 
Table 10.2. Crystallographic data for 3.25. 
net formula C26H46O4Si 
Mr/g mol
−1 450.72 
crystal size/mm 0.429 × 0.195 × 0.103 
T/K 123(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system orthorhombic 
space group 'P 21 21 21' 
a/Å 7.5629(5) 
b/Å 17.4948(9) 
c/Å 20.6940(10) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 2738.1(3) 
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Z 4 
calc. density/g cm−3 1.093 
μ/mm−1 0.112 
absorption correction 'multi-scan' 
transmission factor range 0.99531–1.00000 
refls. measured 14872 
Rint 0.0625 
mean σ(I)/I 0.0832 
θ range 4.413–25.347 
observed refls. 3725 
x, y (weighting scheme) 0.0467, 0.0000 
hydrogen refinement constr 
Flack parameter −0.06(11) 
refls in refinement 4966 
parameters 290 
restraints 0 
R(Fobs) 0.0538 
Rw(F
2) 0.1131 
S 1.023 
shift/errormax 0.001 
max electron density/e Å−3 0.308 
min electron density/e Å−3 −0.209 
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10.3. Supporting Information for Chapter 3.2. 
10.3.1. Experimental Procedures 
 
Synthesis of compound 3.45 
 
 
 
A solution of LiCl (0.154 g, 3.63 mmol, 0.100 eq.) and CuI (0.346 g, 1.82 mmol, 0.050 eq.) in THF 
(200 mL) was stirred for 1 h at r.t.. The solution was cooled to −40 °C, enone 3.44 (4.12 mL, 36.3 
mmol, 1.00 eq.), TMSCl (5.21 mL, 41.0 mmol, 1.13 eq.) were added and the solution was stirred for 
additional 10 min at −40 °C. A solu^on of MeMgCl (3.0 M, 18.2 mL, 54.5 mmol, 1.50 eq.) was 
added dropwise. After 1 h stirring at −40 °C the star^ng material was not consumed yet (TLC 
analysis). Therefore, the solution was warmed up to −30°C. Arer 2.5h additional 
methylmagnesium chloride (5.00 mL, 15.0 mmol, 0.413 eq.) was added dropwise and the solution 
was stirred for overall 4 h until complete consumption of the starting material was observed. The 
reaction was quenched through addition of a sat. aq. solution of NH4Cl (200 mL) and the aqueous 
phase was extracted with Et2O (3 x 200 mL) to give silyl enol ether 3.45 (6.47 g, 32.6 mmol) as a 
yellowish oil which was used in the next step without further purification.  
 
Rf = 0.96 (hexanes/EtOAc 9:1)  
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Synthesis and characterization of compound 3.46 
 
 
A solution of silyl enol ether 3.45 (6.47 g, 32.6 mmol, 1.00 eq.) in THF (106 mL) was cooled to 0 °C. 
A solution of MeLi in Et2O (1.6 M, 22.4 mL, 35.8 mmol 1.10 eq.) was added slowly after which the 
solution was warmed up to r.t.. After 30 min stirring the reaction mixture was cooled to 0 °C and 
added to a suspension of N,N -dimethylmethyleneiminium chloride (3.50) (5.50 g, 58.7 mmol, 
1.80 eq.) in THF (68 mL) at −78 °C. The mixture was allowed to warm to r.t. and then stirred for 1 h 
and 45 min. The reaction was quenched through addition of brine (200mL) and H2O (50 mL). The 
pH of the aqueous phase was increased to 10 through addition of a sat. aq. solution of  Na2CO3. 
The aqueous phase was extracted with EtOAc (3 x 200 mL), the combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (hexanes/EtOAc = 3:7 to 0:1) to afford the amine 3.46 (5.59 g, 30.5 
mmol, 84% over 2 steps) as a yellow oil.  
 
Rf = 0.31, hexanes/EtOAc 9:1. 
 
1
H NMR (400 MHz, CDCl3): δ = 2.87 (dd, J = 12.3, 10.1 Hz, 1H), 2.42 – 2.33 (m, 1H), 2.30 – 2.25 (m, 
1H), 2.25 – 2.20 (m, 1H), 2.15 (s, 6H), 2.04 (dd, J = 12.3, 3.3 Hz, 1H), 1.87 – 1.76 (m, 2H), 1.64 – 
1.49 (m, 2H), 1.01 (s, 3H), 0.75 (s, 3H). 
 
13
C NMR (100 MHz, CDCl3): δ = 212.7, 59.2, 55.2, 45.8, 40.3, 38.8, 37.9, 28.9, 23.7, 23.2. 
 
IR (ATR): ṽ = 2941 (m), 2870 (m), 2819 (m), 2765 (m), 1710 (s), 1461 (m), 1367 (w), 1310 (w), 1260 
(m), 1228 (m), 1184 (w), 1152 (w), 1079 (w), 1043 (m), 1030 (m), 935 (w), 843 (m) cm−1. 
 
HRMS (ESI): calc. for C11H22ON [M+H]
+: 184.1696, found: 184.1693. 
Synthesis of compound 3.41 
 
Experimental   115 
 
 
A solution of amine 3.46 (7.58 g, 41.3 mmol, 1.00 eq.) in DCM (93 mL) was cooled to 0 °C and m-
CPBA (18.5 g, 82.6 mmol, 2.00 eq.) was added. The mixture was stirred at 0 °C for 10 min and then 
for 6 h at r.t. before it was directly subjected to flash column chromatography (n-pentane/Et2O = 
1:0 to 98:2). The solvent was removed in vacuo under ice bath cooling to afford the volatile enone 
3.41 (2.97 g, 21.5 mmol, 52%) which was stored as a 1 M solution in toluene at −25 °C. The 
analytical data of 3.41 was in accordance to the reported one.[87] 
 
Rf = 0.53 (hexanes/EtOAc 9:1) 
 
 
Synthesis and characterization of compound 3.47 
 
 
To a solution of silyl enol ether 3.42 (100 mg, 0.261 mmol, 1.00 eq.) and enone 3.41 (0.5 M in 
toluene, 0.58 mL, 0.290 mmol, 1.10 eq.) in DCM at −78 °C wad added a solution of Tf2NH (0.1 M, 
0.11 mL, 0.011 mmol, 0.04 eq.) dropwise. The reaction mixture was stirred for 80 min before it 
was quenched through the addition of Et3N (0.1 mL), filtered through a short plug of silica and 
concentrated in vacuo. Subsequent flash column chromatography (hexanes/Et2O = 1:0 to 95:5) 
gave product 3.47 (72.1 mg, 0.138 mmol, 53%) as a colorless oil.  
 
Rf = 0.67 (hexanes/EtOAc 9:1). 
 
1
H NMR (400 MHz, C6D6): δ =6.39 (t, J = 1.8 Hz, 1H), 3.28 (d, J = 2.0 Hz, 2H), 3.13 – 2.94 (m, 2H), 
2.75 (ddd, J = 9.1, 7.1, 1.7 Hz, 2H), 2.62 (td, J = 10.3, 9.6, 5.5 Hz, 2H), 1.99 (t, J = 6.4 Hz, 2H), 1.81 – 
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1.71 (m, 1H), 1.53 (ddt, J = 9.0, 6.4, 2.9 Hz, 2H), 1.46 – 1.38 (m, 1H), 1.36 – 1.31 (m, 2H), 1.03 (s, 
3H), 1.02 (s, 3H), 1.00 (s, 3H), 1.00 (s, 9H), 0.95 (s, 9H), 0.12 (s, 6H), 0.01 (d, J = 0.9 Hz, 6H). 
 
13
C NMR (100 MHz, C6D6): δ = 198.6, 147.1, 145.1, 145.1, 122.6, 70.3, 52.6, 39.6, 39.3, 34.9, 33.5, 
31.5, 30.6, 28.7, 28.7, 26.2, 26.1, 22.8, 21.4, 19.9, 18.5, 18.5, −3.4, −3.5, −5.3, −5.3. 
 
IR (ATR): ṽ =2954 (s), 2930 (s), 2857 (m), 1667 (m), 1471 (w), 1360 (w), 1257 (m), 1201 (w), 1148 
(w), 1079 (m), 934 (w), 836 (s), 776 (s), 668 (w) cm−1. 
 
HRMS (EI): calc. for C30H57O3Si2 [M+H]
+: 521.3841, found: 521.3840. 
 
[α]
D
25
 = +15.2 (c = 1.0, DCM) 
 
 
Synthesis of compound 3.49 
 
 
To a solution of Cu(NO3)2·H2O in MeCN was added I2 and the resulting mixture was stirred for 5 
min after which silyl enol ether 3.47 (69 mg, 0.133 mmol, 1.00 eq.) was added in THF/MeCN (1:1, 
1.5 mL). The reaction mixture was stirred for 30 min and then quenched through addition of an aq. 
saturated solution of Na4S2O3 (5 mL). The aqueous phase was extracted with Et2O (3 x 10 mL) and 
the combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo. The crude product (72 mg) was used in the next step without further 
purification.  
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10.3.2. NMR Spectra for Chapter 3.3. 
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10.4. Supporting Information for Chapter 3.3. 
10.4.1. Experimental Procedures 
 
A mixture of (+)-diisopropyl L-tartrate (0.831 mL, 3.94 mmol, 0.075 eq.) with activated 4 Å 
molecular sieves (5.60 g) in DCM (80 mL) was cooled to −10 °C. Freshly dis^lled 
titanium(IV)isopropoxide (0.933 mL, 3.15 mmol, 0.060 eq.) and TBHP in decane (5–6 M, 15.6 mL, 
85.5 mmol, 1.63 eq.) were added. After stirring for additional 20 min at −10 °C, the mixture was 
cooled to −25 °C and geraniol (S1) (9.20 mL, 52.5 mmol, 1.00 eq.) was added. The mixture was 
stirred for 1 h at −25 °C before the reac^on was quenched by adding H2O (16 mL). The suspension 
was stirred for 30 min at r.t. and aqueous NaOH solution (10%, 18 mL) was added. After additional 
stirring for 30 min the reaction mixture was filtered through a pad of celite. Then an aqueous 
solution of citric acid (10%, 18 mL) was added and the suspension was stirred for 1 h. The aqueous 
phase was extracted with DCM (6 x 50 mL) and the combined organic layers were washed with 
brine (300 mL), dried over MgSO4, filtered and concentrated in vacuo. The obtained crude material 
was purified by flash column chromatography (hexanes/EtOAc = 9:1 to 1:1) to afford epoxide S2 as 
a colorless oil (9.06 g, 53.2 mmol, quant.). The analytical data of S2 was in accordance to the 
reported one.[64] The ee was determined to be 80% by Mosher ester analysis.[63]  
 
Rf = 0.28 (hexanes/EtOAc 7:3) 
 
[α]
D
25
 = −4.3 (c = 3.00, CHCl3) 
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A solution of epoxide S2 (8.94 g, 52.5 mmol, 1.00 eq.) in DMF (74 mL) was cooled to 0 °C and 
imidazole (8.94 g, 131 mmol, 2.50 eq.), TBSCl (10.3 g, 68.3 mmol, 1.30 eq.) and 4-
(dimethylamino)pyridine (3.85 g, 31.5 mmol, 0.600 eq.) were added. The mixture was warmed to 
r.t. and stirred for 1 h before the reaction was quenched by adding a solution of sat. aq. NH4Cl 
(100 mL). The layers were separated and the aqueous layer was extracted with Et2O (3 x 100 mL). 
The combined organic phases were washed with brine (300 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The obtained colorless oil was purified by flash column chromatography 
(hexanes/EtOAc = 1:0 to 95:5) to give compound S3 (13.8 g, 48.5 mmol, 93% yield) as a colorless 
oil. The analytical data of S3 was in accordance to the reported one.[64] 
 
Rf = 0.44 (hexanes/EtOAc 95:5) 
 
[α] D
25 = −3.07 (c = 1.00, CHCl3) 
 
 
To a solution of 4-bromo-2,6-di-tert-butylphenol (S16) (12.5 g, 43.7 mmol, 2.30 eq.) in DCM (200 
mL) was added a solution of Me3Al in hexanes (2.0 M, 11.0 mL, 22.0 mmol, 1.15 eq.) (methane 
evolution!). After stirring for 1 h at r.t., the solution was cooled to −78 °C and a solu^on of epoxide 
S3 (5.48 g, 19.3 mmol, 1.00 eq.) in DCM (20 mL) was added. Stirring at −78 °C was con^nued for 
1.5 h before the reaction mixture was quenched through the addition of NaF (3.9 g) and H2O (2 
mL). The mixture was stirred for additional 25 min at −78 °C. The mixture was warmed up to 0 °C 
and was stirred for 30 min at r.t before the suspension was filtered over a pad of silica. The filtrate 
was then concentrated in vacuo to afford a slurry that was taken up in DCM and silica (30 g). 
Purification by flash column chromatography (hexanes/Et2O = 99:1 to 9:1) afforded aldehyde S4 
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(4.42 g, 15.5 mmol, 81%) as a yellow oil. The analytical data of S4 was in accordance to the 
reported one.[64] 
 
Rf = 0.62, hexanes/EtOAc 95:5 
 
[α]
D
25
 = +5.24 (c = 1.00, CHCl3) 
 
 
The solution of aldehyde S4 (8.28 g, 29.1 mmol, 1.00 eq.) in DCM (80 mL) was cooled to −78 °C and 
a solution of Me2AlCl in hexanes (1.0 M, 29.1 mL, 1.00 eq.) was added dropwise. The resulting 
solution was stirred for 1 h at −78 °C before the reac^on was warmed to 0 °C. Arer addi^onal 
stirring for 1.5 h, the reaction was quenched by adding H2O (20 mL) and aq. HCl solution (10%, 40 
mL). The layers were separated and the aqueous layer was extracted with DCM (2 x 100 mL). The 
combined organic layers were washed with a sat. aq. solution of NaHCO3 (100 mL) and brine (100 
mL), dried over MgSO4, filtered and concentrated in vacuo to afford S5 as a yellow oil (8.20 g, 28.8 
mmol). The crude mixture of diastereomers was used in the next step without further purification.  
 
OH
Me
OTBS
S5
1) K2OsO4, 2,6-lutidine,NaIO4,
t-BuOH, H2O
O
Me
OH
2) HCl, THF, 80 °C
7
(81% over 3 steps)
 
To a solution of cyclopentanol S5 (8.20 g, 28.8 mmol, 1.00 eq.) in t-BuOH (134 mL) and H2O (44 
mL) was added potassium osmium(IV) oxide dihydrate (114 mg, 0.310 mmol, 0.011 eq.), 2,6-
lutidine (6.67 mL, 57.6 mmol, 2.00 eq.) and sodium periodate (23.4 g, 109 mmol, 3.80 eq.). The 
suspension was stirred for 15 h at r.t. before the reaction was quenched by adding Na2SO3 (30.8 g) 
at 0 °C. The mixture was allowed to warm to r.t., stirred an additional 1 h and was then diluted 
with H2O (50 mL) and extracted with EtOAc (4 x 100 mL). The combined organic layers were 
washed with brine (400 mL), dried over MgSO4 and concentrated in vacuo to afford a dark yellow 
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oil. The crude product was dissolved in a 1:1 mixture of aq. HCl (6 M, 82 mL) and THF (82 mL) and 
the reaction mixture was refluxed at 80 °C for 4 h. The biphasic mixture was cooled to 0 °C and the 
pH was set to 7 by carefully adding aq. NaOH (10%, 200 mL). The organic layer was separated and 
the aqueous layer was extracted with EtOAc (3 x 400 mL). The organic layers were washed with 
brine (400 mL) and dried over MgSO4, filtered and concentrated in vacuo. The obtained dark 
brown oil was purified by flash column chromatography (hexanes/EtOAc = 7:3 to 4:6) to provide 
enone 7 (3.60 g, 23.3 mmol, 81% over three steps) as a red-brown oil. The analytical data of 7 was 
in accordance to the reported one.[61] 
 
Rf = 0.38 (hexanes/EtOAc 7:3) 
 
[α]
D
25
 = +38.5 (c = 1.00, CHCl3) 
 
 
 
A solution of 7 (6.54 g, 42.4 mmol, 1.00 eq.) in DMF (65 mL) was cooled to 0 °C. Imidazole (7.21 g, 
106 mmol, 2.50 eq.), TBSCl (8.31 g, 55.1 mmol, 1.30 eq.), and DMAP (3.10 g, 25.4 mmol, 0.60 eq.) 
were added and the resulting suspension was stirred at r.t. for 1 h, after which the reaction 
mixture was quenched through the addition of a sat. aq. solution of NH4Cl (100 mL). The layers 
were separated and the aqueous layer was extracted with EtOAc (4 × 100 mL) and the combined 
organic phases were washed with brine (4 × 250 mL), dried over Na2SO4, and concentrated. The 
crude product was purified by column chromatography (SiO2, hexanes/EtOAc = 99:1 to 9:1). The 
product S6 (10.5 g, 39.0 mmol, 92%) was obtained as an orange oil. 
 
Rf = 0.45 (hexanes/EtOAc 9:1) 
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1
H NMR (400 MHz, C6D6): δ = 6.15 (t, J = 1.8 Hz, 1H), 3.24 (d, J = 1.4 Hz, 2H), 2.63 (td, J = 7.5, 1.8 
Hz, 2H), 1.99 (s, 3H), 1.70 (dt, J = 12.8, 7.0 Hz, 1H), 1.37 (dt, J = 12.9, 7.6 Hz, 1H), 0.96 (s, 3H), 0.93 
(s, 9H), 0.00 (d, J = 1.2 Hz, 6H). 
 
13
C NMR (100 MHz, C6D6): δ = 195.3, 148.4, 145.2, 70.2, 52.6, 33.6, 30.3, 26.4, 26.1, 22.7, 18.5, 
−5.3, −5.3. 
 
IR (ATR): ṽ = 2954 (m), 2929 (m), 2887 (w), 2856 (m), 1670 (s), 1618 (w), 1471 (w), 1363 (m), 1312 
(w), 1252 (m), 1087 (s), 1006 (w), 928 (w), 834 (s), 773 (s), 668 (m), 604 (m) cm-1. 
 
HRMS (EI): calc. for C15H28O2Si [M]
+: 268.1853, found: 268.1855. 
 
[α]
D
25
 = +79.4 (c = 1.0, CHCl3) 
 
 
 
To a solution of enone S6 (9.23 g, 34.4 mmol, 1.00 eq.) in DCM (160 mL) at 0 °C was added Et3N 
(16.90 mL, 120.4 mmol, 3.50 eq.) and TBSOTf (11.9 mL, 51.6 mmol, 1.50 eq.). After stirring the 
resulting yellow solution at r.t. for 2 h, the reaction mixture was quenched through the addition of 
a sat. aq. solution of NaHCO3 (200 mL). The layers were separated and the aqueous layer was 
extracted with pentane (3 × 300 mL). The combined organic phases were washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure to yield 6 (10.2 g, 26.6 mmol).as an orange 
oil. The crude product was used in the next step. 
 
Rf = 0.88 (hexanes/EtOAc 95:5) 
 
1
H NMR (400 MHz, C6D6): δ = 6.10 (d, J = 1.7 Hz, 1H), 4.39 (d, J = 1.7 Hz, 2H), 3.37 (s, 2H), 2.48 (td, J 
= 7.6, 1.5 Hz, 2H), 1.89 (ddd, J = 12.7, 7.9, 6.5 Hz, 1H), 1.55 (dt, J = 12.8, 7.8 Hz, 1H), 1.12 (s, 3H), 
1.04 (s, 9H), 0.99 (s, 9H), 0.19 (s, 3H), 0.19 (s, 3H), 0.05 (s, 3H), 0.04 (s, 3H). 
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13
C NMR (100 MHz, C6D6): δ =154.6, 140.9, 135.5, 93.0, 70.9, 51.6, 34.5, 31.7, 26.2, 26.1, 23.6, 
18.5, 18.5, −4.5, −5.3. 
 
 
 
To a solution of enone 5 (3.00 mL, 3.00 mmol, 1.00 eq.) in toluene at −15 °C was added 
sequentially a solution of AlMe3 in toluene (2 M, 0.60 mL, 1.20 mmol, 0.40 eq.), a solution of AlBr3 
in toluene (1 M, 2.00 mL, 2.00 mmol, 0.67 eq.) and a solution of diene 6 (1.20 g, 3.10 mmol, 1.03 
eq.) in toluene (1.6 mL). The resulting red-orange reaction mixture was stirred at −15 °C for 20 min 
after which it was quenched with pyridine (3.2 mL), warmed to r.t. and filtered through a plug of 
silica. Concentration under reduced pressure and purification by flash chromatography (SiO2, 
hexanes/Et2O = 1:0 to 99:1 to 97:3) afforded the product 4 (1.03 g, 1.98 mmol, 66% yield) as a 
yellow oil. 
 
Rf = 0.68 (hexanes/EtOAc 9:1) 
 
1
H NMR (400 MHz, C6D6): δ = 3.42 (d, J = 11.0 Hz, 1H), 3.15 (d, J = 10.8 Hz, 1H), 3.20 – 3.10 (m, 1H), 
2.75 (s, 1H), 2.55 (ddd, J = 15.7, 9.6, 6.6 Hz, 1H), 2.50 – 2.45 (m, 1H), 2.44 – 2.37 (m, 1H), 2.22 (td, J 
= 13.3, 4.8 Hz, 1H), 2.14 – 2.09 (m, 2H), 2.05 (dd, J = 12.1, 6.7 Hz, 1H), 1.99 – 1.91 (m, 1H), 1.84 – 
1.76 (m, 1H), 1.70 – 1.59 (m, 2H), 1.05 (s, 3H), 1.03 (m, 1H), 1.02 (s, 9H), 0.99 – 0.97 (m, 1H), 0.96 
(s, 9H), 0.78 (s, 3H), 0.74 (s, 3H), 0.12 (s, 3H), 0.10 (s, 3H), −0.00 (s, 3H), −0.03 (s, 3H).  
 
13
C NMR (100 MHz, C6D6): δ = 214.4, 143.2, 122.1, 67, 55.9, 45.7, 43.7, 41.5, 41.4, 39.6, 35.3, 29.6, 
28.7, 27.2, 26.1, 26.1, 24.4, 22.2, 21.3, 19.1, 18.5, 18.4, −3.4, −3.6, −5.3, −5.5. 
 
IR (ATR): ṽ = 2954 (m), 2929 (m), 2897 (w),  2857 (m), 1692 (m), 1472 (w), 1463 (w), 1389 (w), 
1361 (w), 1353 (w), 1251 (m), 1221 (w), 1206 (w), 1195 (w), 1181 (w), 1155 (w), 1098 (m), 1087 
(m), 1070 (m), 1042 (w), 1006 (w), 975 (w), 953 (w), 938 (w), 921 (w), 835 (s), 775 (s),  729 (w), 668 
(w) cm-1. 
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HRMS (EI): calc. for C30H56O3Si2 [M]
+: 520.3763, found: 520.3768. 
 
[α]
D
25
 = +51.8 (c = 1.0, DCM) 
 
 
 
To a solution of silyl enol ether 4 (6.40 g, 12.3 mmol, 1.00 eq.) in THF (550 mL) was added p-
TSA•H2O (11.8 g, 62.0 mmol, 5.04 eq.) at r.t.. The reaction mixture was stirred for 11 h after which 
it was quenched with a sat. aq. solution of NaHCO3 (200 mL) and diluted with Et2O (200 mL). The 
layers were separated and the aqueous layer was extracted with Et2O (3 x 200 mL). The combined 
organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude was purified by flash chromatography (SiO2, hexanes/EtOAc = 99:1 to 
95:5) to afford the product 8 (4.31 g, 10.6 mmol, 86% yield) as a pale yellow oil. 
 
Rf = 0.41 (hexanes/EtOAc 9:1). 
 
1
H NMR (400 MHz, C6D6): δ = 3.27 (d, J = 10.8 Hz, 1H), 3.09 – 2.96 (m, 1H), 2.98 (d, J = 10.9 Hz, 1H), 
2.87 – 2.76 (m, 2H), 2.65 – 2.58 (m, 1H), 2.58 – 2.50 (m, 1H), 2.47 (ddd, J = 17.1, 5.9, 4.3 Hz, 1H), 
2.40 – 2.33 (m, 1H), 2.29 (ddd, J = 17.1, 12.8, 6.0 Hz, 1H), 2.06 (ddd, J = 13.8, 11.6, 6.2 Hz, 1H), 1.82 
(ddd, J = 12.5, 10.2, 8.0 Hz, 1H), 1.71 (dddd, J = 15.5, 6.1, 4.3, 1.6 Hz, 1H), 1.60 – 1.46 (m, 3H), 1.07 
(ddt, J = 13.2, 8.9, 4.7 Hz, 1H), 0.97 – 0.94 (m, 1H), 0.92 (s, 9H), 0.87 (s, 3H), 0.64 (s, 3H), 0.62 (s, 
3H), −0.06 (s, 3H), −0.08 (s, 3H). 
 
13
C NMR (200 MHz, C6D6): δ = 213.4, 211.4, 67.6, 56.5, 52.7, 47.0, 44.8, 42.2, 41.2, 38.2, 38.1, 38.0, 
29.9, 26.7, 26.0, 24.8, 22.2, 21.3, 19.9, 18.3, −5.4, −5.6. 
 
IR (ATR): ṽ = 2954 (s), 2929 (s), 2857 (m), 2362 (w), 2336 (w), 1695 (s), 1471 (m), 1389 (w), 1258 
(w), 1093 (m), 838 (s), 777 (m), 668 (w) cm−1. 
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HRMS (EI): calc. for C24H42O3Si [M]
+: 406.2898, found: 406.2905. 
 
[α]
D
25
 = −9.0 (c = 1.0, DCM) 
 
 
 
Diketone 8 (3.21 g, 7.90 mmol, 1.00 eq.) was dissolved in THF (290 mL) and cooled to –78 °C. 
LiAlH4 (448 mg, 11.9 mmol, 1.51 eq.) was added and the reaction was stirred for 3.5 h after which 
Glauber´s salt was added until effervescence stopped. The resulting slurry was then filtered and 
concentrated to give a solid that was purified by flash chromatography (SiO2, pentanes/EtOAc = 
95:5 to 8:2). The desired product S7 (1.88 g, 4.60 mmol, 58% yield) was obtained as a white solid 
together with alcohol S8 (355 mg, 0.869 mmol, 11% yield, viscous oil). 
 
Data for S7: 
 
Rf = 0.61 (hexanes/EtOAc 8:2). 
 
Mp = 110 – 111 °C. 
 
1
H NMR (400 MHz, C6D6): δ = 3.56 – 3.51 (m, 1H), 3.49 (d, J = 10.4 Hz, 1H), 3.27 (d, J = 10.4 Hz, 1H), 
2.91 (td, J = 12.5, 7.7 Hz, 1H), 2.73 (dd, J = 8.1, 1.5 Hz, 1H), 2.48 – 2.36 (m, 3H), 2.19 – 2.09 (m, 1H), 
1.88 – 1.82 (m, 1H), 1.79 – 1.73 (m, 2H), 1.73 – 1.67 (m, 1H), 1.66 – 1.55 (m, 3H), 1.39 – 1.30 (m, 
1H), 1.20 (s, 3H), 1.04 (s, 3H), 1.01 – 0.99 (m, 1H), 0.98 (s, 9H), 0.74 (s, 3H), 0.02 (s, 3H), 0.00 (s, 
3H). 
 
13C NMR (100 MHz, C6D6): δ = 214.4, 71.3, 67.8, 57.3, 46.6, 45.2, 42.9, 42.1, 41.6, 41.1, 39.7, 31.4, 31.2, 
26.1, 25.4, 24.8, 23.1, 22.8, 20.4, 18.4, −5.4, −5.4. 
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IR (ATR): ṽ = 3493 (br), 2954 (s), 2930 (s), 2880 (m), 2858 (m), 1689 (m), 1472 (m), 1448 (w), 1389 
(w), 1361 (w), 1256 (m), 1088 (s), 1006 (w), 984 (w), 941 (w), 851 (s), 837 (s), 815 (w), 775 (m), 668 
(w) cm−1. 
 
HRMS (EI): calc. for C24H44O3Si [M]
+: 408.3054, found: 408.3050. 
 
[α]
D
25
 = +29.6 (c = 0.5, Et2O) 
Data for minor isomer S8: 
 
Rf = 0.28 (hexanes/EtOAc 8:2) 
 
1
H NMR (400 MHz, C6D6): δ = 3.44 (td, J = 10.7, 6.0 Hz, 1H), 3.32 (d, J = 10.6 Hz, 1H), 3.10 (d, J = 
10.6 Hz, 1H), 2.96 (td, J = 12.6, 7.8 Hz, 1H), 2.74 (dd, J = 7.5, 1.8 Hz, 1H), 2.42 (t, J = 3.3 Hz, 1H), 
2.39 (dd, J = 4.4, 2.2 Hz, 1H), 2.29 (td, J = 15.5, 4.6 Hz, 1H), 2.13 (td, J = 13.0, 5.4 Hz, 1H), 1.85 (ddd, 
J = 15.4, 7.5, 4.8 Hz, 2H), 1.79 – 1.73 (m, 1H), 1.72 – 1.63 (m, 2H), 1.62 – 1.50 (m, 3H), 1.25 (dt, J = 
12.5, 7.9 Hz, 1H), 1.15 (s, 3H), 0.98 (q, J = 2.5 Hz, 1H), 0.95 (s, 9H), 0.85 (s, 3H), 0.73 (s, 3H), −0.01 
(s, 3H), −0.04 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 215.0, 72.1, 69.7, 57.3, 49.0, 46.5, 43.3, 42.9, 41.9, 39.7, 39.4, 32.5, 
32.0, 27.2, 26.4, 26.1, 25.3, 23.0, 22.8, 18.4, −5.4, −5.5. 
 
IR (ATR): ṽ = 3364 (br), 2953 (s), 2932 (s), 2879 (m), 2858 (m), 1691 (m), 1506 (w), 1471 (m), 1449 
(w), 1390 (w), 1361 (w), 1325 (w), 1252 (m),  1091 (s), 1044 (m), 1006 (w), 946 (w), 837 (s), 815 
(w), 776 (m), 668 (w) cm-1.  
 
HRMS (EI): calc. for C24H44O3Si [M]
+: 408.3054, found: 408.3054. 
 
[α]
D
25
 = −16.4 (c = 1.0, THF) 
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Alcohol S7 (1.88 g, 4.60 mmol, 1.00 eq.) in benzene (95 mL) was added to Burgess’ reagent (2.52 g, 
10.6 mmol, 2.30 eq.) and the resulting solution was heated to 50 °C for 3 h. The reaction mixture 
was concentrated, redissolved in Et2O (100 mL) and washed with a sat. aq. solution of NH4Cl (100 
mL). The aqueous layer was extracted with Et2O (2 x 100 mL) and the combined organic layers 
were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
The residue was purified by column chromatography (SiO2, pentanes/EtOAc = 99:1 to 96:4) to give 
the product S9 and S17 (1.62 g, 4.15 mmol, 91% yield) as an inseparable 10:1 mixture of alkenes. 
 
Data for S9: 
 
Rf = 0.61 (hexanes/EtOAc 9:1) 
 
1
H NMR (400 MHz, C6D6): δ = 5.47 (dd, J = 5.3, 2.5 Hz, 1H), 3.42 (d, J = 11.0 Hz, 1H), 3.15 (d, J = 
11.0 Hz, 1H), 3.14 – 3.06 (m, 1H), 2.66 (s, 1H), 2.47 (ddt, J = 13.8, 4.4, 2.4 Hz, 1H), 2.29 – 2.21 (m, 
1H), 2.21 – 2.10 (m, 2H), 2.08 – 2.01 (m, 2H), 1.96 (dd, J = 13.6, 4.8 Hz, 1H), 1.85 – 1.78 (m, 1H), 
1.70 – 1.59 (m, 2H), 1.06 (q, J = 3.0 Hz, 1H), 1.02 (s, 3H), 1.00 – 0.98 (m, 1H), 0.96 (s, 9H), 0.80 (s, 
3H), 0.77 (s, 3H), −0.01 (s, 3H), −0.03 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 214.6, 144.4, 119.7, 67.5, 56.3, 45.2, 43.0, 41.6, 41.4, 39.6, 34.7, 
28.3, 26.5, 26.1, 25.8, 24.4, 24.3, 22.3, 20.1, 18.4, −5.3, −5.5. 
 
HRMS (EI): calc. for C24H42O2Si [M]
+: 390.2949, found: 390. 2947. 
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To a solution of mixture of alkenes S9 and S17 (10:1) (1.44 g, 3.69 mmol, 1.00 eq.) in THF/Acetone 
(8:2, 100 mL) was added NMO (870 mg, 7.40 mmol, 2.01 eq.) in water (20 mL) followed by OsO4 
(4 wt% in water, 3.10 mL, 0.488 mmol, 0.13 eq.). The reaction mixture was heated to 55 °C for 36 
h after which it was quenched with a sat. aq. solution of Na2SO3 (100 mL). The layers were 
separated and the aqueous layer was extracted with EtOAc (2 x 100 mL). The combined organic 
layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude product was purified by column chromatography (SiO2, pentanes/EtOAc = 
8:2), giving the diol 9 (1.27 g, 2.99 mmol, 81% yield) as a yellow oil. 
 
Rf = 0.31 (hexanes/EtOAc 7:3) 
 
1
H NMR (400 MHz, C6D6): δ = 3.76 (td, J = 7.1, 4.8 Hz, 1H), 3.57 (d, J = 9.8 Hz, 1H), 3.37 (d, J = 9.8 
Hz, 1H), 2.81 (s, 1H), 2.52 – 2.44 (m, 1H), 2.43 (s, 1H), 2.23 – 2.14 (m, 1H), 2.09 (dd, J = 15.4, 8.0 Hz, 
1H), 2.03 – 1.97 (m, 2H), 1.73 (dt, J = 13.9, 5.4 Hz, 1H), 1.68 – 1.59 (m, 3H), 1.60 – 1.52 (m, 2H), 
1.46 – 1.38 (m, 2H), 1.20 (s, 3H), 1.15 – 1.10 (m, 1H), 1.07 (s, 3H), 0.99 (s, 12H), 0.06 (s, 6H).  
 
13
C NMR (200 MHz, C6D6): δ = 213.9, 84.5, 71.3, 69.2, 59.1, 50.5, 47.2, 41.4, 38.9, 37.2, 36.5, 36.2, 
28.5, 27.6, 27.5, 27.2, 26.2, 23.2, 20.5, 18.6, −5.3, −5.3. 
 
IR (ATR): ṽ = 3426 (br), 2956 (s), 2929 (s), 2858 (m), 2361 (w), 1698 (m), 1472 (w), 1391 (w), 1258 
(m), 1092 (s), 1035 (m), 837(s), 800 (m), 775 (m), 668 (w) cm-1. 
 
HRMS (EI): calc. for C24H44O4Si [M]
+: 424.3003, found: 424.3009. 
 
[α]
D
25
 = −20.5 (c = 0.4, THF) 
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To a solution of PPh3 (1.89 g, 7.20 mmol, 2.20 eq.) in MeCN (55 mL) was added C2Cl6 (1.70 g, 
7.20 mmol, 2.20 eq.). The resulting solution was stirred for 20 minutes at r.t., upon which Et3N 
(1.96 mL, 14.7 mmol, 4.50 eq.) was added. Then the reaction mixture was cooled to 0 °C and diol 9 
(1.39 g¸3.27 mmol, 1.00 eq.) in MeCN (33.5 mL) was added dropwise. After 30 min. the reaction 
was warmed to r.t. and stirred for 1 h. MeOH (17 mL) followed by NaBH4 (1.25 g, 33.0 mmol, 10.1 
eq.) was then added at 0 °C. After 2 h, the reaction was quenched by the addition of water (50 
mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 80 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure. The residue was suspended in Et2O and filtered through a short plug of 
silica to remove parts of triphenylphosphineoxide. The solution was concentrated under reduced 
pressure and the crude product was purified by column chromatography (SiO2, pentanes/EtOAc = 
8:2 to 7:3) giving the alcohol 10 (659 mg, 1.61 mmol, 49% yield) as a colorless oil. 
 
Rf = 0.27 (hexanes/EtOAc 7:3) 
 
1
H NMR (800 MHz, C6D6): δ = 3.72 (d, J = 9.7 Hz, 1H), 3.33 (d, J = 9.7 Hz, 1H), 3.09 (td, J = 10.3, 4.4 
Hz, 1H), 2.60 (tdd, J = 11.4, 10.4, 6.1 Hz, 1H), 2.09 – 2.04 (m, 2H), 2.01 (dddd, J = 13.9, 8.1, 5.6, 2.6 
Hz, 1H), 1.96 (ddd, J = 12.7, 8.7, 2.3 Hz, 1H), 1.90 (ddd, J = 14.2, 4.2, 3.0 Hz, 1H), 1.74 (td, J = 13.7, 
5.5 Hz, 1H), 1.67 (d, J = 11.9 Hz, 1H), 1.64 – 1.58 (m, 2H), 1.52 (ddd, J = 12.7, 11.1, 7.9 Hz, 1H), 1.40 
– 1.35 (m, 1H), 1.34 (s, 3H), 1.20 – 1.16 (m, 1H), 1.16 – 1.11 (m, 1H), 1.00 – 0.99 (m, 3H), 0.99 (s, 
9H), 0.97 – 0.94 (m, 1H), 0.89 (s, 3H), 0.81 – 0.78 (m, 1H), 0.05 (s, 3H), 0.04 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): 212.4, 76.9, 71.4, 62.0, 50.2, 49.1, 47.3, 42.0, 41.0, 38.5, 37.9, 34.0, 
31.8, 29.8, 28.9, 26.2, 24.5, 24.1, 21.1, 18.5, −5.4, −5.4. 
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IR (ATR): ṽ = 3397 (br), 2954 (s), 2930 (s), 2858 (m), 2284 (w), 1704 (m), 1602 (w), 1472 (m), 1387 
(w), 1361 (w), 1313 (w), 1256 (m), 1216 (w), 1087 (s), 1006 (w), 935 (w), 853 (s), 814 (w), 774 (s), 
670 (w) cm−1. 
 
HRMS (EI): calc. for C24H44O3Si [M-H2O]
+: 390.2954, found: 390.2969. 
 
[α]
D
25
 = +34.0 (c = 0.4, THF) 
 
MOMCl, DIPEA,
DMAP
DCM, 0 °C to r.t.
(81%)
10
Me
HO
TBSO
H
OH
S10
Me
HO
TBSO
H
OMOM
 
A solution of alcohol 10 (702 mg, 1.72 mmol, 1.00 eq.) in DCM (47 mL) and DIPEA (0.90 mL, 
5.17 mmol, 3.00 eq.) was cooled to 0 °C and MOMCl (1.18 mL, 15.5 mmol, 9.05 eq.) and DMAP 
(210 mg, 1.72 mmol, 1.00 eq.) was added. The reaction mixture was stirred for 6 h and was 
quenched through the addition of a sat. aq. solution of NH4Cl (50 mL). The aqueous phase was 
extracted with DCM (3 x 50 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated. The resulting residue was purified by column chromatography 
(SiO2, pentanes/EtOAc = 95:5 to 7:3) to afford the desired product S10 (628 mg, 1.39 mmol, 81% 
yield) as a colorless oil. 
 
Rf = 0.52 (hexanes/EtOAc 8:2) 
 
1
H NMR (800 MHz, C6D6): δ = 4.73 (d, J = 6.8 Hz, 1H), 4.60 (d, J = 6.8 Hz, 1H), 3.73 (d, J = 9.7 Hz, 
1H), 3.37 (d, J = 9.7 Hz, 1H), 3.26 (s, 3H), 3.23 – 3.18 (m, 1H), 2.94 (dddd, J = 12.1, 11.2, 10.0, 6.0 
Hz, 1H), 2.25 (dddd, J = 11.6, 8.0, 6.0, 2.1 Hz, 1H), 2.09 – 2.06 (m, 2H), 1.99 (ddd, J = 12.7, 8.6, 2.1 
Hz, 1H), 1.94 (ddd, J = 13.9, 4.3, 2.7 Hz, 1H), 1.82 (dtd, J = 12.0, 4.4, 2.6 Hz, 1H), 1.76 (td, J = 13.7, 
5.6 Hz, 1H), 1.72 (d, J = 12.1 Hz, 1H), 1.64 – 1.58 (m, 1H), 1.58 – 1.54 (m, 1H), 1.40 – 1.36 (m, 1H), 
1.35 (s, 3H), 1.26 (qd, J = 11.3, 8.7 Hz, 1H), 1.16 (td, J = 14.1, 2.6 Hz, 1H), 1.11 – 1.06 (m, 1H), 1.02 – 
1.01 (m, 3H), 0.99 (s, 9H), 0.92 (s, 3H), 0.83 – 0.79 (m, 1H), 0.06 (s, 3H), 0.05 (s, 3H). 
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13
C NMR (100 MHz, C6D6): δ = 212.2, 95.1, 82.2, 71.5, 61.9, 55.0, 49.5, 48.1, 47.2, 41.9, 41.0, 38.5, 
38.0, 33.8, 30.4, 28.9, 28.7, 26.2, 24.5, 24.2, 21.0, 18.5, −5.4, −5.4. 
 
IR (ATR): ṽ = 2954 (s), 2930 (s), 2882 (m), 2862 (m), 2162 (w), 2040 (w), 1706 (m), 1472 (w), 1387 
(w), 1256 (w), 1147 (m), 1091 (s), 1043 (s), 918 (w), 852 (s), 837 (s), 775 (m), 670 (w).   
 
HRMS (EI): calc. for C26H48O4Si [M]
+: 452.3316, found: 452.3308. 
 
[α]
D
25
 = +37.1 (c = 0.21, THF) 
 
 
DIBAL-H
THF, 0 °C
(97%)
S10
Me
HO
TBSO
H
OMOM
11
Me
HHO
TBSO
H
OMOM
 
A solution of ketone S10 (623 mg, 1.38 mmol, 1.00 eq.) in THF (58 mL) was cooled to 0 °C and 
DIBAL-H (1 M solution in toluene, 13.7 mL, 13.7 mmol, 9.93 eq.) was added dropwise. The reaction 
was stirred for 2 h and was quenched through the addition of Glauber’s salt (portionwise addition 
until effervescence ceased). The mixture was then allowed to stir for 15 min at r.t., after which it 
was filtered and concentrated under reduced pressure. The crude product was purified by column 
chromatography (SiO2, pentanes/EtOAc = 90:10 to 85:15). The desired product 11 (611 mg, 1.34 
mmol, 97%) was obtained as a colorless oil. 
 
Rf = 0.42 (hexanes/EtOAc 8:2) 
 
1
H NMR (400 MHz, C6D6): δ = 4.76 (d, J = 6.7 Hz, 1H), 4.61 (d, J = 6.7 Hz, 1H), 3.97 (q, J = 3.5 Hz, 
1H), 3.82 (d, J = 9.6 Hz, 1H), 3.65 (d, J = 9.6 Hz, 1H), 3.33 (dd, J = 10.2, 6.0 Hz, 1H), 3.30 (s, 3H), 2.33 
(dt, J = 20.2, 8.3 Hz, 1H), 2.24 – 2.14 (m, 1H), 2.08 – 1.99 (m, 1H), 1.95 (ddd, J = 18.0, 9.1, 4.7 Hz, 
1H), 1.82 (d, J = 12.3 Hz, 1H), 1.77 (dt, J = 5.8, 3.5 Hz, 1H), 1.71 – 1.57 (m, 2H), 1.51 (s, 3H), 1.50 – 
1.41 (m, 3H), 1.35 – 1.29 (m, 1H), 1.28 (s, 3H), 1.19 (td, J = 13.9, 3.7 Hz, 2H), 1.12 – 1.05 (m, 1H), 
1.03 (s, 9H), 0.95 (s, 3H), 0.11 (s, 6H). 
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13
C NMR (100 MHz, C6D6): δ = 95.2, 82.9, 71.8, 68.6, 55.1, 52.6, 49.2, 47.8, 45.2, 41.5, 39.8, 36.8, 
33.8, 30.4, 29.1, 28.5, 27.8, 27.3, 26.3, 23.6, 18.6, 17.0, −5.2, −5.3. 
 
IR (ATR): ṽ = 3473 (br), 2951 (s), 2928 (s), 2858 (m), 1472 (w), 1388 (w), 1362 (w), 1256 (m), 1214 
(w), 1137 (m), 1086 (s), 1038 (s), 918 (w), 853 (s), 836 (s), 814 (w), 774 (s), 669 (w) cm−1. 
 
HRMS (ESI): calc. for C26H50O4Si [M+H]
+: 455.3551, found: 455.3557. 
 
[α]
D
25
 = +27.0 (c = 0.63, THF) 
 
 
 
Martin’s sulfurane (1.98 g, 2.94 mmol, 2.19 eq.) was dissolved in MTBE (22 mL). To this was added 
a solution of spirocycle 11 (610 mg, 1.34 mmol, 1.00 eq.) in MTBE (25 mL) and the reaction was 
heated to 35 °C for 1.5 h. The reaction mixture was then concentrated under reduced pressure 
and the crude product was purified by column chromatography (SiO2, pentanes/Et2O = 1:0 to 97:3) 
which gave a 2:1 mixture of product 12 and side product 13 (583 mg, 1.33 mmol, 99% combined 
yield). A small sample of pure product could be obtained for characterization. 
 
Data for alkene 12: 
 
Rf = 0.53 (hexanes/EtOAc 9:1) 
 
1
H NMR (400 MHz, C6D6): δ = 5.85 (dt, J = 10.4, 2.0 Hz, 1H), 5.53 (dq, J = 10.6, 2.0 Hz, 1H), 4.76 (d, J 
= 6.7 Hz, 1H), 4.60 (d, J = 6.8 Hz, 1H), 3.82 (d, J = 9.7 Hz, 1H), 3.44 (d, J = 9.7 Hz, 1H), 3.28 (s, 3H), 
3.23 (dt, J = 10.5, 5.2 Hz, 1H), 2.22 (qd, J = 9.7, 5.1 Hz, 1H), 2.18 – 2.10 (m, 1H), 2.06 – 1.93 (m, 3H), 
1.88 – 1.77 (m, 2H), 1.74 (d, J = 12.1 Hz, 1H), 1.62 – 1.50 (m, 1H), 1.39 (dt, J = 13.7, 3.8 Hz, 1H), 
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1.34 – 1.30 (m, 1H), 1.29 (dd, J = 4.3, 2.8 Hz, 1H), 1.24 – 1.16 (m, 1H), 1.15 (dq, J = 12.0, 6.2, 5.2 Hz, 
1H), 1.01 (d, J = 1.9 Hz, 12H), 0.95 (s, 3H), 0.86 (s, 3H), 0.07 (s, 6H). 
 
13
C NMR (100 MHz, C6D6): δ = 130.8, 125.4, 94.7, 81.9, 70.5, 54.6, 49.8, 47.8, 46.6, 44.3, 39.9, 35.6, 
35.0, 33.4, 28.9, 27.7, 27.3, 25.8, 24.4, 23.4, 22.9, 18.2, −5.7, −5.8. 
 
IR (ATR): ṽ = 2953 (m), 2930 (m), 2858 (w), 1472 (w), 1448 (m), 1387 (w), 1310 (m), 1297 (w), 1256 
(w), 1154 (s), 1106 (m), 1042 (m), 999 (w), 852 (w), 837 (m), 763 (m), 734 (w), 690 (m) cm−1. 
 
HRMS (EI): calc. for C26H48O3Si [M]
+: 436.3367, found: 436.3367. 
 
[α]
D
25
 = +49.6 (c = 0.5, CHCl3) 
 
Data for cyclopropane 13: 
 
Rf = 0.53 (hexanes/EtOAc 9:1) 
 
1
H NMR (400 MHz, C6D6): δ = 4.68 (d, J = 6.7 Hz, 1H), 4.58 (d, J = 6.7 Hz, 1H), 3.76 (d, J = 9.7 Hz, 
1H), 3.41 (td, J = 10.1, 5.9 Hz, 1H), 3.33 (d, J = 9.7 Hz, 1H), 3.24 (s, 3H), 2.52 (ddd, J = 13.0, 9.5, 6.0 
Hz, 1H), 2.31 (d, J = 11.3 Hz, 1H), 2.07 (ddd, J = 9.6, 5.9, 3.5 Hz, 1H), 1.99 (dd, J = 12.3, 7.4 Hz, 1H), 
1.95 – 1.87 (m, 1H), 1.63 – 1.50 (m, 1H), 1.46 (ddd, J = 12.8, 10.2, 2.2 Hz, 1H), 1.35 (dd, J = 10.3, 5.0 
Hz, 2H), 1.32 – 1.23 (m, 3H), 1.17 (s, 3H), 1.08 – 1.03 (m, 2H), 1.03 (s, 9H), 1.01 (s, 3H), 0.96 (d, J = 
4.0 Hz, 1H), 0.86 (s, 3H), 0.46 (ddd, J = 9.0, 6.3, 2.1 Hz, 1H), 0.08 (s, 6H).  
 
13
C NMR (100 MHz, C6D6): δ = δ 95.3, 79.0, 71.3, 54.9, 48.1, 46.1, 45.9, 41.5, 38.4, 33.4, 32.4, 31.5, 
30.5, 28.9, 28.5, 27.3, 26.2, 23.0, 22.8, 21.8, 18.8, 18.5, −5.3, −5.4. 
 
IR (ATR): ṽ = 2950 (s), 2928 (s), 2858 (m), 1471 (w), 1383 (w), 1361 (w), 1256 (w), 1148 (w), 1097 
(s), 1040 (s), 918 (w), 853 (s), 836 (s), 774 (m), 668 (w) cm−1.  
 
HRMS (EI): calc. for C26H48O3Si [M]
+: 436.3367, found: 436.3359. 
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EtOAc, 40 °C
(62%)
Mn(OAc)3 • 2H2O,
TBHP, 3 Å MS
12
Me
H
TBSO
H
OMOM
14
Me
H
TBSO
H
OMOM
O
 
To a 2:1 mixture of alkene 12 and side product 13 (combined 583 mg, 1.33 mmol, 1.00 eq.) in 
EtOAc (16.5 mL) and 3 Å molecular sieves (583 mg) was added TBHP (2.66 mL, 5-6 M in decane, 
~13.3 mmol, ~10.0 eq.). The suspension was stirred at r.t. for 30 min. and Mn(OAc)3•2H2O (340 
mg, 1.27 mmol, 0.95 eq.) was added. The red-brown reaction mixture was heated to 40 °C for 21 h 
after which it was filtered over celite and concentrated under reduced pressure. Column 
chromatography (SiO2, hexanes/EtOAc = 1:0 to 85:15) gave the desired product 14 (250 mg, 0.555 
mmol, 62% yield) as a colorless oil. 
 
Rf = 0.38 (hexanes/EtOAc 8:2) 
 
1
H NMR (400 MHz, C6D6, 60 °C): δ = 6.60 (d, J = 10.5 Hz, 1H), 5.95 (d, J = 10.5 Hz, 1H), 4.68 (dd, J = 
6.6, 0.7 Hz, 1H), 4.56 (dd, J = 6.5, 0.7 Hz, 1H), 3.65 (d, J = 10.0 Hz, 1H), 3.29 (dd, J = 10.1, 1.0 Hz, 
1H), 3.26 (d, J = 0.8 Hz, 3H), 3.15 (td, J = 10.3, 4.8 Hz, 1H), 2.71 (d, J = 16.5 Hz, 1H), 2.18 (d, J = 16.5 
Hz, 1H), 2.11 (ddd, J = 14.4, 7.4, 4.4 Hz, 1H), 1.98 – 1.90 (m, 2H), 1.81 (d, J = 12.4 Hz, 1H), 1.77 (dt, J 
= 8.0, 3.8 Hz, 1H), 1.40 – 1.35 (m, 3H), 1.25 – 1.21 (m, 1H), 1.20 – 1.14 (m, 2H), 0.96 (s, 3H), 0.95 (s, 
9H), 0.81 (s, 3H), 0.73 (d, J = 0.8 Hz, 3H), 0.02 (dd, J = 2.6, 0.7 Hz, 6H). 
 
13
C NMR (100 MHz, C6D6, 60 °C): δ = 197.8, 151.6, 95.4, 81.8, 70.3, 55.1, 52.5, 50.6, 48.0, 47.3, 
47.0, 40.3, 39.3, 34.0, 30.2, 29.0, 28.4, 27.6, 26.2, 24.7, 23.5, 18.5, −5.3, −5.4. 
 
IR (ATR): ṽ = 2954 (m), 2929 (m), 2858 (m), 1675 (m), 1471 (w), 1389 (w), 1362 (w), 1258 (m), 1092 
(s), 1041 (s), 917 (m), 837 (s), 815 (m), 776 (s), 668 (m) cm−1. 
 
 
HRMS (EI): calc. for C26H46O4Si [M]
+: 450.3165, found: 450.3162. 
 
[α]
D
25
 = +35.4 (c = 0.39, THF) 
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To a solution of enone 14 (250 mg, 0.555 mmol, 1.00 eq. in THF (25 mL) was added TBAF (2.42 mL, 
1 M in THF, 2.42 mmol, 4.40 eq.) at 0 °C. After 30 min, the reaction was allowed to warm to r.t. and 
stirred for 6 h. The reaction was quenched with a sat. aq. solution of NH4Cl (25 mL) and the 
aqueous phase was extracted with EtOAc (3 x 25 mL). The combined organic layers were washed 
with brine, dried over Na2SO4, filtered and concentrated. The resulting residue was purified by 
column chromatography (SiO2, hexanes/EtOAc = 9:1 to 1:1) to afford the desired product S11 
(141 mg, 0.419 mmol, 76% yield) as a pale brown oil. 
Rf = 0.32 (hexanes/EtOAc 1:1) 
 
1
H NMR (400 MHz, C6D6, 60 °C): δ = 6.55 (d, J = 10.5 Hz, 1H), 5.93 (d, J = 10.5 Hz, 1H), 4.67 (d, J = 
6.7 Hz, 1H), 4.54 (d, J = 6.7 Hz, 1H), 3.40 (d, J = 10.6 Hz, 1H), 3.26 (d, J = 0.5 Hz, 3H), 3.09 (dq, J = 
10.3, 5.2 Hz, 3H), 2.66 (d, J = 16.6 Hz, 1H), 2.16 (d, J = 16.5 Hz, 1H), 2.08 – 2.00 (m, 1H), 1.95 – 1.86 
(m, 1H), 1.80 – 1.70 (m, 2H), 1.64 (d, J = 12.3 Hz, 1H), 1.34 – 1.27 (m, 2H), 1.16 – 1.07 (m, 3H), 0.89 
(s, 3H), 0.78 (s, 3H), 0.66 (s, 3H). 
 
13
C NMR (100 MHz, C6D6, 60 °C): δ = 197.9, 151.5, 129.0, 95.3, 81.5, 69.8, 55.1, 52.4, 50.9, 47.8, 
47.1, 39.5, 39.3, 34.0, 28.5, 28.4, 27.7, 24.4, 23.2. 
 
IR (ATR): ṽ = 3460 (br), 2956 (m), 2935 (m), 2880 (m), 1671 (s), 1441 (w), 1400 (w), 1266 (w), 1202 
(m), 1146 (w), 1102 (m), 1039 (s), 915 (w) cm−1. 
 
HRMS (EI): calc. for C20H32O4 [M]
+: 336.2301, found: 336.2301. 
 
[α]
D
25
 = +74.5 (c = 0.22, THF) 
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DCM, 0 °C
(89%)
MsCl, TEA
S11
Me
H
OH
H
OMOM
O
15
Me
H
OMs
H
OMOM
O
 
Alcohol S11 (140 mg, 0.416 mmol, 1.00 eq.) was dissolved in DCM (14 mL) and cooled to 0 °C. 
Triethylamine (141 µL, 1.01 mmol, 2.43 eq.) and MsCl (91 µL, 1.18 mmol, 2.83 eq.) were added 
and the reaction was stirred for 1.5 h, after which it was quenched with water (10 mL). The layers 
were separated and the aqueous phase was extracted with DCM (3 x 10 mL). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The 
resulting residue was purified by column chromatography (SiO2, hexanes/EtOAc = 8:2 to 1:1) to 
afford the desired product 15 (156 mg, 0.37 mmol, 89% yield) as a colorless oil. 
 
Rf = 0.28 (hexanes/EtOAc 1:1) 
 
1
H NMR (400 MHz, C6D6, 60 °C): δ = 6.45 (d, J = 10.5 Hz, 1H), 5.89 (d, J = 10.5 Hz, 1H), 4.65 (d, J = 
6.7 Hz, 1H), 4.52 (d, J = 6.7 Hz, 1H), 4.04 – 3.97 (m, 2H), 3.25 (s, 3H), 3.02 (td, J = 10.4, 4.8 Hz, 1H), 
2.41 (d, J = 16.7 Hz, 1H), 2.22 (s, 3H), 2.17 (d, J = 16.6 Hz, 1H), 2.01 – 1.94 (m, 1H), 1.81 (ddt, J = 
13.6, 10.2, 3.4 Hz, 2H), 1.72 – 1.65 (m, 1H), 1.40 (d, J = 12.3 Hz, 1H), 1.31 – 1.16 (m, 2H), 1.16 – 
1.02 (m, 3H), 0.80 (s, 3H), 0.71 (s, 3H), 0.66 (s, 3H). 
 
13
C NMR (100 MHz, C6D6, 60 °C): δ = 197.1, 150.9, 129.1, 95.3, 81.0, 76.2, 55.1, 52.2, 51.9, 47.1, 
46.8, 46.1, 39.7, 39.3, 36.8, 34.3, 28.3, 28.1, 27.1, 24.7, 22.4. 
 
IR (ATR): ṽ = 3358 (w), 2957 (s), 2925 (s), 2673 (s), 1633 (w), 1468 (w), 1400 (w), 1357 (s), 1261 
(m), 1212 (w), 1176 (s), 1101 (m), 1039 (s), 957 (m), 800 (m) cm−1.  
 
HRMS (ESI): calc. for C21H34O6S [M+NH4]
+: 432.2414, found: 432.2416. 
 
[α]
D
25
 = +31.8 (c = 0.22, THF) 
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To a solution of KHMDS (0.5 M in toluene, 0.770 mL, 0.385 mmol, 4.00 eq.) in THF (7.6 mL) was 
added enone 15 (40 mg, 0.0965 mmol, 1.00 eq.) in THF (7.6 mL) dropwise at –78 °C. After 1 h, the 
reaction mixture was allowed to warm up to –25 °C over 1 h and kept at that temperature for 2 h, 
after which it was quenched through the addition of water (20 mL). The aqueous phase was 
extracted with Et2O (3 x 25 mL), the combined organic layers were washed with brine, dried over 
sodium sulfate, filtered and concentrated. The resulting residue was purified by column 
chromatography (SiO2, hexanes/EtOAc = 9:1 to 8:2) to afford the desired product 16 (44 mg, 0.138 
mmol, 71% yield) as a white solid. 
 
Rf = 0.38 (hexanes/EtOAc 8:2) 
 
Mp = 77.6 – 79.0 °C 
 
1
H NMR (400 MHz, C6D6): δ = 6.05 (s, 2H), 4.69 (d, J = 6.8 Hz, 1H), 4.58 (d, J = 6.8 Hz, 1H), 3.26 (s, 
3H), 3.11 (td, J = 10.2, 3.9 Hz, 1H), 2.13 (dd, J = 4.6, 3.1 Hz, 1H), 1.94 (dd, J = 13.7, 3.0 Hz, 1H), 1.90 
– 1.82 (m, 1H), 1.82 – 1.76 (m, 1H), 1.68 (dd, J = 13.7, 4.7 Hz, 1H), 1.60 – 1.49 (m, 1H), 1.41 (dddd, J 
= 13.4, 11.1, 7.0, 1.8 Hz, 1H), 1.26 (dd, J = 10.6, 3.9 Hz, 1H), 1.22 – 1.18 (m, 1H), 1.16 (d, J = 13.5 
Hz, 1H), 1.02 (dt, J = 13.9, 3.9 Hz, 1H), 0.98 – 0.90 (m, 2H), 0.82 (s, 3H), 0.77 (s, 3H), 0.67 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 202.9, 149.5, 133.4, 94.9, 82.1, 57.9, 55.0, 48.6, 43.6, 42.2, 41.8, 
40.4, 39.8, 39.0, 29.1, 28.1, 27.1, 23.6, 22.3, 22.2. 
 
IR (ATR): ṽ = 2930 (s), 1674 (s), 1466 (w), 1445 (w), 1386 (w), 1146 (m), 1103 (m), 1042 (s), 918 
(w), 823 (w) cm−1. 
 
HRMS (EI): calc. for C20H30O3 [M]
+: 318.2189, found: 318.2193. 
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[α]
D
25
 = +155 (c = 0.24, THF) 
 
 
(65%)
CuI, MeLi, BF3•Et2O
Et2O, 78 °C to 60 °C OMOM
O
16
O
OMOM
17  
To as suspension of CuCN (11.7 mg, 0.131 mmol, 5.20 eq.) in Et2O at –40 °C was added a solution 
of MeLi (1.54 M in Et2O, 0.080 mL, 0.123 mmol, 4.90 eq.). The mixture was stirred for 15 min., then 
cooled to –78 °C and enone 16 (8.0 mg, 0.0251 mmol, 1.00 eq.) in Et2O (0.25 mL) was added 
dropwise, upon which the reaction turned bright orange. After 1 h, the reaction mixture was 
allowed to warm up to –60 °C and stirred for an additional 1 h, after which it was quenched with a 
9:1 mixture of sat. aq. NH4Cl-solution and aq. NH3-solution (3 mL). The aqueous phase was 
extracted with Et2O (3 x 5 mL), the combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated. The resulting residue was purified by column chromatography 
(SiO2, hexanes/EtOAc = 95:5 to 8:2) to afford the desired product 17 (5.5 mg, 0.0164 mmol, 65% 
yield) as a colorless oil. 
Note: The reaction was sensitive to scale up and gave varying yields on a larger scale. 
 
Rf = 0.32 (hexanes/EtOAc 8:2) 
 
1
H NMR (400 MHz, C6D6): δ = 4.72 (d, J = 6.8 Hz, 1H), 4.59 (d, J = 6.8 Hz, 1H), 3.28 (s, 3H), 3.13 (td, J 
= 10.1, 4.2 Hz, 1H), 2.69 (dd, J = 20.3, 9.3 Hz, 1H), 2.06 – 1.99 (m, 2H), 1.96 (dd, J = 8.6, 4.5 Hz, 2H), 
1.93 – 1.87 (m, 1H), 1.84 (dt, J = 7.6, 4.5 Hz, 1H), 1.72 (dtd, J = 13.0, 9.3, 6.3 Hz, 1H), 1.61 (dd, J = 
13.3, 4.7 Hz, 1H), 1.53 – 1.42 (m, 2H), 1.28 – 1.17 (m, 2H), 1.15 (d, J = 13.2 Hz, 1H), 0.91 (qd, J = 
14.2, 12.7, 9.4 Hz, 2H), 0.77 (d, J = 7.0 Hz, 3H), 0.74 (s, 3H), 0.68 (s, 3H), 0.65 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 214.7, 94.9, 82.7, 58.3, 55.0, 53.9, 48.7, 43.0, 41.0, 39.7, 39.5, 39.0, 
38.2, 30.6, 27.5, 26.9, 26.3, 25.2, 24.4, 21.0, 20.9. 
 
IR (ATR): ṽ = 2937 (m), 2877 (m), 1700 (m), 1446 (w), 1386 (w), 1247 (w), 1219 (w), 1188 (w), 1148 
(m), 1101 (m), 1044 (s), 1033 (m), 926 (w), 915 (w), 799 (w) cm−1. 
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HRMS (EI): calc. for C21H34O3 [M]
+: 334.2508, found: 334.2502. 
 
[α]
D
25
 = +40.5 (c = 0.16, THF) 
 
 
 
A solution of ketone 17 (25.0 mg, 0.0747 mmol, 1.00 eq.) in THF (2.5 mL) was cooled to 0 °C and 
LAH (1 M solution in Et2O, 0.75 mL, 0.750 mmol, 10.0 eq.) was added dropwise. The reaction was 
stirred for 2.5 h and was quenched through the addition of water (0.03 mL), NaOH (0.04 mL of an 
aq. 10% solution) and water (0.08 mL). The mixture was then allowed to stir for 5 min at r.t., after 
which Na2SO4 was added. The mixture was stirred for 10 min and then filtered through a plug of 
silica and concentrated under reduced pressure. The crude product was purified by column 
chromatography (SiO2, hexanes/EtOAc = 98:2 to 9:1). The desired product S12 (23.9 mg, 0.0710 
mmol, 95%) was obtained as a colorless oil. 
 
Rf = 0.32 (hexanes/EtOAc 8:2) 
 
1
H NMR (400 MHz, C6D6): δ = 4.74 (d, J = 6.8 Hz, 1H), 4.62 (d, J = 6.8 Hz, 1H), 4.05 (dd, J = 12.5, 6.8 
Hz, 1H), 3.29 (s, 3H), 3.21 (ddd, J = 14.4, 9.1, 4.2 Hz, 1H), 2.15 – 2.07 (m, 2H), 1.99 – 1.93 (m, 2H), 
1.92 – 1.86 (m, 1H), 1.86 – 1.77 (m, 1H), 1.70 – 1.61 (m, 1H), 1.58 – 1.50 (m, 2H), 1.46 – 1.38 (m, 
3H), 1.31 – 1.20 (m, 2H), 1.16 (d, J = 13.2 Hz, 1H), 1.11 (t, J = 7.0 Hz, 1H), 1.06 (s, 3H), 0.99 (dd, 
J = 14.1, 3.6 Hz, 1H), 0.88 (d, J = 6.6 Hz, 3H), 0.85 (s, 3H), 0.81 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 94.9, 83.0, 66.9, 55.0, 53.5, 47.9, 44.5, 40.4, 40.2, 39.3, 38.1, 37.9, 
33.3, 30.9, 27.8, 27.7, 27.5, 25.8, 24.6, 23.1, 20.9. 
 
IR (ATR): ṽ = 2476 (br), 2930 (s), 2872 (m), 1465 (w), 1448 (w), 1384 (w), 1147 (w), 1101 (m), 1083 
(w), 1050 (s), 919 (w) cm−1. 
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HRMS (EI): calc. for C21H36O3 [M]
+: 336.2659, found: 336.2661. 
 
[α]
D
25
 = +29.2 (c = 0.14, THF) 
 
 
KHMDS, CS2, MeI
(95%)
THF, 78 °C to r.t.OMOM
OH
S12
OMOM
O
S13
S S
 
A solution of alcohol S12 (13.0 mg, 0.0386 mmol, 1.00 eq.) in THF (1.0 mL) was cooled to –78 °C 
and CS2 (0.055 mL, 0.915 mmol, 23.7 eq.) and KHMDS (1 M solution in toluene, 0.12 mL, 0.060 
mmol, 1.55 eq.) were added. After 20 min., the orange reaction mixture was allowed to warm to 
r.t. and stirred for 55 min after which MeI (0.060 mL, 0.964 mmol, 24.9 eq.) was added. The 
yellow-white suspension was stirred for another 45 min and then quenched through the addition 
of water (5 mL). The aqueous phase was extracted with Et2O (3 x 5 mL), the combined organic 
layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The resulting 
residue was purified by column chromatography (SiO2, hexanes/Et2O = 95:5 to 9:1) to afford the 
desired product S13 (15.6 mg, 0.0367 mmol, 95% yield) as a yellow oil. 
 
Rf = 0.57 (hexanes/EtOAc 9:1) 
 
1
H NMR (400 MHz, C6D6): δ = 6.21 (ddd, J = 10.7, 8.9, 3.9 Hz, 1H), 4.72 (d, J = 6.8 Hz, 1H), 4.60 (d, J 
= 6.8 Hz, 1H), 3.28 (s, 3H), 3.15 (td, J = 10.1, 4.1 Hz, 1H), 2.19 (s, 3H), 2.12 – 2.02 (m, 3H), 2.01 – 
1.96 (m, 1H), 1.92 (ddd, J = 14.1, 8.4, 2.7 Hz, 2H), 1.88 – 1.82 (m, 1H), 1.81 – 1.74 (m, 1H), 1.58 – 
1.51 (m, 1H), 1.49 – 1.39 (m, 3H), 1.23 – 1.17 (m, 1H), 1.12 (d, J = 13.2 Hz, 1H), 1.09 – 1.04 (m, 1H), 
1.04 (s, 3H), 0.91 (dd, J = 13.7, 3.3 Hz, 1H), 0.82 (s, 3H), 0.79 (d, J = 6.7 Hz, 3H), 0.77 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 215.2, 94.9, 82.8, 81.9, 55.0, 53.4, 44.2, 43.9, 40.2, 39.3, 38.2, 38.0, 
36.6, 34.7, 30.9, 27.7, 27.4, 25.4, 24.2, 22.6, 20.8, 18.8, 1.4. 
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IR (ATR): ṽ = 2925 (m), 1464 (w), 1381 (w), 1258 (m), 1214 (m), 1145 (w), 1099 (m), 1044 (s), 797 
(m) cm−1. 
 
HRMS (EI): calc. for C23H38O3S2 [M-C2H3S2]
+: 335.2581, found: 335.2586. 
 
[α]
D
25
 = +32.0 (c = 0.13, THF) 
 
 
AIBN, Bu3SnH
(78%)
benzene, 80 °C
OMOM
O
S13
S S
OMOM
S14  
To a solution of xanthate S13 (22.7 mg, 0.0532 mmol, 1.00 eq.) in degassed benzene (2.0 mL) were 
added AIBN (4.1 mg, 0.0250 mmol, 0.47 eq.) and Bu3SnH (0.070 mL, 0.260 mmol, 4.89 eq.). The 
reaction mixture was heated to 80 °C for 40 min after which it was concentrated. The resulting 
residue was purified by column chromatography (SiO2, hexanes/Et2O = 1:0 to 95:5) to afford the 
desired product S14 (13.3 mg, 0.0415 mmol, 78% yield) as a colorless oil. 
 
Rf = 0.43 (hexanes/EtOAc 9:1) 
 
1
H NMR (600 MHz, C6D6): δ = 4.76 (dd, J = 6.9, 1.1 Hz, 1H), 4.63 (dd, J = 6.8, 1.1 Hz, 1H), 3.30 (d, J = 
1.0 Hz, 3H), 3.21 (td, J = 10.1, 4.2 Hz, 1H), 2.16 – 2.08 (m, 1H), 2.07 – 1.99 (m, 1H), 1.99 – 1.94 (m, 
1H), 1.94 – 1.87 (m, 2H), 1.87 – 1.82 (m, 1H), 1.68 (dd, J = 13.4, 4.2 Hz, 1H), 1.64 (dt, J = 13.9, 3.5 
Hz, 1H), 1.61 – 1.54 (m, 2H), 1.49 (dd, J = 13.4, 2.9 Hz, 1H), 1.43 – 1.38 (m, 2H), 1.36 (td, J = 6.9, 
6.1, 1.9 Hz, 1H), 1.34 – 1.28 (m, 1H), 1.14 (d, J = 13.1 Hz, 1H), 1.10 – 1.05 (m, 1H), 1.03 (dd, J = 
14.0, 3.5 Hz, 1H), 1.00 (s, 3H), 0.98 (d, J = 1.3 Hz, 3H), 0.96 (dd, J = 6.9, 1.1 Hz, 3H), 0.84 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 94.9, 83.1, 55.0, 53.8, 43.9, 43.2, 41.5, 40.4, 39.3, 38.8, 38.4, 31.2, 
29.0, 27.8, 27.3, 27.2, 26.0, 25.9, 25.0, 22.8, 20.6. 
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IR (ATR): ṽ = 2931 (s), 2877 (m), 2360 (w), 1462 (w), 1380 (w), 1259 (w), 1146 (w), 1100 (m), 1045 
(s), 1034 (s), 918 (w), 797 (w) cm−1. 
 
HRMS (EI): calc. for C21H36O2 [M]
+: 320.2710, found: 320.2721.  
 
[α]
D
25
 = +46.7 (c = 0.12, THF) 
 
 
 
To a solution of compound S14 (12.0 mg, 0.0374 mmol, 1.00 eq.) in THF (1.4 mL) was added conc. 
HCl (0.090 mL, 1.08 mmol, 28.8 eq.). The reaction mixture was stirred for 4.5 h after which it was 
quenched through the addition of Na2CO3 (3 mL). The aqueous phase was extracted with EtOAc (3 
x 3 mL), the combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated. The resulting residue was purified by column chromatography (SiO2, hexanes/Et2O = 
95:5 to 8:2) to afford the desired alcohol S15 (9.8 mg, 0.0354 mmol, 94% yield) as a milky oil. 
 
Rf = 0.41 (hexanes/EtOAc 8:2) 
 
1
H NMR (400 MHz, C6D6): δ = 3.02 (ddd, J = 10.4, 8.8, 4.3 Hz, 1H), 2.09 – 1.96 (m, 2H), 1.96 – 1.84 
(m, 2H), 1.73 – 1.64 (m, 2H), 1.59 (tt, J = 11.1, 3.5 Hz, 2H), 1.53 – 1.43 (m, 3H), 1.43 – 1.32 (m, 3H), 
1.18 (tdd, J = 13.2, 10.7, 2.9 Hz, 1H), 1.10 – 1.01 (m, 3H), 1.00 (s, 3H), 0.98 – 0.94 (m, 6H), 0.83 (s, 
3H). 
 
13
C NMR (100 MHz, C6D6): δ = 78.0, 53.6, 44.0, 43.2, 42.3, 41.5, 39.3, 38.8, 38.4, 34.7, 29.0, 28.0, 
27.3, 26.7, 26.0, 25.9, 24.9, 22.8, 20.7. 
 
IR (ATR): ṽ = 3323 (br), 3011 (w), 2984 (w), 2931 (s), 2876 (s), 1461 (m), 1380 (m), 1364 (w), 1350 
(w), 1286 (w), 1224 (w), 1186 (w), 1149 (w), 1119 (w), 1082 (w), 1049 (m), 1013 (w), 996(w), 962 
(w), 941(w), 875 (w), 703 (w) cm−1. 
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HRMS (EI): calc. for C19H32O [M]
+: 276.2448, found: 276.2444. 
 
[α]
D
25
 = +33.3 (c = 0.24, THF) 
 
 
To a solution of alcohol S15 (9.5 mg, 0.0344 mmol, 1.00 eq.) in DCM (0.75 mL) were added 
pyridine (0.015 mL, 0.185 mmol, 5.40 eq.) and DMP (81.0 mg, 0191 mmol, 5.56 eq.). The reaction 
mixture was stirred for 4 h after which it was quenched through the addition of aq. Na2S2O3-
solution (0.5 mL) and sat. aq. NaHCO3-solution (3 mL). The aqueous phase was extracted with 
DCM (3 x 3 mL), the combined organic layers were washed with brine, dried over sodium sulfate, 
filtered and concentrated. The resulting residue was purified by column chromatography (SiO2, 
hexanes/Et2O = 95:5 to 9:1) to afford the desired ketone 18 (8.9 mg, 0.0324 mmol, 95% yield) as a 
white solid. 
 
Rf = 0.38 (hexanes/EtOAc 9:1) 
 
Mp = 95.5 – 97.8 °C 
 
1
H NMR (400 MHz, C6D6): δ = 2.43 (dddd, J = 13.3, 11.0, 6.7, 1.6 Hz, 1H), 2.24 – 2.14 (m, 2H), 2.02 – 
1.91 (m, 2H), 1.92 – 1.78 (m, 2H), 1.67 (ddd, J = 13.8, 5.2, 2.9 Hz, 1H), 1.64 – 1.56 (m, 1H), 1.55 – 
1.45 (m, 2H), 1.43 (d, J = 14.4 Hz, 1H), 1.40 – 1.30 (m, 3H), 1.30 – 1.24 (m, 2H), 0.95 (d, J = 10.8 Hz, 
1H), 0.91 (s, 3H), 0.87 (d, J = 6.6 Hz, 3H), 0.84 (s, 3H), 0.64 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 210.1, 57.9, 46.6, 42.9, 42.4, 41.3, 40.7, 40.4, 38.9, 38.8, 31.2, 28.9, 
26.5, 25.7, 25.7, 24.9, 23.2, 20.2, 19.8. 
 
IR (ATR): ṽ = 2955 (m), 2924 (s), 2864 (m), 1720 (m), 1462 (w), 1380 (w), 1260 (m), 1083 (m), 1017 
(m), 797 (m) cm−1. 
 
DMP, pyr
(95%)
DCMOH
S15
O
18
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HRMS (EI): calc. for C19H30O [M]
+: 274.2291, found: 274.2286. 
 
[α]
D
25
 = +17.6 (c = 0.34, CHCl3) 
 
 
 
To a suspension of Ph3CH3Br (82.2 mg, 0.230 mmol, 15.8 eq.) in THF at –78 °C was added n-BuLi 
(2.27 M in hexanes, 0.10 mL, 0.227 mmol, 15.6 eq.). The mixture was allowed to warm to 0 °C and 
stirred for 30 min., after which it was an orange solution. An aliquot (0.13 mL, 0.0260 mmol, 2.47 
eq.) was taken, cooled to –78 °C and ketone 18 (4.0 mg, 0.0146 mmol, 1.00 eq.) in THF (0.48 mL) 
was added. The reaction mixture was stirred for 1 h and then allowed to warm to –50 °C over the 
course of 1 h. The reaction was quenched through the addition of water (3 mL). The aqueous 
phase was extracted with Et2O (3 x 3 mL), the combined organic layers were washed with brine, 
dried over sodium sulfate, filtered and concentrated. The resulting residue was purified by column 
chromatography (SiO2, pentane) to afford the desired alkene 19 (2.6 mg, 0.00954 mmol, 65% 
yield) as a colorless oil. 
 
Rf = 0.73 (hexanes) 
 
1
H NMR (400 MHz, C6D6): δ = 4.83 (dd, J = 20.8, 2.1 Hz, 2H), 2.26 – 2.21 (m, 1H), 2.21 – 2.15 (m, 
1H), 2.11 – 2.00 (m, 3H), 1.99 – 1.92 (m, 1H), 1.91 – 1.86 (m, 1H), 1.86 – 1.78 (m, 1H), 1.78 – 1.73 
(m, 1H), 1.68 (dd, J = 13.4, 4.3 Hz, 1H), 1.59 (ddd, J = 14.3, 10.8, 6.1 Hz, 1H), 1.50 – 1.42 (m, 2H), 
1.38 (dq, J = 10.5, 4.0, 3.1 Hz, 2H), 1.26 (d, J = 13.7 Hz, 1H), 1.24 – 1.16 (m, 1H), 1.09 (td, J = 10.6, 
10.0, 7.7 Hz, 1H), 0.99 (d, J = 6.7 Hz, 9H), 0.84 (s, 3H). 
 
13
C NMR (100 MHz, C6D6): δ = 153.3, 103.2, 56.7, 43.6, 43.3, 41.4, 39.4, 39.3, 39.2, 38.9, 34.8, 30.8, 
29.2, 27.0, 26.0, 25.9, 24.9, 23.5, 23.2, 20.4. 
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IR (ATR): ṽ = 3074 (w), 2985 (m), 2877 (s), 2929 (s), 1650 (m), 1461 (m), 1448 (m), 1378 (m), 1364 
(w), 1349 (w), 1259 (w), 1223 (w), 1192 (w), 1148 (w), 1084 (w), 1056 (w), 1035 (w), 942 (w), 883 
(s), 798 (w), 704 (w) cm−1. 
 
HRMS (EI): calc. for C20H32 [M]
+: 272.2499, found: 272.2507. 
 
[α]
D
25
 = +13.7 (c = 0.19, CHCl3) 
 
 
 
To a solution of alkene 19 (3.0 mg, 0.011 mmol, 1.00 eq.) in 1,4-dioxane (0.46 mL, purged with O2 
for 20 min.) was added Co(acac)2 (0.6 mg, 0.00233 mmol, 0.21 eq.). O2 was bubbled through for 30 
sec and then PhSiH3 was added (1 M in 1,4-dioxane, 55 μL, 5.0 eq.). The pink-purple reaction 
mixture was stirred for 3 h, after which it has turned green and was quenched through the 
addition of aq. Na2S2O3-solution (0.5 mL). The aqueous phase was extracted with Et2O (3 x 0.5 mL), 
the combined organic layers, dried over sodium sulfate, filtered and concentrated. The resulting 
residue was purified by column chromatography (SiO2, hexanes/Et2O = 95:5 to 8:2) to afford epi-
wickerol A (20) (0.90 mg, 30.8 μmol, 28% yield) and wickerol A (1) (1.0 mg, 3.44 μmol, 31% yield) 
as a colorless oil. 
 
Data for epi-wickerol A (20): 
 
Rf = 0.41 (hexanes/EtOAc 9:1) 
 
1
H NMR (600 MHz, C6D6): δ = 2.12 – 2.03 (m, 1H), 1.99 – 1.91 (m, 2H), 1.78 (dd, J = 13.3, 4.2 Hz, 
1H), 1.71 (d, J = 13.2 Hz, 1H), 1.67 – 1.60 (m, 3H), 1.59 – 1.54 (m, 1H), 1.53 (ddd, J = 13.3, 3.0, 1.1 
Hz, 1H), 1.50 – 1.42 (m, 4H), 1.42 – 1.37 (m, 2H), 1.23 (tdd, J = 13.8, 3.4, 1.0 Hz, 1H), 1.12 (dtt, J = 
11.1, 9.8, 1.3 Hz, 1H), 1.04 (s, 3H), 1.03 (d, J = 1.0 Hz, 3H), 1.02 (s, 3H), 0.99 (d, J = 6.0 Hz, 6H). 
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13
C NMR (100 MHz, C6D6): δ = 69.7, 48.3, 44.0, 43.4, 43.0, 41.5, 39.2, 39.1, 38.9, 38.8, 29.8, 29.2, 
26.6, 26.2, 26.1, 24.9, 23.8, 23.6, 21.5, 20.4. 
IR (ATR): ṽ = 3474 (br), 3177(w), 2956 (s), 2929 (s), 2878 (s), 2525 (w), 1583 (m), 1506 (m), 1380 
(s), 1330 (s), 1114 (m), 1039 (m), 911 (m), 891 (s), 695 (m) cm−1. 
 
HRMS (EI): calc. for C20H34O [M]
+: 290.2604, found: 290.2603. 
 
[α]
D
25
 = +15.3 (c = 0.17, CHCl3) 
 
Data for wickerol A (1): 
 
Rf = 0.33 (hexanes/EtOAc 8:2) 
 
IR (ATR): ṽ = 3372 (br), 2954 (s), 2927 (s), 2877 (m), 1584 (w), 1464 (w), 1382 (m), 1329 (w), 1133 
(w), 1099 (w), 907 (w), 891 (w), 698 (w) cm−1. 
 
HRMS (EI): calc. for C20H34O [M]
+: 290.2604, found: 290.2596. 
 
[α]
D
25
 = +21.7 (c = 0.23, CHCl3) 
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Table 1. Comparison of 1H NMR data of synthetic and isolated wickerol A (1). 
 
No. 
1
H NMR Isolation 
600 MHz, CDCl3 [ppm] 
1
H NMR Synthetic 
600 MHz, CDCl3 [ppm] 
1 
1.01 (d, J = 11.2 Hz, 1H) 
1.41 (d, J = 11.2 Hz, 1H) 
1.00 (dd, J = 10.3, 1.3 Hz, 1H) 
1.42 – 1.40 (m, 1H) 
2 
1.56 (m, 1H) 
1.78 (m, 1H) 
1.58 – 1.54 (m, 1H) 
1.82 – 1.75 (m, 1H) 
2a 1.87 (ddd, J = 13.4, 10.0, 6.1 Hz, 1H) 1.87 (ddd, J = 13.2, 10.0, 6.1 Hz, 1H) 
3 - - 
4 
1.44 (m, 1H) 
1.57 (ddd, J = 12.8, 3.6, 3.5 Hz, 1H) 
1.45 – 1.42 (m, 1H) 
1.58 (dt, J = 12.7, 3.5 Hz, 1H) 
5 
1.2  (ddd, J = 14.2, 14.2, 3.5 Hz, 1H) 
1.68 (m, 1H) 
1.21 (td, J = 14.2, 3.5 Hz, 1H) 
1.71 – 1.68 (m, 1H) 
5a - - 
6 2.11 (m, 1H) 2.14 – 2.10 (m, 1H), 
7 
1.46 (m, 1H) 
2.00 (dddd, J = 15.5, 11.2, 11.2, 2.6 Hz, 
1H) 
1.48 – 1.45 (m, 1H) 
2.00 (dtd, J = 15.6, 11.0, 2.7 Hz, 1H) 
8 
1.61 (m, 1H) 
2.09 (m, 1H) 
1.64 – 1.60 (m, 1H) 
2.10 (s, 1H) 
9 1.48 (m, 1H) 1.51 – 1.48 (m, 2H) 
10 
1.49 (m, 1H) 
1.67 (dd, J = 12.3, 4.2 Hz, 1H) 
1.51 – 1.48 (m, 2H) 
1.69 – 1.66 (m, 1H) 
10a - - 
10b 1.27 (d, J = 13.4 Hz, 1H) 1.27 (d, J = 13.5 Hz, 1H) 
11 - - 
12 1.17 (s, 3H) 1.18 (s, 3H) 
13 1.02 (d, J = 7.0 Hz, 3H) 1.02 (d, J = 7.0 Hz, 3H) 
14 1.046 (s, 3H) 1.05 (s, 3H) 
15 0.94 (s, 3H) 0.94 (s, 3H) 
16 1.051 (s, 3H) 1.05 (s, 3H) 
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Table 2. Comparison of 13C NMR data of synthetic and isolated wickerol A (1). 
No.
 
13
C NMR Isolation 
125 MHz, CDCl3 [ppm] 
13
C NMR Synthetic 
100 MHz, CDCl3 [ppm] 
1 43.9 43.0 
2 21.6 21.7 
2a 44.4 44.5 
3 73.9 74.1 
4 40.8 40.9 
5 26.4 26.5 
5a 38.8 38.9 
6 26.6 26.8 
7 28.8 29.0 
8 25.7 25.8 
9 41.1 41.1 
10 43.0 43.1 
10a 39.2 39.4 
10b 52.0 52.1 
11 38.7 38.8 
12 20.5 20.6 
13 22.9 23.1 
14 19.9 20.0 
15 25.6 25.8 
16 24.6 24.8 
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10.4.2. Screening Tables 
Table 3. Hydrolysis of 4.a 
 
Entry Reagent Solvent Observation 
1 HCl (6 M) THF 8 + TBS-deprotection 
2 AcOH THF starting material 4 
3 p-TSA THF 8 
4 p-TSA MeOH starting material 4 
5 Sc(OTf)3 DCM 8 
6 Yb(OTf)3 DCM 8 
7 TiCl4 DCM 8 
a) Reactions were carried out on a 0.010 mmol scale. 
 
Table 4. Dihydroxylation of S9.a 
 
Entry Reagents  Solvent Additive T  Outcome/Yield
b
 
1 AD mix β t-BuOH/H2O - RT 
starting material 
S9 
2 RuCl3, NaIO4, H2SO4 MeCN/EtOAc/H2O - RT 
starting material 
S9 
3 OsO4 (1.0 eq.) pyridine - RT 30% 
4 OsO4 (0.7 eq.) 
THF/ acetone/t-
BuOH/H2O 
- RT 28% 
5 OsO4 (0.3 eq.) t-BuOH/H2O - RT 
starting material 
S9 
6 OsO4 (0.1 eq.) 
THF/ acetone/t-
BuOH/H2O 
- 55 °C 50% 
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7 OsO4 (0.1 eq.) 
THF/ acetone/t-
BuOH/H2O 
methansulfon-
amide 
40 °C 45% 
8 OsO4 (0.1 eq.) 
THF/ acetone/t-
BuOH/H2O 
pyridine 55 °C 23% 
9 OsO4 (0.1 eq.) 
THF/ acetone/t-
BuOH/H2O 
DABCO 55 °C 35% 
10 OsO4 (0.1 eq.) 
THF/ acetone/t-
BuOH/H2O 
quinuclidine 55 °C 20% 
11 OsO4 (0.1 eq.) THF/ acetone/H2O - 55 °C 81% 
a) Reactions were carried out on a 0.010 mmol scale. b) Yields are determined by 1H-NMR analysis 
with tetrachloroethane as external standard. 
 
Table 5. Methyl cuprate addition to enone 16.a 
 
Entry Cu-source Lewis Acid T  Outcome/Yield 
1b 
Li-thienylcyanocuprate (2.3 
eq.) 
BF3·Et2O –78 °C 16 + 17 
2b 
Li-thienylcyanocuprate (5.0 
eq.) 
BF3·Et2O –78 °C 16 + 17 
3b 
Li-thienylcyanocuprate (10.0 
eq.) 
TMSCl/HMPA –78 to –20 °C 
starting material 
16 
4 CuI (10.0 eq.) BF3·Et2O –78 to –10 °C side product 
5 CuBr·DMS (5.0 eq.) BF3·Et2O –78 to –20 °C 16 + 17 
6 CuCN (10.0 eq.) BF3·Et2O –78 to –50 °C 50% 
7c CuCN (10.0 eq.) BF3·Et2O –78 to –50 °C 
starting material 
16 
a) Reactions were carried out in Et2O with MeLi unless otherwise stated. b) Reactions were carried 
out in a mixture of THF and Et2O. c) MeMgBr was used. 
 
 
  
Experimental   152 
 
10.4.3. NMR Spectra for Chapter 3.3. 
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10.4.4. X-ray Crystallographic Data for Chapter 3.3. 
 
Diol 21 
 
Figure 10.3. ORTEP projection of the molecular structure of diol 21. 
 
CCDC 1550221 contains the supplementary crystallographic data for diol 21. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table 10.3. Crystallographic data. for diol 21. 
net formula C18H30O3 
Mr/g mol
−1 294.42 
crystal size/mm 0.100 × 0.090 × 0.020 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/c 1' 
a/Å 8.5414(4) 
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b/Å 27.3619(14) 
c/Å 13.5613(7) 
α/° 90 
β/° 90.133(2) 
γ/° 90 
V/Å3 3169.4(3) 
Z 8 
calc. density/g cm−3 1.234 
μ/mm−1 0.082 
absorption correction Multi-Scan 
transmission factor range 0.8773–0.9705 
refls. measured 37294 
Rint 0.0701 
mean σ(I)/I 0.0672 
θ range 3.185–28.283 
observed refls. 5887 
x, y (weighting scheme) 0.0299, 3.1756 
hydrogen refinement C-H: constr, O-H: refall 
refls in refinement 7852 
parameters 402 
restraints 15 
R(Fobs) 0.0689 
Rw(F
2) 0.1419 
S 1.083 
shift/errormax 0.001 
max electron density/e Å−3 0.386 
min electron density/e Å−3 −0.249 
 
Refined as two-component twin (pseudo-merohedral with TWIN -1 0 0 0 -1 0 0 0 1, BASF 
0.17209(176)). 
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Cyclopropane 22 
 
 
Figure 10.4. ORTEP projection of the molecular structure of cyclopropane 22. 
 
CCDC 1550223 contains the supplementary crystallographic data for cyclopropane 22. These data 
can be obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table 10.4. Crystallographic data. for cyclopropane 22. 
net formula C21H33O2 
Mr/g mol
−1 317.47 
crystal size/mm 0.090 × 0.070 × 0.040 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system triclinic 
space group 'P -1' 
a/Å 8.8933(3) 
b/Å 9.3676(4) 
c/Å 11.1619(5) 
α/° 95.392(2) 
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β/° 104.2140(10) 
γ/° 90.3290(10) 
V/Å3 897.03(6) 
Z 2 
calc. density/g cm−3 1.175 
μ/mm−1 0.073 
absorption correction Multi-Scan 
transmission factor range 0.9347–0.9705 
refls. measured 9511 
Rint 0.0313 
mean σ(I)/I 0.0421 
θ range 3.171–26.368 
observed refls. 2842 
x, y (weighting scheme) 0.0389, 0.4511 
hydrogen refinement H(C) constr, H(O) refall 
refls in refinement 3620 
parameters 219 
restraints 0 
R(Fobs) 0.0446 
Rw(F
2) 0.1102 
S 1.026 
shift/errormax 0.001 
max electron density/e Å−3 0.244 
min electron density/e Å−3 −0.206 
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3. Enone 16 
 
Figure 10.5. ORTEP projection of the molecular structure of enone 16. 
 
CCDC 1550222 contains the supplementary crystallographic data for enone 16. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table 10.5. Crystallographic data for enone 16.  
net formula C20H30O3 
Mr/g mol
−1 318.44 
crystal size/mm 0.090 × 0.070 × 0.010 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system tetragonal 
space group 'P 43 21 2' 
a/Å 10.7220(4) 
b/Å 10.7220(4) 
c/Å 60.769(2) 
α/° 90 
β/° 90 
γ/° 90 
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V/Å3 6986.1(6) 
Z 16 
calc. density/g cm−3 1.211 
μ/mm−1 0.079 
absorption correction Multi-Scan 
transmission factor range 0.8421–0.9705 
refls. measured 18900 
Rint 0.0433 
mean σ(I)/I 0.0471 
θ range 3.167–25.350 
observed refls. 5876 
x, y (weighting scheme) 0.0484, 5.5202 
hydrogen refinement constr 
Flack parameter 0.5 
refls in refinement 6376 
parameters 423 
restraints 10 
R(Fobs) 0.0606 
Rw(F
2) 0.1443 
S 1.198 
shift/errormax 0.002 
max electron density/e Å−3 0.246 
min electron density/e Å−3 −0.292 
 
There are two disordered atoms in a side chain. They have been isotropically refined in a split 
model. Fig. 3 shows only the ordered molecule.  
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10.5. Supporting Information for Chapter 7.1. 
10.5.1. Experimental Procedures 7.1. 
 
Synthesis and characterization of compound 3 
 
To a suspension of compound 2 (3.12 g, 12.0 mmol) in EtOH/H2O (100 mL, 1:1) at r.t. was added 
compound 1 (1.29 g, 11.6 mmol) and Na2CO3 (1.32 g, 12.5 mmol). The resulting mixture was 
heated to 105 °C for 6 h. The reaction mixture was cooled to r.t. and the EtOH was removed under 
reduced pressure. The resulting mixture was diluted with H2O (100 mL) and washed with EtOAc 
(100 mL). The aqueous phase was acidified with 1 m HCl (40 mL) and extracted with EtOAc (3 × 
100 mL). The combined organic extracts were washed with H2O (40 mL), dried over Na2SO4, 
filtered and concentrated under reduced pressure to afford compound 3 (1.37 g, 68%) as a yellow 
solid.  
 
mp: 207 – 209 °C decomp; 1H NMR (400 MHz, CD3OD): δ 8.47 (s, 1H), 7.39 (s, 1H), 3.82 (d, J = 13.0 
Hz, 2H); 13C NMR (100 MHz, CD3OD): δ 148.1 (d, J = 6.0 Hz), 139.9, 131.2, 127.7 (q, J = 6.0 Hz), 
124.0 (q, J = 270.5 Hz), 118.5, 116.0 (q, J = 33.0 Hz), 41.2 (d, J = 152.5 Hz); 19F NMR (376 MHz, 
CD3OD): δ −62.7; 
31
P NMR (162 MHz, CD3OD): δ 18.6; IR (neat): 3350, 2767, 1621, 1575, 1525, 
1511, 1426, 1413, 1353, 1301, 1272, 1234, 1209, 1176, 1131, 1114, 1073, 1014, 946, 917, 877, 
846, 742, 702 cm−1; HRMS (ESI, m/z): [(M−H)−] calcd. for C8H6ClF3N2O5P
−, 332.9660; found 
332.9665. 
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Synthesis and characterization of compound 4 
 
 
To a solution of compound 3 (1.67 g, 5.00 mmol) in triethyl orthoformate (22.3 g, 150 mmol, 25 
mL) at r.t. was added p-TsOH (190 mg, 1.00 mmol). The resulting mixture was heated to 150 °C 
and stirred for 3.5 h. The reaction mixture was cooled to r.t. and concentrated under reduced 
pressure. The residue was diluted with H2O (40 mL) and extracted with EtOAc (2 × 40 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced 
pressure. Purification by flash column chromatography on silica gel eluting with i-Hex/EtOAc (1:1) 
afforded compound 4 (1.61 g, 82%) as a yellow solid.  
 
mp: 87 – 89 °C; TLC (i-Hex/EtOAc, 1:1): Rf = 0.20 (UV/KMnO4); 
1
H NMR (400 MHz, CDCl3): δ 8.51 (s, 
1H), 8.50 – 8.41 (m, 1H), 7.09 (s, 1H), 4.27 – 4.12 (m, 4H), 3.71 (dd, J = 13.5, 6.0 Hz, 2H), 1.35 (t, J = 
7.0 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 146.4 (d, J = 6.5 Hz), 139.9, 130.2, 127.2 (q, J = 5.5 Hz), 
122.3 (q, J = 271.5 Hz), 116.6, 116.5 (q, J = 33.5 Hz), 63.23 (d, J = 7.0 Hz), 39.6 (d, J = 157.8 Hz), 16.6 
(d, J = 6.0 Hz); 19F NMR (376 MHz, CDCl3): δ −61.6; 
31
P NMR (162 MHz, CDCl3): δ 20.0; IR (thin film): 
3361, 2985, 1621, 1579, 1530, 1435, 1354, 1317, 1302, 1243, 1205, 1157, 1126, 1049, 1024, 969, 
945, 917, 897, 838, 781, 764, 702 cm−1; HRMS (ESI, m/z): [(M−H)−] calcd. for C12H14ClF3N2O5P
−, 
389.0286; found 389.0296. 
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Synthesis and characterization of compound 7 
 
 
To a mixture of compound 4 (781 mg, 2.00 mmol) and 3-(N-boc-amino)phenylboronic acid (5) (522 
mg, 2.20 mmol) in PhMe/EtOH (3.5:1, 45 mL) at r.t. under argon was added a solution of Na2CO3 (4 
mL, 2.0 m in H2O) and Pd(PPh3)4 (116 mg, 0.100 mmol). The resulting mixture was degassed and 
flushed with argon (× 3) and then heated to 95 °C for 17 h. The reaction mixture was cooled to r.t., 
concentrated under reduced pressure and the resulting residue was directly purified by flash 
column chromatography eluting with CH2Cl2/EtOAc (4:1) to afford compound 7 (873 mg, 80%) as a 
yellow oil.  
 
TLC (CH2Cl2/EtOAc, 4:1): Rf = 0.41 (UV/ninhydrin); 
1
H NMR (400 MHz, CDCl3): δ 8.57 (s, 1H), 8.45 
(q, J = 6.0 Hz, 1H), 7.44 – 7.36 (m, 2H), 7.35 – 7.28 (m, 1H), 6.97 (d, J = 7.5 Hz, 1H), 6.83 (s, 1H), 
6.64 (s, 1H), 4.18 (dq, J = 8.5, 7.0 Hz, 4H), 3.69 (dd, J = 13.5, 6.0 Hz, 2H), 1.51 (s, 9H), 1.33 (t, J = 7.0 
Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 152.7, 148.6 (q, J = 1.5 Hz), 145.5 (d, J = 7.5 Hz), 139.0, 
138.3, 130.8, 128.8, 126.1 (q, J = 6.0 Hz), 123.4 (q, J = 272.5 Hz), 123.0 (q, J = 1.5 Hz), 118.6, 118.4, 
117.6, 117.4 (q, J = 32.0 Hz), 80.8, 63.1 (d, J = 7.0 Hz), 39.4 (d, J = 157.0 Hz), 28.4, 16.6 (d, J = 5.5 
Hz); 19F NMR (376 MHz, CDCl3): δ −56.6; 
31
P NMR (162 MHz, CDCl3): δ 20.5; IR (thin film): 3355, 
2981, 2931, 1720, 1625, 1609, 1575, 1532, 1486, 1427, 1346, 1305, 1268, 1235, 1153, 1122, 1048, 
1019, 971, 794, 764, 735 cm−1; HRMS (ESI, m/z): [(M+Na)+] calcd. for C23H29F3N3NaO7P
+, 570.1587; 
found 570.1590. 
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Synthesis and characterization of compound 9 
 
 
To a solution of compound 7 (1.04 g, 1.90 mmol) in MeOH (30 mL) at r.t. was added Pd/C (104 mg, 
10 wt. % Pd labelling). The reaction vessel was flushed with hydrogen (× 3) and the resulting 
mixture was stirred at r.t. for 8 h. The reaction mixture was filtered through a pad of Celite® 
washing with MeOH (30 mL). The filtrate was concentrated under reduced pressure to afford 
compound 9 (876 mg, 89%) as a pale brown oil, which was used in the next step without further 
purification. 
 
TLC (CH2Cl2/MeOH, 19:1): Rf = 0.27 (UV/ninhydrin); 
1
H NMR (400 MHz, CD3OD): δ 7.42 – 7.31 (m, 
2H), 7.25 – 7.18 (m, 1H), 7.05 (s, 1H), 6.93 (d, J = 7.5 Hz, 1H), 6.60 (s, 1H), 4.11 (dq, J = 8.0, 7.0 Hz, 
4H), 3.69 (d, J = 10.5 Hz, 2H), 1.51 (s, 9H), 1.27 (dt, J = 7.0, 0.5 Hz, 6H); 13C NMR (100 MHz, CD3OD): 
δ 155.3, 143.1, 139.9, 139.4 – 139.3 (m), 135.0, 133.9 (q, J = 2.0 Hz), 128.8, 126.4 (q, J = 271.5 Hz), 
124.9 (q, J = 2.0 Hz), 121.1 – 120.8 (m), 118.7 (q, J = 30.0 Hz), 118.5 – 118.3 (m), 115.4 – 115.2 (m), 
114.2 (q, J = 5.5 Hz), 80.8, 64.0 (d, J = 7.0 Hz), 40.3 (d, J = 158.5 Hz), 28.7, 16.7 (d, J = 5.5 Hz); 19F 
NMR (376 MHz, CD3OD): δ −56.2; 
31
P NMR (162 MHz, CD3OD): δ 25.0; IR (thin film): 3362, 2979, 
2936, 1703, 1607, 1583, 1530, 1488, 1367, 1302, 1233, 1197, 1152, 1106, 1049, 1019, 973, 789 
cm−1; HRMS (ESI, m/z): [(M−H)−] calcd. for C23H30F3N3O5P
−, 516.1881; found 516.1881. 
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Synthesis and characterization of compound 12 
 
 
To a solution of compound 9 (932 mg, 1.80 mmol) in THF (90 mL) and Et3N (1.28 g, 12.6 mmol, 
1.76 mL) at r.t. was added ethyl chlorooxoacetate (11) (639 mg, 4.68 mmol, 0.52 mL) dropwise. 
The resulting mixture was stirred at r.t. for 20 h. After this time the reaction mixture was filtered 
and the filtrate was concentrated under reduced pressure. The resulting residue was dissolved in 
EtOH (60 mL) and a solution of HCl (60 mL, 1.0 m in H2O) was added. The mixture was heated to 
120 °C for 2.5 h, cooled to r.t. and the ethanol was removed under reduced pressure. The 
resulting aqueous layer was washed with CH2Cl2 (2 × 50 mL) and its pH was adjusted to 10-11 
using a solution of Na2CO3 (2.0 m in H2O). The aqueous layer was then back extracted with CH2Cl2 
(2 × 50 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated 
under reduced pressure. Purification by flash column chromatography on silica gel eluting with 
CH2Cl2/MeOH (19:1) afforded compound 12 (505 mg, 60%) as an off-white solid.  
 
mp: 305 – 308 °C, decomp; TLC (CH2Cl2/MeOH, 19:1): Rf = 0.29 (UV/ninhydrin); 
1
H NMR (400 MHz, 
CD3OD): δ 7.57 (s, 1H), 7.44 (s, 1H), 7.13 (t, J = 8.0 Hz, 1H), 6.80 – 6.69 (m, 2H), 6.65 (d, J = 7.5 Hz, 
1H), 4.80 (d, J = 12.5 Hz, 2H), 4.14 (dq, J = 7.0, 1.0 Hz, 4H), 1.23 (t, J = 7.0, 6H); 13C NMR (100 MHz, 
CD3OD): δ 157.4 (d, J = 1.5 Hz), 155.2, 148.6, 141.0, 138.7 (q, J = 1.5 Hz), 129.6, 126.0, 125.3 (q, J = 
31.0 Hz), 125.1 (q, J = 273.0 Hz), 120.8, 120.0 (q, J = 1.5 Hz), 117.2 (q, J = 1.5 Hz), 116.0, 115.1 (q, J 
= 5.5 Hz), 64.6 (d, J = 6.5 Hz), 39.9 (d, J = 157.0 Hz), 16.5 (d, J = 6.0 Hz); 19F NMR (376 MHz, CD3OD): 
δ −57.9; 31P NMR (162 MHz, CD3OD): δ 20.1; IR (neat): 3851, 3744, 3648, 3334, 2980, 1699, 1652, 
1558, 1489, 1373, 1231, 1163, 1122, 1080, 1019, 787 cm−1; HRMS (ESI, m/z): [(M+H)+] calcd. for 
C20H22F3N3O5P
+, 472.1244; found 472.1242. 
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Synthesis and characterization of compound 15 
 
 
To a solution of compound 12 (95.0 mg, 0.200 mmol) in MeOH (4 mL) at 0 °C was added conc. HCl 
(0.1 mL) dropwise. t-Butyl nitrite (45.0 mg, 0.440 mmol, 52 µL, 90% purity) was added dropwise 
and the resulting solution was stirred at 0 °C for 1 h. The diazonium salt was then added dropwise 
to a flask containing N,N-dimethylaniline (14) (27.0 mg, 0.220 mmol, 28 µL) in MeOH (4 mL) and 
conc. HCl (0.1 mL) at 0 °C. The resulting solution was stirred at 0 °C for 1.5 h and then at r.t. for 2 
h. The reaction was quenched with sat. aq. NaHCO3 (20 mL) and extracted with EtOAc (2 × 20 mL). 
The combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced 
pressure. Purification by flash column chromatography on silica gel eluting with CH2Cl2/MeOH 
(94:6) afforded compound 15 (106 mg, 88%) as an orange oil.  
 
TLC (CH2Cl2/MeOH, 94:6): Rf = 0.31 (UV/ninhydrin); 
1
H NMR (400 MHz, CDCl3): δ 7.88 – 7.77 (m, 
3H), 7.70 – 7.61 (m, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.41 – 7.29 (m, 3H), 6.76 – 6.69 (m, 2H), 4.70 – 
4.57 (m, 2H), 4.24 – 4.10 (m, 4H), 3.07 (s, 6H), 1.27 – 1.18 (m, 6H); 13C NMR (200 MHz, CDCl3): δ 
155.6 – 155.1 (m), 153.8 – 153.3 (m), 152.8, 152.7, 143.6, 139.5, 136.9, 130.1, 129.4 – 129.0 (m), 
128.6, 128.1, 128.0, 125.2, 123.5 (q, J = 274.0 Hz), 123.0, 122.0, 119.3, 115.3 – 114.7 (m), 111.6, 
63.6 (d, J = 6.0 Hz), 40.4, 39.4 (d, J = 156.5 Hz), 16.4 (d, J = 7.0 Hz); 19F NMR (282 MHz, CDCl3): δ 
−56.6; 31P NMR (162 MHz, CDCl3): δ 19.2; IR (thin film): 3058, 2983, 2905, 1698, 1622, 1598, 1518, 
1364, 1264, 1235, 1153, 1120, 1047, 1017, 945, 822, 733, 700 cm−1; HRMS (ESI, m/z): [(M+H)+] 
calcd. for C28H30F3N5O5P
+, 604.1931; found 604.1930. 
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Synthesis and characterization of ShuBQX-1 
 
 
To a suspension of compound 15 (36.0 mg, 0.0600 mmol) in H2O (1.5 mL) at r.t. was added conc. 
HCl (1.5 mL) dropwise. The resulting mixture was heated to 120 °C for 1.5 h and then cooled to 
r.t.. The reaction mixture was directly purified by reverse phase column chromatography eluting 
with H2O [0.1% TFA]/MeCN [0.1% TFA] (9:1 → 7:3). The H2O was removed by lyophilisation to 
afford compound ShuBQX-1 (21 mg, 52%) as a dark red powder. 
 
mp: >350 °C; 1H NMR (800 MHz, (CD3)2SO): δ 12.35 (s, 1H), 7.83 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.81 
– 7.78 (m, 2H), 7.76 (t, J = 2.0 Hz, 1H), 7.64 (s, 1H), 7.61 (s, 1H), 7.60 (t, J = 8.0 Hz, 1H), 7.41 – 7.39 
(m, 1H), 6.86 – 6.81 (m, 2H), 4.56 (d, J = 12.0 Hz, 2H), 3.06 (s, 6H); 13C NMR (200 MHz, (CD3)2SO): δ 
171.5, 158.1 (q, J = 35.0 Hz), 155.0, 153.2, 152.7, 152.0, 142.5, 139.7, 134.1, 130.1, 129.0 – 128.8 
(m), 125.1, 124.9, 123.9 (q, J = 273.5 Hz), 122.7, 121.6 (q, J = 31.5 Hz), 121.0, 120.5, 113.1 (q, J = 
6.0 Hz), 111.6, 40.0 (d, J = 156.0 Hz, estimated from HSQC), 39.6 (estimated from HSQC); note that 
only one CF3 peak was observed in this spectrum; 
19
F NMR (376 MHz, (CD3)2SO): δ −54.8, −74.5; 
31
P NMR (162 MHz, CD3OD): δ 14.0; IR (neat): 3070, 2892, 1697, 1608, 1559, 1374, 1276, 1241, 
1159, 1132, 1079, 932, 850, 828, 799, 714 cm−1; HRMS (ESI, m/z): [(M+H)+] calcd. for 
C24H22F3N5O5P
+, 548.1305; found 548.1311; LCMS: H2O [0.1% FA]/MeCN [0.1% FA] (90:10 → 5:95), 
flow rate 1.0 mL/min over 8 min; tR = 6.062 min, MS (ESI, m/z): [(M+H)
+] = 548.0, UV-Vis: λmax = 
430 nm. 
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Synthesis and characterization of compound 8 
 
To a mixture of compound 4 (254 mg, 0.650 mmol) and 4-(N-boc-amino)phenylboronic acid (6) 
(170 mg, 0.715 mmol) in PhMe/EtOH (3.5:1, 15.5 mL) at r.t. under argon was added a solution of 
Na2CO3 (1.5 mL, 2.0 m in H2O) and Pd(PPh3)4 (38.0 mg, 0.0330 mmol). The resulting mixture was 
degassed and flushed with argon (× 3) and then heated to 95 °C for 16 h. The reaction mixture was 
cooled to r.t., concentrated under reduced pressure and the resulting residue was directly purified 
by flash column chromatography eluting with CH2Cl2/EtOAc (4:1) to afford compound 8 (273 mg, 
77%) as a yellow oil.  
 
TLC (CH2Cl2/EtOAc, 4:1): Rf = 0.22 (UV/ninhydrin); 
1
H NMR (400 MHz, CDCl3): δ 8.57 (s, 1H), 8.44 
(q, J = 6.0 Hz, 1H), 7.47 – 7.40 (m, 2H), 7.29 – 7.22 (m, 2H), 6.82 (s, 1H), 6.71 (s, 1H), 4.17 (dq, J = 
8.5, 7.0 Hz, 4H), 3.70 (dd, J = 13.5, 6.0 Hz, 2H), 1.52 (s, 9H), 1.32 (t, J = 7.0 Hz, 6H); 13C NMR (100 
MHz, CDCl3): δ 152.7, 148.6 (q, J = 1.0 Hz), 145.6 – 145.4 (m), 139.1, 132.7, 130.7, 129.2 (q, J = 2.0 
Hz), 126.2 (q, J = 6.0 Hz), 123.5 (q, J = 272.5 Hz), 118.0, 117.7, 117.5 (q, J = 32.0 Hz), 81.0, 63.1 (d, J 
= 7.0 Hz), 39.4 (d, J = 157.5 Hz), 28.4, 16.6 (d, J = 5.5 Hz); 19F NMR (282 MHz, CDCl3): δ −56.5; 
31
P 
NMR (162 MHz, CD3OD): δ 20.6; IR (thin film): 3355, 3100, 2980, 2930, 1721, 1624, 1574, 1521, 
1405, 1366, 1346, 1314, 1287, 1264, 1232, 1151, 1115, 1047, 1016, 971, 836, 764, 735 cm−1; 
HRMS (ESI, m/z): [(M+Na)+] calcd. for C23H29F3N3NaO7P
+, 570.1587; found 570.1587. 
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Synthesis and characterization of compound 10 
 
To a solution of compound 8 (328 mg, 0.600 mmol) in MeOH (12 mL) at r.t. was added Pd/C (33.0 
mg, 10 wt. % Pd labelling). The reaction vessel was flushed with hydrogen (× 3) and the resulting 
mixture was stirred at r.t. for 16 h. The reaction mixture was filtered through a pad of Celite® 
washing with MeOH (20 mL) and the filtrate was concentrated under reduced pressure. 
Purification by flash column chromatography on silica gel eluting with EtOAc/MeOH (19:1 → 9:1) 
to afford compound 10 (168 mg, 54%) as a colourless oil. 
 
TLC (EtOAc/MeOH, 19:1): Rf = 0.55 (UV/ninhydrin); 
1
H NMR (400 MHz, CD3OD): δ 7.38 (d, J = 8.0 
Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 7.06 (s, 1H), 6.58 (s, 1H), 4.10 (q, J = 7.0 Hz, 4H), 3.67 (d, J = 10.5 
Hz, 2H), 1.52 (s, 9H), 1.25 (t, J = 7.0 Hz, 6H); 13C NMR (100 MHz, CD3OD): δ 155.3, 139.4, 139.4, 
136.8, 134.7, 133.8 (q, J = 2.0 Hz), 130.7 (q, J = 1.0 Hz), 126.4 (q, J = 271.5 Hz), 118.9, 118.8 (q, J = 
30.0 Hz), 115.5, 114.3 (q, J = 5.5 Hz), 80.8, 64.1 (d, J = 7.0 Hz), 40.4 (d, J = 159.0 Hz), 28.7, 16.7 (d, J 
= 6.0 Hz); 19F NMR (376 MHz, CD3OD): δ −56.2; 
31
P NMR (162 MHz, CD3OD): δ 24.8; IR (neat): 
3364, 2978, 2930, 1703, 1584, 1511, 1431, 1403, 1391, 1366, 1312, 1232, 1150, 1103, 1048, 1017, 
971, 897, 838, 805, 773 cm−1; HRMS (ESI, m/z): [(M+Na)+] calcd. for C23H31F3N3NaO5P
+, 540.1846; 
found 540.1844. 
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Synthesis and characterization of compound 13 
 
To a solution of compound 10 (124 mg, 0.240 mmol) in THF (12 mL) and Et3N (170 mg, 1.68 mmol, 
234 µL) at r.t. was added ethyl chlorooxoacetate (11) (85.0 mg, 0.624 mmol, 69 µL) dropwise. The 
resulting mixture was stirred at r.t. for 20 h. After this time the reaction mixture was filtered and 
the filtrate was concentrated under reduced pressure. The resulting residue was dissolved in EtOH 
(8 mL) and a solution of HCl (8 mL, 1.0 m in H2O) was added. The mixture was heated to 120 °C for 
2.5 h, cooled to r.t. and the ethanol was removed under reduced pressure. The resulting aqueous 
layer was washed with CH2Cl2 (2 × 20 mL) and its pH was adjusted to 10-11 using a solution of 
Na2CO3 (2.0 m in H2O). The aqueous layer was then back extracted with CH2Cl2 (2 × 20 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced 
pressure. Purification by flash column chromatography on silica gel eluting with CH2Cl2/MeOH 
(19:1) afforded compound 13 (62 mg, 55%) as an off-white solid.  
 
mp: 315 – 318 °C, decomp; TLC (CH2Cl2/MeOH, 19:1): Rf = 0.27 (UV/ninhydrin); 
1
H NMR (400 MHz, 
CD3OD): δ 7.57 (s, 1H), 7.42 (s, 1H), 7.15 – 7.08 (m, 2H), 6.79 – 6.73 (m, 2H), 4.82 (d, J = 12.0 Hz, 
2H), 4.19 – 4.08 (m, 4H), 1.23 (t, J = 7.0 Hz, 6H); 13C NMR (100 MHz, CD3OD): δ 157.8, 156.0 – 
155.7 (m), 149.1, 138.8 (q, J = 2.0 Hz), 131.0 (q, J = 2.0 Hz), 129.7, 129.5, 126.5 – 126.3 (m), 125.6 
(q, J = 30.5 Hz), 125.3 (q, J = 273.0 Hz), 121.1, 116.1 – 115.8 (m), 115.7, 64.6 (d, J = 6.5 Hz), 39.9 (d, 
J = 156.5 Hz), 16.6 (d, J = 6.0 Hz); 19F NMR (376 MHz, CD3OD): δ −57.9; 
31
P NMR (162 MHz, CD3OD): 
δ 20.2; IR (neat): 3360, 2984, 1698, 1620, 1505, 1381, 1350, 1238, 1182, 1158, 1119, 1080, 1019, 
835 cm−1; HRMS (ESI, m/z): [(M+H)+] calcd. for C20H22F3N3O5P
+, 472.1244; found 472.1240. 
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Synthesis and characterization of compound 16 
 
To a solution of compound 13 (38.0 mg, 0.0800 mmol) in MeOH (1.6 mL) at 0 °C was added conc. 
HCl (0.04 mL) dropwise. t-Butyl nitrite (17.0 mg, 0.160 mmol, 21 µL, 90% purity) was added 
dropwise and the resulting solution was stirred at 0 °C for 30 min. The diazonium salt was then 
added dropwise to a flask containing N,N-dimethylaniline (14) (11.0 mg, 0.0880 mmol, 11 µL) in 
MeOH (1.6 mL) and conc. HCl (0.04 mL) at 0 °C. The resulting solution was stirred at 0 °C for 2 h 
and then at r.t. for 2 h. The reaction was quenched with sat. aq. NaHCO3 (10 mL) and extracted 
with EtOAc (2 × 10 mL). The combined organic extracts were dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification by flash column chromatography on silica gel 
eluting with CH2Cl2/MeOH (98:2 → 95:5) afforded compound 16 (28 mg, 58%) as an orange solid.  
 
mp: 215 – 218 °C; TLC (CH2Cl2/MeOH, 19:1): Rf = 0.36 (UV/CAM); 
1
H NMR (400 MHz, CDCl3): δ 7.91 
– 7.84 (m, 2H), 7.83 – 7.75 (m, 2H), 7.61 (s, 1H), 7.47 – 7.40 (m, 2H), 7.36 (s, 1H), 6.79 – 6.70 (m, 
2H), 4.69 (d, J = 12.0 Hz, 2H), 4.30 – 4.13 (m, 4H), 3.09 (s, 6H), 1.26 (t, J = 7.0 Hz, 6H); 13C NMR (100 
MHz, CDCl3): δ 155.2, 153.5, 152.8, 152.7, 143.7, 139.7, 136.8 (q, J = 1.5 Hz), 130.0, 128.1, 125.3, 
125.0 (q, J = 31.5 Hz), 124.3, 123.5 (q, J = 273.5 Hz), 121.8, 119.3, 114.9 (q, J = 5.0 Hz), 111.7, 63.7 
(d, J = 6.5 Hz), 40.4, 39.4 (d, J = 156.0 Hz), 16.4 (d, J = 6.0 Hz), 19F NMR (376 MHz, CDCl3): δ −56.5; 
31
P NMR (162 MHz, CDCl3): δ 19.2; IR (thin film): 3153, 3075, 2984, 2909, 1704, 1622, 1600, 1519, 
1421, 1366, 1312, 1237, 1157, 1139, 1082, 1047, 1020, 846, 822 cm−1; HRMS (ESI, m/z): [(M+H)+] 
calcd. for C28H30F3N5O5P
+, 604.1931; found 604.1941. 
 
  
Experimental   208 
 
Synthesis and characterization of ShuBQX-2 
 
To a suspension of compound 16 (24.0 mg, 0.0400 mmol) in H2O (1 mL) at r.t. was added conc. HCl 
(1 mL) dropwise. The resulting mixture was heated to 120 °C for 12 h and then cooled to r.t.. The 
reaction mixture was directly purified by reverse phase column chromatography eluting with H2O 
[0.1% TFA]/MeCN [0.1% TFA] (9:1 → 7:3). The H2O was removed by lyophilisation to afford 
compound ShuBQX-2 (5.6 mg, 21%) as a dark brown solid. 
 
mp: >350 °C; 1H NMR (800 MHz, (CD3)2SO): δ 12.33 (s, 1H), 7.86 – 7.77 (m, 4H), 7.65 (s, 1H), 7.59 
(s, 1H), 7.52 – 7.46 (m, 2H), 6.89 – 6.81 (m, 2H), 4.49 (br s, 2H), 3.07 (s, 6H); 13C NMR (200 MHz, 
(CD3)2SO): δ 157.7, 157.6, 154.9, 153.2, 152.7, 151.9, 142.6, 139.8, 134.0, 130.1, 128.9, 125.0, 
124.9, 123.9 (q, J = 274.0 Hz), 121.3, 120.6, 113.1 (q, J = 5.0 Hz), 111.6, 40.0 (d, J = 155.5 Hz, 
estimated by HSQC), 39.6 (estimated by HSQC); note that only one CF3 peak was observed in this 
spectrum; 19F NMR (376 MHz, (CD3)2SO): δ −54.7, −73.4; 
31
P NMR (162 MHz, (CD3)2SO): δ 13.4; IR 
(neat): 3063, 2950, 1682, 1671, 1620, 1594, 1543, 1367, 1350, 1274, 1241, 1207, 1169, 1137, 
1123, 1108, 1074, 955, 937, 909, 894, 838, 824, 726 cm−1; HRMS (ESI, m/z): [(M+H)+] calcd. for 
C24H22F3N5O5P
+, 548.1305; found 548.1212; LCMS: H2O [0.1% FA]/MeCN [0.1% FA] (90:10 → 5:95), 
flow rate 1.0 mL/min over 8 min; tR = 6.095 min, MS (ESI, m/z): [(M+H)
+] = 548.0, UV-Vis: λmax = 
435 nm. 
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Synthesis and characterisation of compound 18 
 
To a mixture of compound 4 (200 mg, 0.512 mmol) and hydrazide 17 (120 mg, 0.576 mmol) in 
PhMe (6 mL) at r.t. was added Cs2CO3 (280 mg, 0.726 mmol), Pd(OAc)2 (44.0 mg, 0.196 mmol) and 
a solution of P(t-Bu)3 (0.510 mL, 0.510 mmol, 1.0 m in PhMe). The resulting mixture was stirred for 
30 min. at r.t. and then heated to 120 °C for 2 h. The reaction mixture was cooled to r.t., 
concentrated under reduced pressure and the resulting residue was directly purified by flash 
column chromatography eluting with i-Hex/EtOAc (8:2 → 1:1) to afford compound 18 (163 mg, 
57%) as an orange solid. 
 
mp: 230 °C, decomp; TLC (i-Hex/EtOAc, 1:1): Rf = 0.37 (UV/ninhydrin); 
1
H NMR (400 MHz, CD3OD): 
δ 8.40 (s, 1H), 7.64 – 7.55 (m, 2H), 7.42 – 7.33 (m, 2H), 7.24 – 7.14 (m, 1H), 6.30 (s, 1H), 4.12 – 3.97 
(m, 4H), 3.71 (d, J = 12.0 Hz, 2H), 1.47 (s, 9H), 1.23 (t, J = 7.0 Hz, 6H); 13C NMR (100 MHz, CD3OD): δ 
154.9, 151.7, 149.4 (d, J = 5.0 Hz), 143.0, 129.8, 128.6 (q, J = 6.0 Hz), 126.6, 125.9, 123.7, 104.6 (q, 
J = 32.5 Hz), 94.4, 83.8, 64.4 (d, J = 7.0 Hz), 39.7 (d, J = 158.0 Hz), 28.4, 16.7 (d, J = 5.5 Hz); note 
that the CF3 peak was not observed in this spectrum; 
19
F NMR (376 MHz, CD3OD): δ −62.8; 
31
P 
NMR (162 MHz, CD3OD): δ 22.3; IR (neat): 3346, 2981, 2931, 1723, 1633, 1577, 1541, 1425, 1355, 
1339, 1301, 1251, 1213, 1153, 1112, 1048, 1022, 972, 761 cm−1; HRMS (ESI, m/z): [(M−H)−] calcd. 
for C23H30F3N4NaO7P
−, 561.1731; found 561.1739. 
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Synthesis and characterisation of compound 19 
 
 
To a solution of compound 18 (163 mg, 0.290 mmol) in MeOH (5 mL) at r.t. was added Pd/C (34.0 
mg, 20 wt. % Pd labelling). The reaction vessel was flushed with hydrogen (× 3) and the resulting 
mixture was stirred at r.t. for 5.5 h after which more Pd/C (16.0 mg, 10 wt. % Pd labelling) was 
added. The reaction mixture was stirred for 2.5 h at r.t. and then filtered through a pad of Celite® 
washing with EtOAc (20 mL). The filtrate was concentrated under reduced pressure to give a 
brown solid (132 mg, 86%), which was used in the next step without further purification. An 
analytical sample was obtained by purification using preparative TLC eluting with CH2Cl2/MeOH 
(19:1). 
 
mp: 155 – 156 °C; TLC (CH2Cl2/MeOH, 19:1): Rf = 0.29 (UV/ninhydrin); 
1
H NMR (400 MHz, CD3OD): 
δ 7.67 – 7.59 (m, 2H), 7.39 – 7.28 (m, 2H), 7.13 (t, J = 7.5 Hz, 1H), 6.94 (s, 1H), 6.25 (s, 1H), 4.08 – 
3.92 (m, 4H), 3.51 (d, J = 10.5 Hz, 2H), 1.40 (s, 9H), 1.20 (t, J = 7.1 Hz, 6H); 13C NMR (100 MHz, 
CD3OD): δ 155.9, 142.9 (d, J = 4.6 Hz), 142.1 – 141.9 (m), 129.4, 127.6, 126.8 (q, J = 270.0 Hz), 
125.8, 123.5, 116.2 – 115.8 (m), 104.0 (q, J = 31.0 Hz), 97.1 (q, J = 2.0 Hz), 83.2, 64.4 – 63.7 (m), 
41.5 – 41.3 (m, part of NCH2PO multiplet), 39.9 – 39.7 (m, part of NCH2PO multiplet), 28.7 – 28.0 
(m), 17.0 – 16.3 (m); 19F NMR (376 MHz, CD3OD): δ −60.4; 
31
P NMR (162 MHz, CD3OD): δ 24.4; IR 
(neat): 3370, 2981, 2931, 1713, 1622, 1597, 1537, 1489, 1453, 1392, 1369, 1335, 1300, 1245, 
1198, 1150, 1094, 1048, 1023, 970, 867, 824, 757 cm−1; HRMS (ESI, m/z): [(M+Na)+] calcd. for 
C23H32F3N4NaO5P
+, 555.1955; found 555.1959. 
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Synthesis and characterisation of ShuBQX-3 
 
To a solution of compound 19 (132 mg, 0.248 mmol) in THF (11 mL) and Et3N (174 mg, 1.72 mmol, 
0.240 mL) at r.t. was added ethyl chlorooxoacetate (11) (88 mg, 0.644 mmol, 72 µL) dropwise. The 
resulting mixture was stirred at r.t. for 19 h. After this time the reaction mixture was filtered and 
the filtrate was concentrated under reduced pressure. The resulting residue was dissolved in EtOH 
(2 mL) and a solution of HCl (9 mL, 6.0 m in H2O) was added. The resulting mixture was heated to 
90 °C for 3 h and then cooled to r.t.. The reaction mixture was directly purified by reverse phase 
column chromatography eluting with H2O [0.1% TFA]/MeCN [0.1% TFA] (9:1 → 6:4). The H2O was 
removed by lyophilisation to afford compound ShuBQX-3 (14.0 mg, 18% over three steps) as a 
dark brown solid. 
 
mp: 275 – 280 °C, decomp; 1H NMR (400 MHz, CD3OD): δ 8.12 (s, 1H), 7.99 – 7.89 (m, 2H), 7.63 (s, 
1H), 7.58 – 7.49 (m, 3H), 4.72 (d, J = 12.0 Hz, 2H); 13C NMR (100 MHz, CD3OD): δ 157.0, 155.3, 
153.8, 145.8, 133.2, 131.1, 130.4, 129.0, 125.9 (q, J = 32.0 Hz), 124.8, q, J = 272.5 Hz), 124.4, 115.2, 
(q, J = 6.0 Hz), 105.5, 41.7 (d, J = 152.0 Hz); 19F NMR (376 MHz, CD3OD): δ −58.5; 
31
P NMR (162 
MHz, CD3OD): δ 15.3; IR (neat): 3415, 3073, 2961, 1694, 1619, 1393, 1358, 1298, 1269, 1241, 
1136, 1062, 1019, 933, 771, 732, 687 cm−1; HRMS (ESI, m/z): [(M+H)+] calcd. for C16H13F3N4O5P
+, 
429.0570; found 429.0580; LCMS: H2O [0.1% FA]/MeCN [0.1% FA] (90:10 → 10:90), flow rate 2.0 
mL/min over 5 min; tR = 2.858 min, MS (ESI, m/z): [(M+H)
+] = 429.0, UV-Vis: λmax = 360 nm. 
 
  
Experimental   212 
 
10.5.2. NMR Spectra for Chapter 7.1. 
1H NMR spectrum of compound 3 
 
 
13C NMR spectrum of compound 3  
 
1H NMR spectrum of compound 4 
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13C NMR spectrum of compound 4  
 
 
1H NMR spectrum of compound 7  
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13C NMR spectrum of compound 7  
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1H NMR spectrum of compound 9  
 
 
13C NMR spectrum of compound 9  
 
 
Experimental   216 
 
1H NMR spectrum of compound 12  
 
 
13C NMR spectrum of compound 12  
 
 
Experimental   217 
 
1H NMR spectrum of compound 15  
 
 
13C NMR spectrum of compound 15  
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1H NMR spectrum of compound ShuBQX-1 
 
 
13C NMR spectrum of compound ShuBQX-1  
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1H NMR spectrum of compound 8  
 
 
13C NMR spectrum of compound 8  
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1H NMR spectrum of compound 10  
 
 
13C NMR spectrum of compound 10  
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1H NMR spectrum of compound 13  
 
 
13C NMR spectrum of compound 13  
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1H NMR spectrum of compound 16  
 
 
13C NMR spectrum of compound 16  
 
 
Experimental   223 
 
1H NMR spectrum of compound ShuBQX-2 
 
 
13C NMR spectrum of compound ShuBQX-2 
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1H NMR spectrum of compound 18  
 
 
13C NMR spectrum of compound 18 
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1H NMR spectrum of compound 19  
 
 
13C NMR spectrum of compound 19  
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1H NMR spectrum of ShuBQX-3  
 
 
13C NMR spectrum of ShuBQX-3  
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10.5.3. Supplementary Figures 
 
Figure S1. UV-Vis absorption spectra of ShuBQX-1, ShuBQX-2 and ShuBQX-3. Solutions of 
ShuBQX-1 (50 µM in DMSO), ShuBQX-2 (50 µM in DMSO), ShuBQX-3 (50 µM in DMSO, left and 50 
µM in Ringer buffer, right) were placed in a 1 mL quartz cuvette (10 mm diameter). A light-fibre 
cable connected to a Till Photonics Polychrome 5000 monochromator was placed in the cuvette 
until it penetrated the surface of the solution. Illumination was screened from wavelengths 380-
600 nm in 20 nm steps (ShuBQX-1 and ShuBQX-2) and 340-500 nm in 20 nm steps (ShuBQX-3) 
going from higher to lower wavelengths. Every wavelength was applied for 5 min before a UV-Vis 
spectrum was recorded. Illumination conditions that afforded the highest trans-isomer and cis-
isomer enrichment are shown in Figure S1. 
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Figure S2. Action spectra of ShuBQX-1 and ShuBQX-2. Action spectra of ShuBQX-1 (5 µM, left) and 
ShuBQX-2 (5 µM, right) in the presence of glutamate (300 μM) under illumination with green light 
(580 nm) and varying wavelengths.  
 
Figure S3. ShuBQX-3 dose-response studies. Normalized dose-response curve of ShuBQX-3 in the 
presence of glutamate (300 µm). The trans-isomer of ShuBQX-3 (black, IC50 = 3.1 µM) displayed 
almost full antagonism (95.8% ± 1.8%) of HEK293T cells expressing GluA1-L497Y receptors at 50 
µM. The cis-isomer of ShuBQX-3 (blue) was significantly less potent, exhibiting nearly half the 
antagonism (52.0% ± 1.9%) of the trans-isomer. The dose-response curve of ShuBQX-3 (IC50 = 3.3 
µM) illuminated with orange light (600 nm) is not shown for clarity. Data points were fitted using 
the Hill equation from n=5 independent cells. Values represent mean ± SEM. 
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Figure S4. ShuBQX-3 is a competitive antagonist of AMPA receptors. ShuBQX-3 (5 µM) exhibits 
differing amounts of AMPA receptor antagonism when varying the concentration of glutamate 
(n=5 cells). Large light-dependent currents were observed when using 100 µM and 300 µM 
glutamate. Increasing the concentration of glutamate to 1 mM resulted in a significant reduction of 
light-dependent currents. Values represent mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
Figure S5. Action spectrum of ShuBQX-3. The current magnitude can be controlled by varying the 
wavelength of light (400-500 nm) used for photoswitching (ShuBQX-3, 20 μM). It was consistently 
shown that illuminating with blue light (440 nm and 460 nm) provided the maximum inward 
current (n=5 cells). Values represent mean ± SEM.  
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Figure S6. Current-clamp photoswitching of ShuBQX-3. The photoswitching of ShuBQX-3 (10 μM) 
was also highly reproducible when in current-clamp mode.  
 
 
 
Figure S7. Optical control of action potential firing in hippocampal CA1 neurons using ShuBQX-3 
(10 µM) in the presence of AMPA (50 µM). 
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Figure S8. UV-Vis absorption spectrum of ShuBQX-3. Comparison of ShuBQX-3 (50 µM) alone 
(blue) and in the presence of 1mM L-arginine (green) and 1 mM guanidine (red) in DMSO. 
Illumination conditions that afforded the highest trans-isomer enrichment are shown. 
 
 
Figure S9. UV-Vis absorption spectrum of ShuBQX-3 diethyl phosphonate (S1). Comparison of S1 
(50 µM) alone (blue) and in the presence of 1mM l-arginine (green) and 1 mM guanidine (red) in 
DMSO. Illumination conditions that afforded the highest trans-isomer enrichment are shown. 
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10.5.4. Electrophysiology 
 
HEK293T Cell Electrophysiology 
HEK293T cells were incubated in dulbecco ́s minimal essential medium + 10% FBS and split at 80 to 
90% confluency. For detachment, growth medium was removed, cells were washed with calcium 
free PBS buffer and cells were treated with trypsin solution at 37 °C for 2 min. Detached cells were 
diluted with growth medium and singularised by pipetting. For transfection, acid-etched coverslips 
were coated with poly-L-lysin and placed in a 24-well plate. 40 000 cells were added to each well in 
500 µL standard growth medium. DNA (per coverslip: 350 ng GluA1-L497Y and 50 ng YFP) was 
mixed with 1 µL polyplus jetprime in 50 µL jetprime buffer. After standing at room temperature 
for 10-15 min, the DNA-mix was added to the cells shortly after seeding them into the 
abovementioned 24-well plate. After 3-5 hours the medium was exchanged for standard growth 
medium. Cells were used for electrophysiological recordings 24 hours post transfection. 
Whole-cell patch clamp experiments were performed using a standard electrophysiology setup 
equipped with a HEKA Patch Clamp EPC10 USB amplifier and PatchMaster software (HEKA 
Electronik). Micropipettes were generated from a Science Products GB200-F-8P with filament 
pipettes using a vertical puller. Resistance varied between 3-7 MΩ. The extracellular solution 
contained in mM: 138 NaCl, 1.5 KCl, 2.5 CaCl2, 1.2 MgCl2, 10 glucose and 5 HEPES (NaOH to pH 7.4). 
The intracellular solution contained in mM: 140 K-gluconate, 5 NaCl, 15 KCl, 5.0 MgATP, 0.5 
Na2ATP and 12.5 HEPES (pH 7.3). The holding potential for voltage clamp experiments was −60 
mV. The antagonists ShuBQX-1, ShuBQX-2 and ShuBQX-3 were diluted into the extracellular 
solution from 100 mM DMSO stock solutions. Glutamate was diluted into the extracellular solution 
from a 100 mM H2O stock solution. Illumination during electrophysiology experiments was 
provided by a Poly V, FEI monochromator. 
 
Brain Slice Electrophysiology 
All animal procedures were performed in accordance with the guidelines of the Regierung 
Oberbayern. Horizontal slices were prepared from C57Bl6JRj mice (postnatal day 12-14). Following 
decapitation, the brain was rapidly removed and transferred to an ice-cold saline solution 
composed of (in mM) 87 NaCl, 75 sucrose, 25 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 7 MgCl2, 
25 glucose saturated with carbogen (95% O2/5% CO2). Slices (300 µm thick) were cut with a 
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vibratome (NPI Electronic), incubated at 34 °C for 1 h in saline solution and then kept at room 
temperature for up to 6 h before being used in patch-clamp recordings. Experiments were carried 
out in ACSF composed of (in mM) 125 NaCl, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, 20 
glucose and AP-5 (50 µM) saturated with carbogen at room temperature. 
Pyramidal CA1 neurons of the hippocampus were patched using glass electrodes (Science 
Products) with a resistance of 6–9 MΩ. Current-clamp recordings were carried out using the 
following intracellular solution (in mM): 140 K-gluconate, 10 HEPES, 12 KCl, 4 NaCl, 4 MgATP, 0.4 
Na2GTP. Recordings were made with an EPC 10 USB amplifier, controlled by the Patchmaster 
software (HEKA). Data was filtered at 2.9 and 10 kHz. Data was analyzed using the Patcher’s Power 
Tools (MPI Göttingen) and IgorPro (Wavemetrics). ShuBQX-3 (10 µM) together with either (RS)-
AMPA (50 µM) or glutamate (100 µM) dissolved in ACSF were locally applied through a glass 
pipette using a pressure application system at 2 psi (NPI Electronic). Photoswitching was achieved 
through a microscope coupled monochromator (Poly V, FEI). 
 
Xenopus Oocytes Electrophysiology 
cRNA was synthesized from cDNA clones of GluN1-1a (GenBank accession number U08261), 
GluN2A (NM_012573), NR2B (U11419), NR2C (NM_012575), NR2D (NM_022797), GluA1(Q)flip 
(P19490.2), GluA1(Q)flop (P19490.1), GluA2(R)flip (P19491.2), and GluK2(P42260) subcloned in 
the X. laevis oocyte expression vector pSGEM using the T7 mMESSAGE mMACHINE Kit (Ambion). 
Synthesized cRNA was isolated via the Clean & Concentrator 25 kit (Zymo), the quality of the cRNA 
controlled via denaturating agarose gel electrophoresis and the concentration, after 
photometrical determination, adjusted to 400 ng·µL-1 with nuclease-free water. 
All animal procedures were performed in accordance with the Tierschutzgesetz (TierSchG) and the 
TierschutzVersuchstierverordnung (TierSchVersV). Frog oocytes of stages V or VI were obtained by 
surgical removal of the ovaries of a X. laevis frog previously anesthetized with ethyl 3-
aminobenzoate methanesulfonate (2.3 g·L-1; Sigma). The ovaries were cut and under constant 
shaking incubated with 300 U·mL-1 (10 mg mL-1) collagenase type I (Worthington Biochemicals) for 
3 h at 21 °C in Ca2+-free Barth's solution (in mM: 88 NaCl, 1.1 KCl, 2.4 NaHCO3, 0.8 MgSO4, 15 
HEPES, pH adjusted to 7.6 with NaOH). The Ca2+-sensitive collagenase reaction was stopped by 
rinsing with Barth's solution with (in mM: 88 NaCl, 1.1 KCl, 2.4 NaHCO3, 0.8 MgSO4, 0.4 CaCl2, 0.3 
Ca(NO3)2, 15 HEPES, pH adjusted to 7.6 with NaOH). Oocytes were kept in Barth's medium 
supplemented with 100 µg·mL-1 gentamycin, 40 µg·mL-1 streptomycin, and 63 mg/mL penicillin. 
Experimental   234 
 
Oocytes of stages V or VI were selected and injected with cRNA within 8 h after surgery using a 
Nanoliter 2010 injector (WPI). 
For expression of GluA1(Q)flip and GluA1(Q)flop homomeric and GluA1(Q)flip / GluA2(R)flip 
heteromeric receptors, 4 ng (25 nL) cRNA per subunit were injected. To express the GluK2(Q) 
homomeric receptor, 4 ng (20 nL) cRNA was injected. For the expression of the heteromeric 
NMDA receptors, 4 ng (10 nL) GluN1-1a cRNA were coinjected with one of the following: 7 ng (17 
nL) GluN2A, or 6 ng (15 nL) GluN2B, or 5 ng (13 nL) GluN2C, or 5 ng (13 nL) GluN2D.  
Electrophysiological recordings were performed on days 4-7. Two-electrode voltage clamping was 
performed using a TurboTec-10CX amplifier (npi electronic) controlled by Pulse software (HEKA). 
Borosilicate glass capillaries (Harvard Instruments) were pulled to resistances of 0.1-1.0 MΩ and 
filled with 3m KCl. Oocytes were clamped at 70 mV. All recordings were performed in barium 
ringer (BaR, in mM: 115 NaCl, 2.5 KCl, 1.8 BaCl2, 10 HEPES-NaOH, pH 7.2) supplemented with 250 
mM niflumic acid (NFA) to prevent the opening of endogenous calcium-induced chloride channels. 
For the recording of kainate receptor currents either 100 µM or 30 µM glutamate were used, for 
the recording of AMPA receptor currents 100 µM kainic acid, and for the recording of the NMDA 
receptor currents 100 µM glutamate / 10 µM glycine. Also, agonist solutions additionally containing 
5 µM ShuBQX-3 were prepared. For the recording of the ShuBQX-3-mediated block of current 
responses, agonist solution without ShuBQX-3 was perfused at least for 10 s until a steady state 
was reached, followed by a 10 s application of agonist solution containing 5 µM ShuBQX-3. After a 
subsequent second application of agonist solution without ShuBQX-3 a washout with BaR without 
agonist followed. The ShuBQX-3-mediated block was then calculated as the ShuBQX-3-induced 
percent inhibition of the total agonist-induced current response. 
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